var title_f9_52_10048="Knee arthrocentesis";
var content_f9_52_10048=[" <div id=\"graphicsToolbar\">",
"  <div id=\"graphicsCopy\">",
"   &copy;2013 UpToDate",
"   <sup>",
"    &reg;",
"   </sup>",
"  </div>",
"  <div id=\"graphicsLinks\">",
"   <a href=\"?imageKey=RHEUM%2F52630&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=2\" onclick=\"\">",
"    <img alt=\"Print this page\" src=\"./../images/icn_print.myextg\" title=\"Print this page\"/>",
"   </a>",
"   <a class=\"icontxt textLink\" href=\"?imageKey=RHEUM%2F52630&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=2\" onclick=\"\" title=\"Print this page\">",
"    Print",
"   </a>",
"   <a class=\"etacLink\" href=\"#\">",
"    <img alt=\"Email graphic(s)\" src=\"./../images/icn_email.myextg\" title=\"Email graphic(s)\"/>",
"   </a>",
"   <a class=\"icontxt textLink etacLink\" href=\"#\" title=\"Email graphic(s)\">",
"    Email",
"   </a>",
"  </div>",
" </div>",
" <div class=\"graphic\">",
"  <div class=\"figure\" style=\"width: 470px\">",
"   <div class=\"ttl\">",
"    Knee arthrocentesis",
"   </div>",
"   <div class=\"cntnt\" style=\"width: 371px; height: 393px; background-image: url(data:image/jpeg;base64,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);\">",
"   </div>",
"   <div class=\"lgnd\">",
"    The needle is inserted just posterior to the medial portion of the patella and is directed slightly posteriorly and slightly inferiorly.",
"    <div class=\"footnotes\">",
"    </div>",
"    <div class=\"reference\">",
"     Reproduced from Owen, DS. Aspiration and injection of joints in soft tissue. In: Textbook of Rheumatology, 4th edition, Kelley, WN, Harris, ED Jr, Ruddy S, et al (Eds), WB Saunders, Philadelphia 1993. p.545.",
"    </div>",
"   </div>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f9_52_10048=[""].join("\n");
var outline_f9_52_10048=null;
var title_f9_52_10049="Isolating the vas during vasectomy";
var content_f9_52_10049=[" <div id=\"graphicsToolbar\">",
"  <div id=\"graphicsCopy\">",
"   &copy;2013 UpToDate",
"   <sup>",
"    &reg;",
"   </sup>",
"  </div>",
"  <div id=\"graphicsLinks\">",
"   <a href=\"?imageKey=PC%2F74357&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=2\" onclick=\"\">",
"    <img alt=\"Print this page\" src=\"./../images/icn_print.myextg\" title=\"Print this page\"/>",
"   </a>",
"   <a class=\"icontxt textLink\" href=\"?imageKey=PC%2F74357&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=2\" onclick=\"\" title=\"Print this page\">",
"    Print",
"   </a>",
"   <a class=\"etacLink\" href=\"#\">",
"    <img alt=\"Email graphic(s)\" src=\"./../images/icn_email.myextg\" title=\"Email graphic(s)\"/>",
"   </a>",
"   <a class=\"icontxt textLink etacLink\" href=\"#\" title=\"Email graphic(s)\">",
"    Email",
"   </a>",
"  </div>",
" </div>",
" <div class=\"graphic\">",
"  <div class=\"figure\" style=\"width: 470px\">",
"   <div class=\"ttl\">",
"    Isolating the vas during vasectomy",
"   </div>",
"   <div class=\"cntnt\" style=\"width: 360px; height: 329px; background-image: url(data:image/jpeg;base64,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);\">",
"   </div>",
"   <div class=\"lgnd\">",
"    A loop of vas deferens is brought up through the wound, divided, and a segment removed.",
"    <div class=\"footnotes\">",
"    </div>",
"    <div class=\"reference\">",
"     Reproduced with permission from: Clenney, TL, Higgins, JC. Vasectomy Techniques. American Family Physician 1999; 60:137. Copyright &copy;1999 Timothy Clenney, MD, MPH.",
"    </div>",
"   </div>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f9_52_10049=[""].join("\n");
var outline_f9_52_10049=null;
var title_f9_52_10050="Amplatzer septal occluder";
var content_f9_52_10050=[" <div id=\"graphicsToolbar\">",
"  <div id=\"graphicsCopy\">",
"   &copy;2013 UpToDate",
"   <sup>",
"    &reg;",
"   </sup>",
"  </div>",
"  <div id=\"graphicsLinks\">",
"   <a href=\"?imageKey=CARD%2F52160&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=1\" onclick=\"\">",
"    <img alt=\"Print this page\" src=\"./../images/icn_print.myextg\" title=\"Print this page\"/>",
"   </a>",
"   <a class=\"icontxt textLink\" href=\"?imageKey=CARD%2F52160&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=1\" onclick=\"\" title=\"Print this page\">",
"    Print",
"   </a>",
"   <a class=\"etacLink\" href=\"#\">",
"    <img alt=\"Email graphic(s)\" src=\"./../images/icn_email.myextg\" title=\"Email graphic(s)\"/>",
"   </a>",
"   <a class=\"icontxt textLink etacLink\" href=\"#\" title=\"Email graphic(s)\">",
"    Email",
"   </a>",
"  </div>",
" </div>",
" <div class=\"graphic\">",
"  <div class=\"figure\" style=\"width: 483px\">",
"   <div class=\"ttl\">",
"    Amplatzer septal occluder and measurements of its profile",
"   </div>",
"   <div class=\"cntnt\" style=\"width: 463px; height: 227px; background-image: url(data:image/jpeg;base64,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);\">",
"   </div>",
"   <div class=\"lgnd\">",
"    In the lateral view the Amplatzer septal occluder has a waist between the left and right atrial discs; the left atrial disc is slightly larger than the right one. Broken lines and red arrows indicate measurement sites.",
"    <div class=\"footnotes\">",
"    </div>",
"    <div class=\"reference\">",
"     Reproduced with permission from Cao Q, Du Z, Joseph A. Am J Cardiol 2001; 88:754. Copyright &copy; 2001 Excerpta Medica Inc.",
"    </div>",
"    <div class=\"contractual\">",
"     <br/>",
"     <a href=\"file://www.elsevier.com/locate/jacc\">",
"      file://www.elsevier.com/locate/jacc",
"     </a>",
"     <br/>",
"     <a href=\" file://www.sciencedirect.com\">",
"      file://www.sciencedirect.com",
"     </a>",
"    </div>",
"   </div>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f9_52_10050=[""].join("\n");
var outline_f9_52_10050=null;
var title_f9_52_10051="Prophylactic hemoclip Endosc";
var content_f9_52_10051=[" <div id=\"graphicsToolbar\">",
"  <div id=\"graphicsCopy\">",
"   &copy;2013 UpToDate",
"   <sup>",
"    &reg;",
"   </sup>",
"  </div>",
"  <div id=\"graphicsLinks\">",
"   <a href=\"?imageKey=GAST%2F56809&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=1\" onclick=\"\">",
"    <img alt=\"Print this page\" src=\"./../images/icn_print.myextg\" title=\"Print this page\"/>",
"   </a>",
"   <a class=\"icontxt textLink\" href=\"?imageKey=GAST%2F56809&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=1\" onclick=\"\" title=\"Print this page\">",
"    Print",
"   </a>",
"   <a class=\"etacLink\" href=\"#\">",
"    <img alt=\"Email graphic(s)\" src=\"./../images/icn_email.myextg\" title=\"Email graphic(s)\"/>",
"   </a>",
"   <a class=\"icontxt textLink etacLink\" href=\"#\" title=\"Email graphic(s)\">",
"    Email",
"   </a>",
"  </div>",
" </div>",
" <div class=\"graphic\">",
"  <div class=\"figure\" style=\"width: 470px\">",
"   <div class=\"ttl\">",
"    Prophylactic hemoclip placement prior to colonic polypectomy",
"   </div>",
"   <div class=\"cntnt\" style=\"width: 301px; height: 340px; background-image: url(data:image/jpeg;base64,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);\">",
"   </div>",
"   <div class=\"lgnd\">",
"    A hemoclip has been placed prophylactically to ligate a long thin polyp stalk prior to snare transection.",
"    <div class=\"footnotes\">",
"    </div>",
"    <div class=\"reference\">",
"     Courtesy of Uwe Seitz, MD, Sabine Bohnacker, MD, and Nib Soehendra, MD.",
"    </div>",
"   </div>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f9_52_10051=[""].join("\n");
var outline_f9_52_10051=null;
var title_f9_52_10052="Oropharynx of a snorer II";
var content_f9_52_10052=[" <div id=\"graphicsToolbar\">",
"  <div id=\"graphicsCopy\">",
"   &copy;2013 UpToDate",
"   <sup>",
"    &reg;",
"   </sup>",
"  </div>",
"  <div id=\"graphicsLinks\">",
"   <a href=\"?imageKey=PULM%2F67818&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=1\" onclick=\"\">",
"    <img alt=\"Print this page\" src=\"./../images/icn_print.myextg\" title=\"Print this page\"/>",
"   </a>",
"   <a class=\"icontxt textLink\" href=\"?imageKey=PULM%2F67818&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=1\" onclick=\"\" title=\"Print this page\">",
"    Print",
"   </a>",
"   <a class=\"etacLink\" href=\"#\">",
"    <img alt=\"Email graphic(s)\" src=\"./../images/icn_email.myextg\" title=\"Email graphic(s)\"/>",
"   </a>",
"   <a class=\"icontxt textLink etacLink\" href=\"#\" title=\"Email graphic(s)\">",
"    Email",
"   </a>",
"  </div>",
" </div>",
" <div class=\"graphic\">",
"  <div class=\"figure\" style=\"width: 470px\">",
"   <div class=\"ttl\">",
"    Oropharynx of a snorer",
"   </div>",
"   <div class=\"cntnt\" style=\"width: 358px; height: 253px; background-image: url(data:image/jpeg;base64,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);\">",
"   </div>",
"   <div class=\"lgnd\">",
"    This photograph is from a snoring patient in whom obstructive sleep apnea was excluded by polysomnography. Oropharyngeal narrowing is present in the lateral dimension due to residual tonsilar tissue.",
"    <div class=\"footnotes\">",
"    </div>",
"    <div class=\"reference\">",
"    </div>",
"   </div>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f9_52_10052=[""].join("\n");
var outline_f9_52_10052=null;
var title_f9_52_10053="Periductal mastitis piercing";
var content_f9_52_10053=[" <div id=\"graphicsToolbar\">",
"  <div id=\"graphicsCopy\">",
"   &copy;2013 UpToDate",
"   <sup>",
"    &reg;",
"   </sup>",
"  </div>",
"  <div id=\"graphicsLinks\">",
"   <a href=\"?imageKey=PC%2F63150&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=2\" onclick=\"\">",
"    <img alt=\"Print this page\" src=\"./../images/icn_print.myextg\" title=\"Print this page\"/>",
"   </a>",
"   <a class=\"icontxt textLink\" href=\"?imageKey=PC%2F63150&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=2\" onclick=\"\" title=\"Print this page\">",
"    Print",
"   </a>",
"   <a class=\"etacLink\" href=\"#\">",
"    <img alt=\"Email graphic(s)\" src=\"./../images/icn_email.myextg\" title=\"Email graphic(s)\"/>",
"   </a>",
"   <a class=\"icontxt textLink etacLink\" href=\"#\" title=\"Email graphic(s)\">",
"    Email",
"   </a>",
"  </div>",
" </div>",
" <div class=\"graphic\">",
"  <div class=\"figure\" style=\"width: 470px\">",
"   <div class=\"ttl\">",
"    Nipple ring infection",
"   </div>",
"   <div class=\"cntnt\" style=\"width: 396px; height: 391px; background-image: url(data:image/jpeg;base64,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);\">",
"   </div>",
"   <div class=\"lgnd\">",
"    Nipple rings can cause problems with recurrent infections.",
"    <div class=\"footnotes\">",
"    </div>",
"    <div class=\"reference\">",
"     Courtesy of Michael J Dixon, MD.",
"    </div>",
"   </div>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f9_52_10053=[""].join("\n");
var outline_f9_52_10053=null;
var title_f9_52_10054="Evaluating diagnostic tests";
var content_f9_52_10054=[" <noscript>",
"  <div id=\"javascriptDisabled\">",
"   It seems to us that you have your JavaScript turned off on your browser. JavaScript is required in order for our site to behave correctly.  Please enable your JavaScript to continue use our site.",
"  </div>",
" </noscript>",
" <div id=\"printHeader\">",
"  <div id=\"printHeaderLogo\">",
"   <img alt=\"UpToDate\" src=\"./../images/UTD2_masthead.myextg\">",
"    <img align=\"right\" alt=\"Wolters Kluwer Health\" height=\"40\" src=\"./../images/logoWKH.myextg\" width=\"175\">",
"     <br>",
"      <div id=\"printHeaderText\">",
"       Official reprint from  UpToDate",
"       <sup>",
"        &reg;",
"       </sup>",
"       <br>",
"        <a href=\"file://www.uptodate.com\">",
"         www.uptodate.com",
"        </a>",
"        &copy;2013 UpToDate",
"        <sup>",
"         &reg;",
"        </sup>",
"       </br>",
"      </div>",
"     </br>",
"    </img>",
"   </img>",
"  </div>",
"  <div id=\"printHeaderLinks\">",
"   <a class=\"TOPIC\" href=\"#\" id=\"printHeaderPrint\" rel=\"2\" title=\"Click here to print\">",
"    Print",
"   </a>",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <a href=\"#\" id=\"printHeaderBack\" title=\"Back to normal view\">",
"    Back",
"   </a>",
"  </div>",
" </div>",
" <!-- TC:TOPIC_PAGE -->",
" <div id=\"topicContent\">",
"  <div id=\"topicTitle\">",
"   Evaluating diagnostic tests",
"  </div>",
"  <div id=\"topicContributors\">",
"   <div>",
"    <a id=\"authors\">",
"    </a>",
"    <a class=\"contributor contributor_credentials contributorType\" href=\"UTD.htm?9/52/10054/contributors\">",
"     Authors",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"UTD.htm?9/52/10054/contributors\">",
"     Neal G Mahutte, MD",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"UTD.htm?9/52/10054/contributors\">",
"     Antoni J Duleba, MD",
"    </a>",
"    <br/>",
"   </div>",
"   <div>",
"    <a class=\"contributor contributor_credentials contributorType\" href=\"UTD.htm?9/52/10054/contributors\">",
"     Section Editor",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"UTD.htm?9/52/10054/contributors\">",
"     Suzanne W Fletcher, MD",
"    </a>",
"    <br/>",
"   </div>",
"   <div>",
"    <a class=\"contributor contributor_credentials contributorType\" href=\"UTD.htm?9/52/10054/contributors\">",
"     Deputy Editor",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"UTD.htm?9/52/10054/contributors\">",
"     Fenny H Lin, MD",
"    </a>",
"    <br/>",
"   </div>",
"  </div>",
"  <div id=\"disclosures\">",
"   <a href=\"UTD.htm?9/52/10054/contributor-disclosure\" target=\"_blank\">",
"    Disclosures",
"   </a>",
"  </div>",
"  <div id=\"reviewProcess\">",
"   <span>",
"    All topics are updated as new evidence becomes available and our",
"   </span>",
"   <a href=\"/home/editorial-policy\" target=\"_blank\">",
"    peer review process",
"   </a>",
"   <span>",
"    is complete.",
"   </span>",
"  </div>",
"  <div id=\"literatureReviewDate\">",
"   <span class=\"emphasis\">",
"    Literature review current through:",
"   </span>",
"   Oct 2013.",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <span class=\"emphasis\">",
"    This topic last updated:",
"   </span>",
"   Apr 12, 2013.",
"  </div>",
"  <div id=\"topicText\">",
"   <p class=\"headingAnchor\" id=\"H1\">",
"    <span class=\"h1\">",
"     INTRODUCTION",
"    </span>",
"    &nbsp;&mdash;&nbsp;The introduction of new diagnostic tests that claim to improve screening or provide definitive diagnosis is a major dilemma for all clinicians. The decision to embrace or reject these tests is often made individually with incomplete information and without thoughtful reflection.",
"   </p>",
"   <p>",
"    In this topic review we will outline a simple seven-step process that can be used to evaluate the utility of any diagnostic test:",
"   </p>",
"   <p>",
"    <ul class=\"bulletCompact-block\">",
"     <li>",
"      Can the test be reliably performed?",
"     </li>",
"     <li>",
"      Was the test evaluated on an appropriate population?",
"     </li>",
"     <li>",
"      Was an appropriate gold standard used?",
"     </li>",
"     <li>",
"      Was an appropriate cut-off value chosen to optimize sensitivity and specificity?",
"     </li>",
"     <li>",
"      What are the positive and negative likelihood ratios?",
"     </li>",
"     <li>",
"      How well does the test perform in specific populations?",
"     </li>",
"     <li>",
"      What is the balance between cost of the disease and cost of the test?",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    A catalog of common biostatistical and epidemiological terms encountered in the medical literature, an evidence based approach to prevention, and issues around hypothesis testing are presented separately. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?22/18/22823?source=see_link\">",
"     \"Glossary of common biostatistical and epidemiological terms\"",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"UTD.htm?33/46/34537?source=see_link\">",
"     \"Evidence-based approach to prevention\"",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"UTD.htm?8/19/8500?source=see_link\">",
"     \"Proof, p-values, and hypothesis testing\"",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H2\">",
"    <span class=\"h1\">",
"     CAN THE TEST BE PERFORMED RELIABLY?",
"    </span>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H3\">",
"    <span class=\"h2\">",
"     Accuracy and precision",
"    </span>",
"    &nbsp;&mdash;&nbsp;It is helpful to determine the extent to which the test is accurate, precise, and user dependent to objectively answer this question. \"Accuracy\" refers to the ability of the test to actually measure what it claims to measure, and is defined as the proportion of all test results (both positive and negative) that are correct (",
"    <a class=\"graphic graphic_table graphicRef55297 \" href=\"UTD.htm?0/18/299\">",
"     table 1",
"    </a>",
"    ). Precision refers to the ability of the test to reproduce the same result when repeated on the same patient or sample. The two concepts are related, but different. For example, a test could be precise, but not accurate if on three occasions it produced roughly the same result, but that result differed greatly from the actual value determined by a reference-standard. Both accuracy and precision may be presented in the form of a confidence interval (CI) or standard error (SE).",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H4\">",
"    <span class=\"h2\">",
"     Expertise",
"    </span>",
"    &nbsp;&mdash;&nbsp;One of the great challenges in evaluating a diagnostic test is determining to what extent user expertise influences accuracy and precision. Studies in the literature often emanate from tertiary care centers with advanced capabilities for diagnostic equipment and personnel. Such environments may bear little resemblance to the facilities found at a local level. As an example, high \"user dependence\" makes it difficult to apply advances in screening ultrasonography found at specialized centers to the population at large [",
"    <a class=\"abstract\" href=\"UTD.htm?9/52/10054/abstract/1\">",
"     1",
"    </a>",
"    ]. The test may be accurate and precise in an expert's hands, but may be imprecise, inaccurate, and unreliable when performed by a less experienced practitioner. These factors should be taken into account when determining if a given test should be implemented in a given situation.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H5\">",
"    <span class=\"h1\">",
"     WAS THE TEST EVALUATED ON AN APPROPRIATE POPULATION?",
"    </span>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H6\">",
"    <span class=\"h2\">",
"     Population",
"    </span>",
"    &nbsp;&mdash;&nbsp;This step examines the population from which test data was derived, a point that is often overlooked. A test should be conducted on a broad spectrum of patients with and without the disorder in question to maximize generalizability. Those with the disorder should represent all stages and manifestations of the disease. Even more importantly, individuals without the disorder should have some clinical manifestations similar to, and perhaps easily confused with, the disease in question. This is critical in demonstrating the ability of the test to distinguish among clinical entities in the differential diagnosis.",
"   </p>",
"   <p>",
"    As an example, the utility of obtaining a serum CA125 concentration for detection of endometriosis depends upon studying a population that includes a range of patients with minimal, mild, moderate, and severe endometriosis. If the study population has a disproportionate number of women with severe disease, this might falsely inflate the capability of the test to identify cases. It is also essential to include a large cohort of patients without endometriosis, but with similar signs or symptoms (eg, dysmenorrhea, dyspareunia, pelvic pain, infertility, adnexal mass, fibroids). Neglecting to include these patients might falsely inflate the performance of the test.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H7\">",
"    <span class=\"h2\">",
"     Sample size",
"    </span>",
"    &nbsp;&mdash;&nbsp;Sample size is part of the question of population appropriateness. An adequate number of patients must be studied to encompass a broad spectrum of manifestations in diseased and nondiseased subjects. However, an overly large sample size may detect a statistically significant test difference that is not clinically meaningful, while a sample size that is too small may yield inconclusive results due to low power.",
"   </p>",
"   <p>",
"    One indirect way of evaluating sample size is to examine the confidence intervals for sensitivity, specificity, and likelihood ratio (see below) reported in the study.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H8\">",
"    <span class=\"h1\">",
"     WAS AN APPROPRIATE REFERENCE-STANDARD USED?",
"    </span>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H9\">",
"    <span class=\"h2\">",
"     Reference-standards",
"    </span>",
"    &nbsp;&mdash;&nbsp;Evaluation of a test necessarily involves comparison with a reference-standard. Ideally, a reference-standard allows unambiguous identification of diseased and nondiseased patients. However, in the real world, reference-standards often involve some degree of error or user-dependence.",
"   </p>",
"   <p>",
"    As an example, histopathology is often used as a reference-standard for the diagnosis of endometriosis; however, histopathology is not infallible. Cases can be misdiagnosed because of sampling error or individual differences among pathologists in histological interpretation. The presence of ectopic endometrial glands, but not stroma (or vice versa), in a woman with clinical signs and symptoms of endometriosis is suggestive of this disorder, but does not meet strict criteria for the disease (ie, ectopically located endometrial glands and stroma). By comparison, does an asymptomatic woman have endometriosis if a random biopsy of her normal appearing peritoneum finds endometrial glands and stroma? These questions address issues of both disease definition and what is normal.",
"   </p>",
"   <p>",
"    Real world considerations compel us to use practical definitions. Reference-standards represent \"the best we've got\" for distinguishing normal from abnormal. The reference-standard is the test that thus far has been shown to most reliably detect the disease. Therefore, any new test that may purport to have value must be compared with the reference-standard if we are to minimize the chance of misdiagnosis.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H10\">",
"    <span class=\"h2\">",
"     Defining normal",
"    </span>",
"    &nbsp;&mdash;&nbsp;\"Normal\" is a deceptive term. While it is used commonly to refer to good health or the absence of disease, defining normal can be complex and arbitrary. Many tests define normal based upon assigned cut-off values that assume a fixed prevalence of disease. Intrauterine growth restriction (IUGR), for example, may be defined as an estimated fetal weight less than the 10th percentile, less than the 5th percentile, or less than two standard deviations from the mean. Such definitions may be convenient, but clearly do not reflect the true prevalence of the disease in divergent populations.",
"   </p>",
"   <p>",
"    In addition, the cutoff value may not accurately reflect the diseased condition. As an example, the concept of growth restriction implies a pathologic process resulting in failure to achieve the genetically programmed size. A neonate with a birth weight at the 12th percentile who has three older brothers whose birth weights were at the 90th percentile would be categorized as normal under the standard definitions described above, even though the neonate appears not to have reached its genetic potential. In contrast, an infant whose actual weight and true genetic potential were at the 4th percentile might be mislabeled IUGR.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H11\">",
"    <span class=\"h1\">",
"     WAS AN APPROPRIATE CUT-OFF VALUE CHOSEN TO OPTIMIZE SENSITIVITY AND SPECIFICITY?",
"    </span>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H12\">",
"    <span class=\"h2\">",
"     Balancing sensitivity and specificity",
"    </span>",
"    &nbsp;&mdash;&nbsp;A cut-off value must be chosen to separate normal from abnormal. Selecting this value virtually always involves balancing sensitivity and specificity, although the actual value may be arbitrary.",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      Sensitivity is the probability that an individual with the disease will test positive. It is the number of patients with a positive test who have the disease (true positives) divided by all patients who have the disease. A test with high sensitivity will not miss many patients who have the disease (ie, low false negative rate).",
"     </li>",
"     <li>",
"      Specificity is the probability that an individual without the disease will test negative. It is the number of patients who have a negative test and do not have the disease (true negatives) divided by the number of patients who do not have the disease. A test with high specificity will infrequently identify patients as having a disease when they do not (ie, low false positive results).",
"     </li>",
"    </ul>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H13\">",
"    <span class=\"h2\">",
"     Two by two tables",
"    </span>",
"    &nbsp;&mdash;&nbsp;A two-by-two table (",
"    <a class=\"graphic graphic_table graphicRef73504 \" href=\"UTD.htm?2/23/2427\">",
"     table 2",
"    </a>",
"    ) is the simplest way to calculate sensitivity and specificity. However, understanding the interrelationship among sensitivity, specificity, and cut-off values is easiest in graphic form (",
"    <a class=\"graphic graphic_figure graphicRef73854 \" href=\"UTD.htm?9/2/9263\">",
"     figure 1",
"    </a>",
"    ).",
"   </p>",
"   <p>",
"    Two-by-two tables can also be used for calculating the false positive and false negative rates.",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      The false positive rate = false positives",
"      <span class=\"nowrap\">",
"       /",
"      </span>",
"      (false positives + true negatives). It is also equal to 1- specificity.",
"     </li>",
"     <li>",
"      The false negative rate = false negatives",
"      <span class=\"nowrap\">",
"       /",
"      </span>",
"      (false negatives + true positives). It is also equal to 1 &ndash; sensitivity.",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    An ideal test maximizes both sensitivity and specificity, thereby minimizing the false positive and false negative rates.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H14\">",
"    <span class=\"h2\">",
"     Receiver operating characteristic curves",
"    </span>",
"    &nbsp;&mdash;&nbsp;Receiver operating characteristic (ROC) curves allow one to identify the cut-off value that minimizes both false positives and false negatives. A ROC curve plots sensitivity on the y axis and 1 &ndash; specificity on the x axis (",
"    <a class=\"graphic graphic_figure graphicRef82175 \" href=\"UTD.htm?31/56/32653\">",
"     figure 2",
"    </a>",
"    ). Applying a variety of cutoff values to the same reference population allows one to generate the curve. The perfect test would have a cut-off value that allowed an exact split of diseased and nondiseased populations (ie, a cut-off that gave both 100 percent sensitivity and 100 percent specificity). It would plot as a right angle with the fulcrum in the far upper left corner (x = 0, y = 1). This case, however, is very rare. For the vast majority of cases, as one moves from left to right on the ROC curve the sensitivity increases while the specificity decreases.",
"   </p>",
"   <p>",
"    Calculation of the area under the ROC curve allows comparison of different tests. A perfect test has an area under the curve equal to one. Therefore, the closer the area under the curve is to one, the better the test. Similarly, if one wants to know the cut-off value for a test that minimizes both false positives and false negatives (and hence maximizes both sensitivity and specificity), one would select the point on the ROC curve closest to the far upper left corner (x = 0, y = 1).",
"   </p>",
"   <p>",
"    However, finding the right balance between optimal sensitivity and specificity may not involve simultaneously minimizing false positives and false negatives in all situations. For example, when screening for a deadly disease that is curable, it may be desirable to accept more false positives (lower specificity) in return for fewer false negatives (higher sensitivity). ROC curves allow a more thorough evaluation of a test and potential cut-off values, but are not the ultimate arbiters of how to set sensitivity and specificity.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H15\">",
"    <span class=\"h1\">",
"     WHAT ARE THE POSITIVE AND NEGATIVE LIKELIHOOD RATIOS?",
"    </span>",
"   </p>",
"   <p>",
"    Epidemiologists have devised another method by which to judge diagnostic tests: positive and negative likelihood ratios which, like sensitivity and specificity, are independent of disease prevalence.",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      The positive likelihood ratio = sensitivity",
"      <span class=\"nowrap\">",
"       /",
"      </span>",
"      (1 &ndash; specificity). This ratio divides the probability that a patient with the disease will test positive by the probability that a patient without the disease will test positive. It can also be written as the true positive rate",
"      <span class=\"nowrap\">",
"       /",
"      </span>",
"      false positive rate. Thus, the higher the positive likelihood ratio, the better the test (a perfect test has a positive likelihood ratio equal to infinity).",
"     </li>",
"     <li>",
"      The negative likelihood ratio = (1 &ndash; sensitivity)",
"      <span class=\"nowrap\">",
"       /",
"      </span>",
"      specificity. This ratio divides the probability that a patient with the disease will test negative by the probability that a patient without the disease will test negative. It can also be written as the false negative rate",
"      <span class=\"nowrap\">",
"       /",
"      </span>",
"      true negative rate. Therefore, the lower the negative likelihood ratio, the better the test (a perfect test has a negative likelihood ratio of zero).",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    In most instances one can evaluate likelihood ratios as shown in the table (",
"    <a class=\"graphic graphic_table graphicRef69816 \" href=\"UTD.htm?2/42/2731\">",
"     table 3",
"    </a>",
"    ). For example, suppose you were attempting to interpret the significance of a CA125 value of 80 in a 46-year-old woman with an ovarian cyst. If 70 percent of patients with ovarian cancer have a CA125 at this level, but 35 percent of patients with benign cysts have a CA125 at the same level, then the positive likelihood ratio would only be two (ie,",
"    <span class=\"nowrap\">",
"     0.70/0.35).",
"    </span>",
"    This would be considered a poor test for diagnosis of cancer.",
"   </p>",
"   <p>",
"    Although likelihood ratios are independent of disease prevalence, their direct validity is only within the original study population. They are generalizable to other populations to the extent that:",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      The test can be reliably performed with minimal interobserver and intraobserver variation.",
"     </li>",
"     <li>",
"      The study population(s) from which the values were derived was adequate in size and composition of normal and diseased phenotypes.",
"     </li>",
"     <li>",
"      An appropriate reference-standard was used.",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    If a diagnostic test was investigated in a narrow subpopulation or the test relied heavily on user",
"    <span class=\"nowrap\">",
"     skill/interpretation,",
"    </span>",
"    then the sensitivity, specificity, and likelihood ratios reported in the study may not be generalizable outside the original research population. In other words, the test performance parameters may have internal validity, but not external validity.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H16\">",
"    <span class=\"h1\">",
"     HOW WELL DOES THE TEST PERFORM IN SPECIFIC POPULATIONS?",
"    </span>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H17\">",
"    <span class=\"h2\">",
"     Disease prevalence",
"    </span>",
"    &nbsp;&mdash;&nbsp;If the sensitivity, specificity, and likelihood ratios are well defined, the penultimate factor determining the utility of a test is disease prevalence (",
"    <a class=\"calc calc_professional\" href=\"UTD.htm?35/55/36722?source=see_link\">",
"     calculator 1",
"    </a>",
"    and",
"    <a class=\"calc calc_professional\" href=\"UTD.htm?10/3/10291?source=see_link\">",
"     calculator 2",
"    </a>",
"    ). The usefulness of a positive test decreases as disease prevalence decreases. This concept is the basis of predictive values or post-test probabilities.",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      Positive predictive value (PPV) refers to the probability that a positive test correctly identifies an individual who actually has the disease. It is computed from two-by-two tables: true positives",
"      <span class=\"nowrap\">",
"       /(true",
"      </span>",
"      positives + false positives) (",
"      <a class=\"graphic graphic_table graphicRef77832 \" href=\"UTD.htm?7/50/7979\">",
"       table 4",
"      </a>",
"      ).",
"     </li>",
"     <li>",
"      Negative predictive value (NPV) refers to the probability that a negative test correctly identifies an individual who does not have the disease. It is computed from two-by-two tables: true negatives",
"      <span class=\"nowrap\">",
"       /(false",
"      </span>",
"      negatives + true negatives) (",
"      <a class=\"graphic graphic_table graphicRef77832 \" href=\"UTD.htm?7/50/7979\">",
"       table 4",
"      </a>",
"      ).",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    For example, assuming a constant sensitivity and specificity, the PPV and NPV for a disease with prevalence of 10, 1, or 0.1 percent are shown in a table (",
"    <a class=\"graphic graphic_table graphicRef51763 \" href=\"UTD.htm?28/26/29100\">",
"     table 5",
"    </a>",
"    ). This example illustrates how a positive result from the same test with near-perfect sensitivity (99 percent) and high specificity (90 percent) may have completely different significance depending upon the baseline prevalence of disease in the population. When applied to a population in which the disease is common (prevalence = 10 percent), the positive predictive value is 53 percent. By comparison, when applied to a different population in which the disease is uncommon (prevalence = 0.1 percent), the positive predictive value is only 1 percent; thus 99 percent of all individuals who test positive are actually free of the disease. All the test has accomplished in this population is to slightly upgrade the probability of disease from extremely unlikely (0.1 percent) to very unlikely (1 percent), and in the process subjected numerous individuals without the disease to further testing. A second example, using a different combination of sensitivity, specificity, and prevalence, is illustrated in a figure (",
"    <a class=\"graphic graphic_figure graphicRef68072 \" href=\"UTD.htm?23/36/24142\">",
"     figure 3",
"    </a>",
"    ).",
"   </p>",
"   <p>",
"    A clinical example of the importance of prevalence on test utility is in fetal fibronectin testing for prediction of preterm delivery. A systematic review reported the overall sensitivity and specificity of this test (in symptomatic and asymptomatic patients) for delivery before 34 weeks was 52 and 85 percent, respectively [",
"    <a class=\"abstract\" href=\"UTD.htm?9/52/10054/abstract/2\">",
"     2",
"    </a>",
"    ]. If the prevalence of preterm birth in an asymptomatic low risk population is 10 percent, then PPV of a positive fetal fibronectin result would be 28 percent, whereas in a high risk symptomatic population with a prevalence of preterm birth of 50 percent, the PPV would be 78 percent.",
"   </p>",
"   <p>",
"    The internet site (",
"    <a class=\"external\" href=\"file://faculty.vassar.edu/lowry/clin1.html\">",
"     file://faculty.vassar.edu/lowry/clin1.html",
"    </a>",
"    ) allows one to perform calculations from entered data and thereby illustrate the relationship between pretest probabilities (prevalence), likelihood ratios and post-test probabilities (predictive values).",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H18\">",
"    <span class=\"h1\">",
"     WHAT IS THE BALANCE BETWEEN COST OF THE DISEASE AND COST OF THE TEST?",
"    </span>",
"   </p>",
"   <p>",
"    The final judgment involved in considering the value of a test is the balance between cost of the disease and cost of the test. These costs involve charges to an individual, to an insurer, to an institution, or to society. We live in a world with finite resources, but burgeoning demand for better health care, more accurate tests, and rapid diagnosis. Cost is often the determinant in deciding when, where, and how a diagnostic test is utilized.",
"   </p>",
"   <p>",
"    A society and its health care payers and providers might be willing to accept low positive predictive values in return for saved lives for a rare disease that is universally fatal, but easily curable. By comparison, an accurate but extremely expensive test might be less desirable than one of lesser quality if the consequences of misdiagnosis are not serious.",
"   </p>",
"   <p>",
"    Cost analysis involves direct monetary costs, as well as all of the indirect costs of disease, testing, and misdiagnosis. Unfortunately, these costs are often rough estimates, which hampers the accuracy of this type of analysis. In addition, cost studies typically suffer from poor external validity; values used in the analysis may not be readily generalizable to other areas of the country, other health systems, or other countries. Finally, because markets are never static, costs often change, with the potential to alter or entirely invalidate the thrust of the analysis.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H826056464\">",
"    <span class=\"h1\">",
"     SUMMARY AND RECOMMENDATIONS",
"    </span>",
"    &nbsp;&mdash;&nbsp;It is not an easy task to evaluate fully the utility of a diagnostic test; many variables must be considered. This topic review attempts to provide a framework from which any test may be objectively and systematically analyzed. The seven steps outlined need not be followed in exact order. For example, one may wish to consider cost and predictive values before delving deeper into the validity of applying the test to a specific population. Nevertheless, careful consideration of all seven questions is important in making a final decision regarding the utility of a diagnostic test.",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      In order to determine the reliability of a test, it is helpful to assess the extent to which the test is accurate, precise, and user dependent. (See",
"      <a class=\"local\" href=\"#H2\">",
"       'Can the test be performed reliably?'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      A test should be evaluated on a broad spectrum of patients with and without the disorder in question to maximize generalizability. (See",
"      <a class=\"local\" href=\"#H5\">",
"       'Was the test evaluated on an appropriate population?'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      A reference-standard allows unambiguous identification of diseased and nondiseased patients. However, in the real world, reference-standards often involve some degree of error or user-dependence. (See",
"      <a class=\"local\" href=\"#H8\">",
"       'Was an appropriate reference-standard used?'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      A cut-off value must be chosen to separate normal from abnormal. Selecting this value virtually always involves balancing sensitivity and specificity, although the actual value may be arbitrary (",
"      <a class=\"graphic graphic_figure graphicRef73854 \" href=\"UTD.htm?9/2/9263\">",
"       figure 1",
"      </a>",
"      ). (See",
"      <a class=\"local\" href=\"#H11\">",
"       'Was an appropriate cut-off value chosen to optimize sensitivity and specificity?'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      Positive and negative likelihood ratios which, like sensitivity and specificity, are independent of disease prevalence. In most instances one can evaluate likelihood ratios across a range of possible values, unlike sensitivity and specificity which determine the crude presence and absence of a condition (",
"      <a class=\"graphic graphic_table graphicRef69816 \" href=\"UTD.htm?2/42/2731\">",
"       table 3",
"      </a>",
"      ). (See",
"      <a class=\"local\" href=\"#H15\">",
"       'What are the positive and negative likelihood ratios?'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      If the sensitivity, specificity, and likelihood ratios are well defined, the penultimate factor determining the utility of a test is disease prevalence (",
"      <a class=\"calc calc_professional\" href=\"UTD.htm?35/55/36722?source=see_link\">",
"       calculator 1",
"      </a>",
"      and",
"      <a class=\"calc calc_professional\" href=\"UTD.htm?10/3/10291?source=see_link\">",
"       calculator 2",
"      </a>",
"      ). The usefulness of a positive test decreases as disease prevalence decreases. This concept is the basis of predictive values or post-test probabilities. (See",
"      <a class=\"local\" href=\"#H16\">",
"       'How well does the test perform in specific populations?'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      The final judgment involved in considering the value of a test is the balance between cost of the disease and cost of the test. These costs involve charges to an individual, to an insurer, to an institution, or to society. Cost is often the determinant in deciding when, where, and how a diagnostic test is utilized. (See",
"      <a class=\"local\" href=\"#H18\">",
"       'What is the balance between cost of the disease and cost of the test?'",
"      </a>",
"      above.)",
"     </li>",
"    </ul>",
"   </p>",
"  </div>",
"  <div id=\"topicAgreement\">",
"   Use of UpToDate is subject to the",
"   <a class=\"licenseLink\" href=\"./license\" id=\"sla_in_page\" target=\"_blank\">",
"    Subscription and License Agreement",
"   </a>",
"   .",
"  </div>",
"  <div class=\"headingAnchor\" id=\"references\">",
"   <h1>",
"    REFERENCES",
"   </h1>",
"   <ol id=\"reference\">",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?9/52/10054/abstract/1\">",
"      Ewigman BG, Crane JP, Frigoletto FD, et al. Effect of prenatal ultrasound screening on perinatal outcome. RADIUS Study Group. N Engl J Med 1993; 329:821.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?9/52/10054/abstract/2\">",
"      Leitich H, Kaider A. Fetal fibronectin--how useful is it in the prediction of preterm birth? BJOG 2003; 110 Suppl 20:66.",
"     </a>",
"    </li>",
"   </ol>",
"  </div>",
"  <div id=\"topicVersionRevision\">",
"   Topic 2769 Version 6.0",
"  </div>",
" </div>",
" <div id=\"footer\">",
"  <div id=\"supportFooter\">",
"   <span class=\"sfInfo\">",
"    &copy; 2013 UpToDate, Inc. All rights reserved.",
"   </span>",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <a class=\"licenseLink\" href=\"./license\" id=\"sla_footer\">",
"    Subscription and License Agreement",
"   </a>",
"   <span class=\"sfInfo\">",
"    <span class=\"pipeSpace\">",
"     |",
"    </span>",
"    Release: 21.6- C21.56",
"   </span>",
"   <br/>",
"   <span class=\"sfInfo\">",
"    Licensed to:",
"    <span class=\"emphasis\">",
"     AsanBook Dig. Med. Lib.",
"    </span>",
"   </span>",
"   <span class=\"sfInfo\">",
"    <span class=\"pipeSpace\">",
"     |",
"    </span>",
"    Support Tag: [1004-122.72.76.133-9F69235DB9-S244013.14]",
"    <br/>",
"   </span>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f9_52_10054=[""].join("\n");
var outline_f9_52_10054=[" <div id=\"toggleOutline\">",
"  <a href=\"#\" title=\"Collapse Topic Outline\">",
"   <img alt=\"\" src=\"./../images/orange_arrow_left.myextg\"/>",
"  </a>",
" </div>",
" <div id=\"innerOutline\">",
"  <h1>",
"   TOPIC OUTLINE",
"  </h1>",
"  <div id=\"outline\">",
"   <ul>",
"    <li>",
"     <a class=\"sr_button\" href=\"#H826056464\" id=\"summRecButton\">",
"      <span>",
"       SUMMARY &amp; RECOMMENDATIONS",
"      </span>",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H1\">",
"      INTRODUCTION",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H2\">",
"      CAN THE TEST BE PERFORMED RELIABLY?",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H3\">",
"      Accuracy and precision",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H4\">",
"      Expertise",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H5\">",
"      WAS THE TEST EVALUATED ON AN APPROPRIATE POPULATION?",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H6\">",
"      Population",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H7\">",
"      Sample size",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H8\">",
"      WAS AN APPROPRIATE REFERENCE-STANDARD USED?",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H9\">",
"      Reference-standards",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H10\">",
"      Defining normal",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H11\">",
"      WAS AN APPROPRIATE CUT-OFF VALUE CHOSEN TO OPTIMIZE SENSITIVITY AND SPECIFICITY?",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H12\">",
"      Balancing sensitivity and specificity",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H13\">",
"      Two by two tables",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H14\">",
"      Receiver operating characteristic curves",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H15\">",
"      WHAT ARE THE POSITIVE AND NEGATIVE LIKELIHOOD RATIOS?",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H16\">",
"      HOW WELL DOES THE TEST PERFORM IN SPECIFIC POPULATIONS?",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H17\">",
"      Disease prevalence",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H18\">",
"      WHAT IS THE BALANCE BETWEEN COST OF THE DISEASE AND COST OF THE TEST?",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H826056464\">",
"      SUMMARY AND RECOMMENDATIONS",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a href=\"#references\">",
"      REFERENCES",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
"  <h1>",
"   <div class=\"openRelatedGraphics\" id=\"PC/2769\" rel=\"outline_link\">",
"    GRAPHICS",
"    <a class=\"graphics_icon\" href=\"#\" title=\"View All Related Graphics\">",
"     View All",
"    </a>",
"   </div>",
"  </h1>",
"  <div id=\"relatedGraphics\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <div class=\"openRelatedGraphics\" id=\"PC/2769|FIG\">",
"      <a href=\"#\" title=\"FIGURES\">",
"       FIGURES",
"      </a>",
"     </div>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_figure\" href=\"UTD.htm?9/2/9263\" title=\"figure 1\">",
"      Cut off value",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_figure\" href=\"UTD.htm?31/56/32653\" title=\"figure 2\">",
"      Sample ROC curve",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_figure\" href=\"UTD.htm?23/36/24142\" title=\"figure 3\">",
"      Prevalence on PPV and NPV",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <div class=\"openRelatedGraphics\" id=\"PC/2769|TAB\">",
"      <a href=\"#\" title=\"TABLES\">",
"       TABLES",
"      </a>",
"     </div>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_table\" href=\"UTD.htm?0/18/299\" title=\"table 1\">",
"      Definition of accuracy",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_table\" href=\"UTD.htm?2/23/2427\" title=\"table 2\">",
"      Two by two table",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_table\" href=\"UTD.htm?2/42/2731\" title=\"table 3\">",
"      Positive vs neg likelihood",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_table\" href=\"UTD.htm?7/50/7979\" title=\"table 4\">",
"      Sensitivity specificity PPV NPV",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_table\" href=\"UTD.htm?28/26/29100\" title=\"table 5\">",
"      Prevalence vs PPV and NPV",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
"  <h1>",
"   CALCULATORS",
"  </h1>",
"  <div id=\"relatedCalculators\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <a class=\"calc calc_professional\" href=\"UTD.htm?35/55/36722?source=related_link\" title=\"calculator 1\">",
"      Calculator: Post Test Probability from Pre Test Probability, Sensitivity and Specificity",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"calc calc_professional\" href=\"UTD.htm?10/3/10291?source=related_link\" title=\"calculator 2\">",
"      Calculator: Post-test probability from likelihood ratios and multiple test results",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
"  <h1>",
"   RELATED TOPICS",
"  </h1>",
"  <div id=\"relatedTopics\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?33/46/34537?source=related_link\">",
"      Evidence-based approach to prevention",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?22/18/22823?source=related_link\">",
"      Glossary of common biostatistical and epidemiological terms",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?8/19/8500?source=related_link\">",
"      Proof, p-values, and hypothesis testing",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
" </div>"].join("\n");
var title_f9_52_10055="Follow-up surveillance during and after treatment for prostate cancer";
var content_f9_52_10055=[" <noscript>",
"  <div id=\"javascriptDisabled\">",
"   It seems to us that you have your JavaScript turned off on your browser. JavaScript is required in order for our site to behave correctly.  Please enable your JavaScript to continue use our site.",
"  </div>",
" </noscript>",
" <div id=\"printHeader\">",
"  <div id=\"printHeaderLogo\">",
"   <img alt=\"UpToDate\" src=\"./../images/UTD2_masthead.myextg\">",
"    <img align=\"right\" alt=\"Wolters Kluwer Health\" height=\"40\" src=\"./../images/logoWKH.myextg\" width=\"175\">",
"     <br>",
"      <div id=\"printHeaderText\">",
"       Official reprint from  UpToDate",
"       <sup>",
"        &reg;",
"       </sup>",
"       <br>",
"        <a href=\"file://www.uptodate.com\">",
"         www.uptodate.com",
"        </a>",
"        &copy;2013 UpToDate",
"        <sup>",
"         &reg;",
"        </sup>",
"       </br>",
"      </div>",
"     </br>",
"    </img>",
"   </img>",
"  </div>",
"  <div id=\"printHeaderLinks\">",
"   <a class=\"TOPIC\" href=\"#\" id=\"printHeaderPrint\" rel=\"3\" title=\"Click here to print\">",
"    Print",
"   </a>",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <a href=\"#\" id=\"printHeaderBack\" title=\"Back to normal view\">",
"    Back",
"   </a>",
"  </div>",
" </div>",
" <!-- TC:TOPIC_PAGE -->",
" <div id=\"topicContent\">",
"  <div id=\"topicTitle\">",
"   Follow-up surveillance during and after treatment for prostate cancer",
"  </div>",
"  <div id=\"topicContributors\">",
"   <div>",
"    <a id=\"authors\">",
"    </a>",
"    <a class=\"contributor contributor_credentials contributorType\" href=\"UTD.htm?9/52/10055/contributors\">",
"     Author",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"UTD.htm?9/52/10055/contributors\">",
"     David F Penson, MD, MPH",
"    </a>",
"    <br/>",
"   </div>",
"   <div>",
"    <a class=\"contributor contributor_credentials contributorType\" href=\"UTD.htm?9/52/10055/contributors\">",
"     Section Editors",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"UTD.htm?9/52/10055/contributors\">",
"     Nicholas Vogelzang, MD",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"UTD.htm?9/52/10055/contributors\">",
"     W Robert Lee, MD, MS, MEd",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"UTD.htm?9/52/10055/contributors\">",
"     Jerome P Richie, MD, FACS",
"    </a>",
"    <br/>",
"   </div>",
"   <div>",
"    <a class=\"contributor contributor_credentials contributorType\" href=\"UTD.htm?9/52/10055/contributors\">",
"     Deputy Editor",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"UTD.htm?9/52/10055/contributors\">",
"     Michael E Ross, MD",
"    </a>",
"    <br/>",
"   </div>",
"  </div>",
"  <div id=\"disclosures\">",
"   <a href=\"UTD.htm?9/52/10055/contributor-disclosure\" target=\"_blank\">",
"    Disclosures",
"   </a>",
"  </div>",
"  <div id=\"reviewProcess\">",
"   <span>",
"    All topics are updated as new evidence becomes available and our",
"   </span>",
"   <a href=\"/home/editorial-policy\" target=\"_blank\">",
"    peer review process",
"   </a>",
"   <span>",
"    is complete.",
"   </span>",
"  </div>",
"  <div id=\"literatureReviewDate\">",
"   <span class=\"emphasis\">",
"    Literature review current through:",
"   </span>",
"   Oct 2013.",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <span class=\"emphasis\">",
"    This topic last updated:",
"   </span>",
"   Jan 2, 2013.",
"  </div>",
"  <div id=\"topicText\">",
"   <p class=\"headingAnchor\" id=\"H7448935\">",
"    <span class=\"h1\">",
"     INTRODUCTION",
"    </span>",
"    &nbsp;&mdash;&nbsp;The widespread availability of highly sensitive testing for serum prostate specific antigen (PSA) has led to major shifts in the epidemiology of prostate cancer. These shifts have been manifested by an increased number of cases, a younger age, and an earlier clinical stage at diagnosis.",
"   </p>",
"   <p>",
"    Thus, clinicians are managing an increasing number of men with localized prostate cancer who have received definitive treatment of their primary tumor (generally with radical prostatectomy or radiation therapy [RT]). These men require follow-up to detect local recurrence or disseminated disease, as well as for complications of their treatment. (See",
"    <a class=\"local\" href=\"#H7449313\">",
"     'Localized prostate cancer'",
"    </a>",
"    below and",
"    <a class=\"medical medical_review\" href=\"UTD.htm?16/36/16969?source=see_link\">",
"     \"Initial approach to low-risk clinically localized prostate cancer\"",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"UTD.htm?21/26/21930?source=see_link\">",
"     \"Initial management of regionally localized intermediate and high risk prostate cancer\"",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    In addition, men who have metastatic disease require follow-up to assess the efficacy of their treatment and identify patients who might benefit from alternative treatments. (See",
"    <a class=\"local\" href=\"#H11088148\">",
"     'Metastatic prostate cancer'",
"    </a>",
"    below and",
"    <a class=\"medical medical_review\" href=\"UTD.htm?10/12/10442?source=see_link\">",
"     \"Overview of the treatment of disseminated prostate cancer\"",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    The follow-up surveillance for men who have received definitive treatment for prostate cancer as well as those being treated for metastatic disease is discussed in this topic. The natural history and follow-up of patients who have a rising serum PSA following definitive treatment and the follow-up of those being managed initial with active surveillance are discussed separately. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?12/62/13288?source=see_link&amp;anchor=H6#H6\">",
"     \"Active surveillance for men with early prostate cancer\", section on 'Surveillance strategy'",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"UTD.htm?20/31/20983?source=see_link\">",
"     \"Rising serum PSA following local therapy for prostate cancer: Diagnostic evaluation\"",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H7449313\">",
"    <span class=\"h1\">",
"     LOCALIZED PROSTATE CANCER",
"    </span>",
"    &nbsp;&mdash;&nbsp;Most men with newly diagnosed prostate cancer have localized disease and undergo definitive therapy with curative intent (radical prostatectomy, external beam RT, brachytherapy). A subset of carefully selected patients with low risk disease may be managed with active surveillance, with definitive therapy deferred until there is evidence of progressive disease. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?16/36/16969?source=see_link\">",
"     \"Initial approach to low-risk clinically localized prostate cancer\"",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    For patients who do develop either a local or disseminated recurrence, disease generally is detected biochemically by a rise in the serum PSA, a highly specific marker for prostate tissue. The development of an overt local recurrence or distant metastases usually occurs significantly later than a rise in the serum PSA. (See",
"    <a class=\"local\" href=\"#H11086781\">",
"     'Serum PSA'",
"    </a>",
"    below and",
"    <a class=\"medical medical_review\" href=\"UTD.htm?40/41/41622?source=see_link&amp;anchor=H19253279#H19253279\">",
"     \"Bone metastases in advanced prostate cancer: Clinical manifestations and diagnosis\", section on 'Clinical manifestations'",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    There are no randomized trials that have defined the optimal follow-up strategy for men following their initial treatment for localized prostate cancer. Regular monitoring of the serum PSA is indicated following definitive therapy, with possible early intervention if a recurrence is detected, since many recurrences following initial treatment can be successfully treated. The natural history of many prostate cancers from the time from biochemical recurrence to symptomatic disease or death is often prolonged and, as such, not all biochemical failures require aggressive treatment. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?32/48/33544?source=see_link&amp;anchor=H10#H10\">",
"     \"Rising serum PSA following local therapy for prostate cancer: Definition, natural history, and risk stratification\", section on 'Natural history'",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    When considering surveillance strategies for prostate cancer, the impact of therapy for recurrent disease on both overall survival and quality of life should be discussed with the patient. The patient's individual preferences and overall health status are of primary importance in choosing a surveillance strategy after treatment for localized prostate cancer. If a man does not desire additional treatment or if his life expectancy is limited due to comorbid conditions, early detection of recurrent disease would only cause psychological distress and could detract from quality of life, while not affecting overall survival.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H11086744\">",
"    <span class=\"h2\">",
"     Surveillance strategies",
"    </span>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H11086752\">",
"    <span class=\"h3\">",
"     History and physical examination",
"    </span>",
"    &nbsp;&mdash;&nbsp;The majority of recurrences following radical prostatectomy or RT for localized prostate cancer are asymptomatic and manifested only by a rising serum PSA. While regular physician visits may serve to reassure the patient, they are of questionable utility in detecting recurrent tumor. Nevertheless, periodic evaluation by a health care provider is important to evaluate potential complications of therapy and for overall health care. The value of serial digital rectal exams in this setting is unclear, particularly after surgery.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H11086781\">",
"    <span class=\"h3\">",
"     Serum PSA",
"    </span>",
"    &nbsp;&mdash;&nbsp;Serum PSA is the mainstay of surveillance testing in men who have undergone therapy for localized prostate cancer. There are no clinical trials that define the optimal frequency of measuring the serum PSA. Guidelines from the NCCN recommend that the serum PSA be monitored every 6 to 12 months for the first five years, and annually thereafter [",
"    <a class=\"abstract\" href=\"UTD.htm?9/52/10055/abstract/1\">",
"     1",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    Serum PSA is a sensitive marker for recurrent prostate adenocarcinoma in this setting and is elevated in 95 percent of men with recurrent disease. While the use of PSA for cancer screening is controversial, there is little debate that it is an excellent tumor marker in men with an established diagnosis of prostate cancer.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H11086797\">",
"    <span class=\"h4\">",
"     Definition",
"    </span>",
"    &nbsp;&mdash;&nbsp;The definition of a PSA recurrence depends upon the initial treatment:",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      Surgery &ndash; All prostate tissue is removed during a successful radical prostatectomy. Thus, any detectable PSA in the serum using the standard immunoassay (the typical limit of detection is 0.1",
"      <span class=\"nowrap\">",
"       ng/mL)",
"      </span>",
"      theoretically indicates remaining prostate tissue, and presumably represents persistent or recurrent disease. Ultrasensitive PSA assays may detect lower levels of PSA, but the use of lower levels to base treatment decisions is not recommended. (See",
"      <a class=\"medical medical_review\" href=\"UTD.htm?32/48/33544?source=see_link&amp;anchor=H5#H5\">",
"       \"Rising serum PSA following local therapy for prostate cancer: Definition, natural history, and risk stratification\", section on 'Radical prostatectomy'",
"      </a>",
"      .)",
"     </li>",
"     <li>",
"      Radiation therapy &ndash; The definition of a biochemical failure following RT is more complicated, since there is benign prostate tissue remaining after RT. The American Society for Radiation Oncology (ASTRO) has established guidelines to define PSA recurrence following RT. The 1996 ASTRO and 2005 Phoenix criteria are presented separately. (See",
"      <a class=\"medical medical_review\" href=\"UTD.htm?32/48/33544?source=see_link&amp;anchor=H6#H6\">",
"       \"Rising serum PSA following local therapy for prostate cancer: Definition, natural history, and risk stratification\", section on 'Radiation therapy'",
"      </a>",
"      .)",
"      <br/>",
"      <br/>",
"      The interpretation of an increase in serum PSA following RT is further complicated by the observation that serum PSA levels can fluctuate (\"bounce\") significantly after RT (particularly brachytherapy), before returning toward the posttreatment nadir. Thus increases in PSA must be interpreted with caution and do not necessarily indicate recurrence. The PSA bounce phenomenon is discussed separately. (See",
"      <a class=\"medical medical_review\" href=\"UTD.htm?32/48/33544?source=see_link&amp;anchor=H9#H9\">",
"       \"Rising serum PSA following local therapy for prostate cancer: Definition, natural history, and risk stratification\", section on 'PSA bounce'",
"      </a>",
"      .)",
"     </li>",
"    </ul>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H11086864\">",
"    <span class=\"h4\">",
"     Natural history of PSA-only recurrence",
"    </span>",
"    &nbsp;&mdash;&nbsp;The natural history of prostate cancer disease in men with a PSA-only (biochemical) recurrence is often prolonged, and a biochemical recurrence alone is not necessarily an indication for therapy. Because PSA is a specific tumor marker following local therapy, the absence of a rise in PSA can provide significant psychological reassurance. If \"PSA-only failure\" occurs, other clinical characteristics, such as time to biochemical recurrence or PSA doubling time, can be used to counsel patients and help guide treatment decisions regarding secondary therapy. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?32/48/33544?source=see_link&amp;anchor=H10#H10\">",
"     \"Rising serum PSA following local therapy for prostate cancer: Definition, natural history, and risk stratification\", section on 'Natural history'",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H11086884\">",
"    <span class=\"h3\">",
"     Digital rectal examination",
"    </span>",
"    &nbsp;&mdash;&nbsp;Digital rectal examination (DRE) is considered a regular component of the physical examination since the examination is inexpensive and has little or no risk associated with it. However, monitoring serum PSA rather than DRE is the \"gold standard\" for early detection of recurrence following definitive local therapy in patients with localized prostate cancer.",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      Following radical prostatectomy, the prostatic fossa should be empty on DRE. However, DRE is not sensitive enough to detect local recurrence early [",
"      <a class=\"abstract\" href=\"UTD.htm?9/52/10055/abstract/2-5\">",
"       2-5",
"      </a>",
"      ]. As an example, in a retrospective analysis of 501 men who had undergone radical prostatectomy, 72 had a rising PSA [",
"      <a class=\"abstract\" href=\"UTD.htm?9/52/10055/abstract/2\">",
"       2",
"      </a>",
"      ]. Only 4 of the 501 men (0.8 percent) had an abnormal DRE, and the PSA was elevated in each of these cases.",
"     </li>",
"     <li>",
"      In men treated initially with RT, the role of DRE is also unclear. DRE was used routinely prior to the availability of PSA, but this outcome is now seldom reported. However, the clinical significance of a change in DRE following RT is unclear. Furthermore, there is considerable intraobserver variability in assessing change in DRE, which limits the utility of this endpoint.",
"     </li>",
"    </ul>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H11087094\">",
"    <span class=\"h3\">",
"     Imaging studies",
"    </span>",
"    &nbsp;&mdash;&nbsp;Imaging studies do not have a routine role in surveillance for recurrence in patients who have undergone definitive therapy for localized prostate cancer in the absence of a rising serum PSA or specific symptoms. A variety of imaging studies are potentially useful in identifying the specific sites of recurrence in men with biochemical evidence of recurrence (rising PSA) or in evaluating symptoms suggestive of recurrent disease. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?20/31/20983?source=see_link\">",
"     \"Rising serum PSA following local therapy for prostate cancer: Diagnostic evaluation\"",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"UTD.htm?40/41/41622?source=see_link&amp;anchor=H538652451#H538652451\">",
"     \"Bone metastases in advanced prostate cancer: Clinical manifestations and diagnosis\", section on 'Diagnosis'",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H11087114\">",
"    <span class=\"h4\">",
"     Bone scan",
"    </span>",
"    &nbsp;&mdash;&nbsp;The technecium-99 radionuclide bone scan is a sensitive and reliable test for detecting the presence of skeletal metastases. However, bone scan has been replaced by PSA testing for the early detection of asymptomatic recurrence.",
"   </p>",
"   <p>",
"    In a retrospective study of 118 men who were followed with both serial bone scans and serum PSA after radical prostatectomy for localized disease, 75 percent had no evidence of disease by either study, 9 percent had an elevated PSA with a negative bone scan, and 9 percent had an abnormal bone scan, all of whom had an abnormal PSA [",
"    <a class=\"abstract\" href=\"UTD.htm?9/52/10055/abstract/6\">",
"     6",
"    </a>",
"    ]. The remaining seven patients with positive or indeterminate bone scans and negative PSA were determined to have recurrent disease.",
"   </p>",
"   <p>",
"    Bone scans are more likely to detect metastases when the serum PSA level is markedly elevated [",
"    <a class=\"abstract\" href=\"UTD.htm?9/52/10055/abstract/7\">",
"     7",
"    </a>",
"    ]. However, almost all men are evaluated when the serum PSA is much lower (often &lt;1.0",
"    <span class=\"nowrap\">",
"     ng/mL),",
"    </span>",
"    and bone scans are unnecessary unless there are symptoms referable to bone. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?20/31/20983?source=see_link&amp;anchor=H2#H2\">",
"     \"Rising serum PSA following local therapy for prostate cancer: Diagnostic evaluation\", section on 'Imaging studies'",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"UTD.htm?40/41/41622?source=see_link&amp;anchor=H538652451#H538652451\">",
"     \"Bone metastases in advanced prostate cancer: Clinical manifestations and diagnosis\", section on 'Diagnosis'",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H11087997\">",
"    <span class=\"h4\">",
"     Transrectal ultrasound",
"    </span>",
"    &nbsp;&mdash;&nbsp;There is no role for transrectal ultrasound (TRUS) of the prostate or prostatic fossa as a screening test for recurrence of localized prostate cancer. However, in men with a suspected biochemical recurrence and no evidence of systemic disease, TRUS with biopsy may be useful for confirming a local recurrence and in planning secondary treatment. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?20/31/20983?source=see_link&amp;anchor=H14#H14\">",
"     \"Rising serum PSA following local therapy for prostate cancer: Diagnostic evaluation\", section on 'Prostate biopsy'",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H11088017\">",
"    <span class=\"h4\">",
"     Pelvic CT",
"    </span>",
"    &nbsp;&mdash;&nbsp;Pelvic CT is not indicated for routine surveillance of men who have received definitive treatment for localized prostate cancer because of the limited sensitivity of CT to detect low volume recurrent disease [",
"    <a class=\"abstract\" href=\"UTD.htm?9/52/10055/abstract/8\">",
"     8",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H11088037\">",
"    <span class=\"h4\">",
"     Immunoscintography",
"    </span>",
"    &nbsp;&mdash;&nbsp;Immunoscintography using a radiolabeled monoclonal antibody imaging test may be helpful in determining the site of recurrence (local versus distant) in men with a PSA-only recurrence after radical prostatectomy. However, it has no utility in posttreatment surveillance. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?20/31/20983?source=see_link\">",
"     \"Rising serum PSA following local therapy for prostate cancer: Diagnostic evaluation\"",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H11088057\">",
"    <span class=\"h3\">",
"     Monitoring for complications of therapy",
"    </span>",
"    &nbsp;&mdash;&nbsp;One of the most important aspects of follow-up care for men who have undergone definitive local treatment for prostate cancer is the identification of therapy-related complications. The complications of both radical prostatectomy and radiation therapy are discussed elsewhere. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?16/36/16969?source=see_link\">",
"     \"Initial approach to low-risk clinically localized prostate cancer\"",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H1114410\">",
"    <span class=\"h2\">",
"     Treatment options following recurrence",
"    </span>",
"    &nbsp;&mdash;&nbsp;The detection of early asymptomatic recurrence following treatment for localized prostate cancer is useful only if it decreases morbidity or mortality. While data directly addressing this issue are lacking, there is some indirect evidence that early detection and treatment of a recurrence can improve outcomes. Treatment options are dictated by whether the recurrence is local or systemic, and whether the initial treatment was surgery or radiation.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H1114417\">",
"    <span class=\"h3\">",
"     Local recurrence following radical prostatectomy",
"    </span>",
"    &nbsp;&mdash;&nbsp;For men with a local recurrence following radical prostatectomy, radiation therapy (RT) is a reasonable option for salvage therapy in some cases. Salvage RT is most successful when the disease burden is low and when the relapse-free interval is 12 months or longer. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?20/31/20983?source=see_link\">",
"     \"Rising serum PSA following local therapy for prostate cancer: Diagnostic evaluation\"",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"UTD.htm?32/48/33544?source=see_link&amp;anchor=H10#H10\">",
"     \"Rising serum PSA following local therapy for prostate cancer: Definition, natural history, and risk stratification\", section on 'Natural history'",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    The role of salvage RT for the treatment of locally recurrent disease is discussed separately. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?38/0/38918?source=see_link\">",
"     \"Rising serum PSA following radical prostatectomy for prostate cancer: Salvage radiation therapy\"",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H1114424\">",
"    <span class=\"h3\">",
"     Local recurrence following RT",
"    </span>",
"    &nbsp;&mdash;&nbsp;Radical prostatectomy or ablation with cryotherapy may provide effective salvage therapy in appropriately selected cases for men with a local recurrence following RT. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?1/39/1656?source=see_link\">",
"     \"Rising serum PSA after radiation therapy for localized prostate cancer: Salvage local therapy\"",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H1114431\">",
"    <span class=\"h3\">",
"     Systemic recurrence",
"    </span>",
"    &nbsp;&mdash;&nbsp;For men with a systemic recurrence of prostate cancer or who are not candidates for salvage therapy because of age or comorbidity, systemic treatment may be indicated. However, the optimal timing of such treatment is uncertain, since treatment-related side effects can adversely affect quality of life (QOL). (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?29/48/30470?source=see_link\">",
"     \"Rising serum PSA after treatment for localized prostate cancer: Systemic therapy\"",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H11088148\">",
"    <span class=\"h1\">",
"     METASTATIC PROSTATE CANCER",
"    </span>",
"    &nbsp;&mdash;&nbsp;For men with metastatic prostate cancer, surveillance should be geared toward identifying signs and symptoms of disease progression as an indication of treatment failure. While there are no data to guide the frequency of clinician visits, it is common clinical practice to examine men at three to six month intervals, which often coincide with the time of administration of long-acting gonadotrophin agonist therapy [",
"    <a class=\"abstract\" href=\"UTD.htm?9/52/10055/abstract/1\">",
"     1",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    The onset of new symptoms during therapy may suggest the need for further diagnostic evaluation (eg, back pain with neurologic abnormalities due to spinal cord compression, bone pain due to pathologic fracture) or specific site-directed therapy (eg, radiation therapy to a painful bone metastasis). (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?40/41/41622?source=see_link&amp;anchor=H538652451#H538652451\">",
"     \"Bone metastases in advanced prostate cancer: Clinical manifestations and diagnosis\", section on 'Diagnosis'",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    Although serial PSA testing in men with metastatic disease has not been shown to prolong life expectancy, rising PSA is an indication of treatment failure, signaling the need to consider alternative therapies. Serial PSA testing can also provide reassurance to patients of a continuing response to treatment.",
"   </p>",
"   <p>",
"    Measurement of serum PSA in men with metastatic disease every three to six months is reasonable; more frequent evaluation, potentially including imaging studies, is indicated if the serum PSA begins to rise or the patient complains of symptoms. More frequent testing, as well as imaging studies, is often required for men participating in research protocols.",
"   </p>",
"   <p>",
"    Not all prostate cancers make significant amounts of PSA. Some of these are neuroendocrine tumors that may respond to cisplatin-based chemotherapy rather than hormonal manipulation. Others lack neuroendocrine features, but are poorly differentiated prostatic adenocarcinomas with a serum PSA &lt;10",
"    <span class=\"nowrap\">",
"     ng/mL.",
"    </span>",
"    Objective responses in such patients are difficult to measure but their response duration and median survival tend to be shorter after initial androgen ablation compared to men with PSA-producing prostate adenocarcinoma [",
"    <a class=\"abstract\" href=\"UTD.htm?9/52/10055/abstract/9\">",
"     9",
"    </a>",
"    ]. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?6/8/6280?source=see_link&amp;anchor=H19#H19\">",
"     \"Chemotherapy in castrate-resistant prostate cancer\", section on 'Prostate cancer with low PSA production'",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    An important component of follow-up in men with advanced prostate cancer is monitoring for the adverse effects of androgen ablation, including gynecomastia and loss of bone and lean muscle loss. Bisphosphonates such as",
"    <a class=\"drug drug_general\" href=\"UTD.htm?9/1/9241?source=see_link\">",
"     zoledronic acid",
"    </a>",
"    can prevent treatment-related bone loss in men who are receiving ADT, and can reduce the number of skeletal events and need for radiation therapy in men with bony metastases. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?21/30/21993?source=see_link&amp;anchor=H7#H7\">",
"     \"Side effects of androgen deprivation therapy\", section on 'Osteoporosis and bone fractures'",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"UTD.htm?36/8/36999?source=see_link&amp;anchor=H19250956#H19250956\">",
"     \"Management of bone metastases in advanced prostate cancer\", section on 'Osteoclast inhibition'",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H1114717\">",
"    <span class=\"h1\">",
"     RISING PSA AFTER INITIAL DEFINITIVE THERAPY",
"    </span>",
"    &nbsp;&mdash;&nbsp;For patients who have a rising serum PSA following initial definitive therapy with surgery or radiation therapy, the natural history of prostate cancer can be highly variable and does not necessarily constitute an indication for treatment. The roles of surveillance and evaluation in this setting are discussed separately. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?20/31/20983?source=see_link&amp;anchor=H15#H15\">",
"     \"Rising serum PSA following local therapy for prostate cancer: Diagnostic evaluation\", section on 'Imaging studies'",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"UTD.htm?32/48/33544?source=see_link&amp;anchor=H10#H10\">",
"     \"Rising serum PSA following local therapy for prostate cancer: Definition, natural history, and risk stratification\", section on 'Natural history'",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H1114681\">",
"    <span class=\"h1\">",
"     ACTIVE SURVEILLANCE FOR EARLY PROSTATE CANCER",
"    </span>",
"    &nbsp;&mdash;&nbsp;Active surveillance (expectant management) for men with prostate cancer involves the postponement of immediate therapy, with definitive treatment used if there is evidence that the patient is at increased risk for disease progression. Follow-up for patients being managed with active surveillance and the criteria for therapeutic intervention are discussed separately. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?12/62/13288?source=see_link&amp;anchor=H6#H6\">",
"     \"Active surveillance for men with early prostate cancer\", section on 'Surveillance strategy'",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"PATIENT_INFORMATION\">",
"    <span class=\"h1\">",
"     INFORMATION FOR PATIENTS",
"    </span>",
"    &nbsp;&mdash;&nbsp;UpToDate offers two types of patient education materials, &ldquo;The Basics&rdquo; and &ldquo;Beyond the Basics.&rdquo; The Basics patient education pieces are written in plain language, at the 5",
"    <sup>",
"     th",
"    </sup>",
"    to 6",
"    <sup>",
"     th",
"    </sup>",
"    grade reading level, and they answer the four or five key questions a patient might have about a given condition. These articles are best for patients who want a general overview and who prefer short, easy-to-read materials. Beyond the Basics patient education pieces are longer, more sophisticated, and more detailed. These articles are written at the 10",
"    <sup>",
"     th",
"    </sup>",
"    to 12",
"    <sup>",
"     th",
"    </sup>",
"    grade reading level and are best for patients who want in-depth information and are comfortable with some medical jargon.",
"   </p>",
"   <p>",
"    Here are the patient education articles that are relevant to this topic. We encourage you to print or e-mail these topics to your patients. (You can also locate patient education articles on a variety of subjects by searching on &ldquo;patient info&rdquo; and the keyword(s) of interest.)",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      Beyond the Basics (see",
"      <a class=\"medical medical_patient\" href=\"UTD.htm?39/39/40565?source=see_link\">",
"       \"Patient information: Prostate cancer treatment; stage I to III cancer (Beyond the Basics)\"",
"      </a>",
"      )",
"     </li>",
"    </ul>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H11088342\">",
"    <span class=\"h1\">",
"     SUMMARY",
"    </span>",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      There are no randomized trials that define the optimal surveillance strategy following definitive therapy for localized prostate cancer. The mainstay of follow-up in all patients is PSA testing and clinical evaluation. (See",
"      <a class=\"local\" href=\"#H11086744\">",
"       'Surveillance strategies'",
"      </a>",
"      above.)",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    <ul class=\"hyphen-block\">",
"     <li>",
"      For men who have undergone definitive therapy for localized disease, we suggest monitoring the serum PSA every 6 to 12 months for five years and then annually thereafter. (See",
"      <a class=\"local\" href=\"#H11086781\">",
"       'Serum PSA'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      Routine imaging procedures are not indicated in the absence of symptoms or a rising serum PSA. (See",
"      <a class=\"local\" href=\"#H11087094\">",
"       'Imaging studies'",
"      </a>",
"      above.)",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      In patients with metastatic prostate cancer, surveillance should be geared toward the detection of progressive disease and the side effects of long-term androgen deprivation therapy. A physician visit and serum PSA level every three to six months is reasonable. (See",
"      <a class=\"local\" href=\"#H11088148\">",
"       'Metastatic prostate cancer'",
"      </a>",
"      above.)",
"     </li>",
"    </ul>",
"   </p>",
"  </div>",
"  <div id=\"topicAgreement\">",
"   Use of UpToDate is subject to the",
"   <a class=\"licenseLink\" href=\"./license\" id=\"sla_in_page\" target=\"_blank\">",
"    Subscription and License Agreement",
"   </a>",
"   .",
"  </div>",
"  <div class=\"headingAnchor\" id=\"references\">",
"   <h1>",
"    REFERENCES",
"   </h1>",
"   <ol id=\"reference\">",
"    <li>",
"     National Comprehensive Cancer Network (NCCN) guidelines. Available at: www.nccn.org (Accessed on May 15, 2012).",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?9/52/10055/abstract/2\">",
"      Obek C, Neulander E, Sadek S, Soloway MS. Is there a role for digital rectal examination in the followup of patients after radical prostatectomy? J Urol 1999; 162:762.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?9/52/10055/abstract/3\">",
"      Pound CR, Christens-Barry OW, Gurganus RT, et al. Digital rectal examination and imaging studies are unnecessary in men with undetectable prostate specific antigen following radical prostatectomy. J Urol 1999; 162:1337.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?9/52/10055/abstract/4\">",
"      Johnstone PA, McFarland JT, Riffenburgh RH, Amling CL. Efficacy of digital rectal examination after radiotherapy for prostate cancer. J Urol 2001; 166:1684.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?9/52/10055/abstract/5\">",
"      Lightner DJ, Lange PH, Reddy PK, Moore L. Prostate specific antigen and local recurrence after radical prostatectomy. J Urol 1990; 144:921.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?9/52/10055/abstract/6\">",
"      Terris MK, Klonecke AS, McDougall IR, Stamey TA. Utilization of bone scans in conjunction with prostate-specific antigen levels in the surveillance for recurrence of adenocarcinoma after radical prostatectomy. J Nucl Med 1991; 32:1713.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?9/52/10055/abstract/7\">",
"      Cher ML, Bianco FJ Jr, Lam JS, et al. Limited role of radionuclide bone scintigraphy in patients with prostate specific antigen elevations after radical prostatectomy. J Urol 1998; 160:1387.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?9/52/10055/abstract/8\">",
"      Kr&auml;mer S, G&ouml;rich J, Gottfried HW, et al. Sensitivity of computed tomography in detecting local recurrence of prostatic carcinoma following radical prostatectomy. Br J Radiol 1997; 70:995.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?9/52/10055/abstract/9\">",
"      Birtle AJ, Freeman A, Masters JR, et al. Clinical features of patients who present with metastatic prostate carcinoma and serum prostate-specific antigen (PSA) levels &lt; 10 ng/mL: the \"PSA negative\" patients. Cancer 2003; 98:2362.",
"     </a>",
"    </li>",
"   </ol>",
"  </div>",
"  <div id=\"topicVersionRevision\">",
"   Topic 6928 Version 5.0",
"  </div>",
" </div>",
" <div id=\"footer\">",
"  <div id=\"supportFooter\">",
"   <span class=\"sfInfo\">",
"    &copy; 2013 UpToDate, Inc. All rights reserved.",
"   </span>",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <a class=\"licenseLink\" href=\"./license\" id=\"sla_footer\">",
"    Subscription and License Agreement",
"   </a>",
"   <span class=\"sfInfo\">",
"    <span class=\"pipeSpace\">",
"     |",
"    </span>",
"    Release: 21.6- C21.56",
"   </span>",
"   <br/>",
"   <span class=\"sfInfo\">",
"    Licensed to:",
"    <span class=\"emphasis\">",
"     AsanBook Dig. Med. Lib.",
"    </span>",
"   </span>",
"   <span class=\"sfInfo\">",
"    <span class=\"pipeSpace\">",
"     |",
"    </span>",
"    Support Tag: [1104-202.43.93.2-481E12C6DB-S244013.14]",
"    <br/>",
"   </span>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f9_52_10055=[""].join("\n");
var outline_f9_52_10055=[" <div id=\"toggleOutline\">",
"  <a href=\"#\" title=\"Collapse Topic Outline\">",
"   <img alt=\"\" src=\"./../images/orange_arrow_left.myextg\"/>",
"  </a>",
" </div>",
" <div id=\"innerOutline\">",
"  <h1>",
"   TOPIC OUTLINE",
"  </h1>",
"  <div id=\"outline\">",
"   <ul>",
"    <li>",
"     <a class=\"sr_button\" href=\"#H11088342\" id=\"summRecButton\">",
"      <span>",
"       SUMMARY",
"      </span>",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H7448935\">",
"      INTRODUCTION",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H7449313\">",
"      LOCALIZED PROSTATE CANCER",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H11086744\">",
"      Surveillance strategies",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H11086752\">",
"      - History and physical examination",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H11086781\">",
"      - Serum PSA",
"     </a>",
"    </li>",
"    <li class=\"bulletItem2\">",
"     <a class=\"outlineLink\" href=\"#H11086797\">",
"      Definition",
"     </a>",
"    </li>",
"    <li class=\"bulletItem2\">",
"     <a class=\"outlineLink\" href=\"#H11086864\">",
"      Natural history of PSA-only recurrence",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H11086884\">",
"      - Digital rectal examination",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H11087094\">",
"      - Imaging studies",
"     </a>",
"    </li>",
"    <li class=\"bulletItem2\">",
"     <a class=\"outlineLink\" href=\"#H11087114\">",
"      Bone scan",
"     </a>",
"    </li>",
"    <li class=\"bulletItem2\">",
"     <a class=\"outlineLink\" href=\"#H11087997\">",
"      Transrectal ultrasound",
"     </a>",
"    </li>",
"    <li class=\"bulletItem2\">",
"     <a class=\"outlineLink\" href=\"#H11088017\">",
"      Pelvic CT",
"     </a>",
"    </li>",
"    <li class=\"bulletItem2\">",
"     <a class=\"outlineLink\" href=\"#H11088037\">",
"      Immunoscintography",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H11088057\">",
"      - Monitoring for complications of therapy",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H1114410\">",
"      Treatment options following recurrence",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H1114417\">",
"      - Local recurrence following radical prostatectomy",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H1114424\">",
"      - Local recurrence following RT",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H1114431\">",
"      - Systemic recurrence",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H11088148\">",
"      METASTATIC PROSTATE CANCER",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H1114717\">",
"      RISING PSA AFTER INITIAL DEFINITIVE THERAPY",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H1114681\">",
"      ACTIVE SURVEILLANCE FOR EARLY PROSTATE CANCER",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#PATIENT_INFORMATION\">",
"      INFORMATION FOR PATIENTS",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H11088342\">",
"      SUMMARY",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a href=\"#references\">",
"      REFERENCES",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
"  <h1>",
"   RELATED TOPICS",
"  </h1>",
"  <div id=\"relatedTopics\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?12/62/13288?source=related_link\">",
"      Active surveillance for men with early prostate cancer",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?40/41/41622?source=related_link\">",
"      Bone metastases in advanced prostate cancer: Clinical manifestations and diagnosis",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?6/8/6280?source=related_link\">",
"      Chemotherapy in castrate-resistant prostate cancer",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?16/36/16969?source=related_link\">",
"      Initial approach to low-risk clinically localized prostate cancer",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?21/26/21930?source=related_link\">",
"      Initial management of regionally localized intermediate and high risk prostate cancer",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?36/8/36999?source=related_link\">",
"      Management of bone metastases in advanced prostate cancer",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?10/12/10442?source=related_link\">",
"      Overview of the treatment of disseminated prostate cancer",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_patient\" href=\"UTD.htm?39/39/40565?source=related_link\">",
"      Patient information: Prostate cancer treatment; stage I to III cancer (Beyond the Basics)",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?1/39/1656?source=related_link\">",
"      Rising serum PSA after radiation therapy for localized prostate cancer: Salvage local therapy",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?29/48/30470?source=related_link\">",
"      Rising serum PSA after treatment for localized prostate cancer: Systemic therapy",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?32/48/33544?source=related_link\">",
"      Rising serum PSA following local therapy for prostate cancer: Definition, natural history, and risk stratification",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?20/31/20983?source=related_link\">",
"      Rising serum PSA following local therapy for prostate cancer: Diagnostic evaluation",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?38/0/38918?source=related_link\">",
"      Rising serum PSA following radical prostatectomy for prostate cancer: Salvage radiation therapy",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?21/30/21993?source=related_link\">",
"      Side effects of androgen deprivation therapy",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
" </div>"].join("\n");
var title_f9_52_10056="Cervical spine joints and ligaments";
var content_f9_52_10056=[" <div id=\"graphicsToolbar\">",
"  <div id=\"graphicsCopy\">",
"   &copy;2013 UpToDate",
"   <sup>",
"    &reg;",
"   </sup>",
"  </div>",
"  <div id=\"graphicsLinks\">",
"   <a href=\"?imageKey=EM%2F79763&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=1\" onclick=\"\">",
"    <img alt=\"Print this page\" src=\"./../images/icn_print.myextg\" title=\"Print this page\"/>",
"   </a>",
"   <a class=\"icontxt textLink\" href=\"?imageKey=EM%2F79763&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=1\" onclick=\"\" title=\"Print this page\">",
"    Print",
"   </a>",
"   <a class=\"etacLink\" href=\"#\">",
"    <img alt=\"Email graphic(s)\" src=\"./../images/icn_email.myextg\" title=\"Email graphic(s)\"/>",
"   </a>",
"   <a class=\"icontxt textLink etacLink\" href=\"#\" title=\"Email graphic(s)\">",
"    Email",
"   </a>",
"  </div>",
" </div>",
" <div class=\"graphic\">",
"  <div class=\"figure\" style=\"width: 627px\">",
"   <div class=\"ttl\">",
"    Cervical spine joints and ligaments",
"   </div>",
"   <div class=\"cntnt\" style=\"width: 607px; height: 389px; background-image: url(data:image/jpeg;base64,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);\">",
"   </div>",
"   <div class=\"lgnd\">",
"    (A) The ligaments in the cervical region are shown. Superior to the prominent spinous process of C7 (vertebra prominens), the spinous processes are deeply placed and attached to an overlying nuchal ligament.",
"    <br>",
"     (B) The ligaments in the thoracic region are shown. The pedicles of the superior two vertebrae have been sawn through and the vertebral arches removed to reveal the posterior longitudinal ligament. Intertransverse, supraspinous, and interspinous ligaments are demonstrated in association with the vertebrae with intact vertebral arches.",
"     <div class=\"footnotes\">",
"     </div>",
"     <div class=\"reference\">",
"      Reproduced with permission from: Moore KL, Dalley AF. Clinically Oriented Anatomy, 5th ed, Lippincott Williams &amp; Wilkins, Philadelphia 2006. Copyright &copy; 2006 Lippincott Williams &amp; Wilkins.",
"     </div>",
"     <div class=\"contractual\">",
"      <br/>",
"      <a href=\"file://www.lww.com\">",
"       file://www.lww.com",
"      </a>",
"     </div>",
"    </br>",
"   </div>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f9_52_10056=[""].join("\n");
var outline_f9_52_10056=null;
var title_f9_52_10057="Lentigo maligna: Clinical manifestations, diagnosis, and management";
var content_f9_52_10057=[" <noscript>",
"  <div id=\"javascriptDisabled\">",
"   It seems to us that you have your JavaScript turned off on your browser. JavaScript is required in order for our site to behave correctly.  Please enable your JavaScript to continue use our site.",
"  </div>",
" </noscript>",
" <div id=\"printHeader\">",
"  <div id=\"printHeaderLogo\">",
"   <img alt=\"UpToDate\" src=\"./../images/wk_utd-rgb.myextg\" width=\"220px\">",
"   </img>",
"  </div>",
"  <div id=\"printHeaderText\">",
"   Official reprint from  UpToDate",
"   <sup>",
"    &reg;",
"   </sup>",
"   <a href=\"file://www.uptodate.com\">",
"    www.uptodate.com",
"   </a>",
"   <br>",
"    &copy;2013 UpToDate",
"    <sup>",
"     &reg;",
"    </sup>",
"   </br>",
"  </div>",
"  <div id=\"printHeaderLinks\">",
"   <a class=\"TOPIC\" href=\"#\" id=\"printHeaderPrint\" rel=\"3\" title=\"Click here to print\">",
"    Print",
"   </a>",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <a href=\"#\" id=\"printHeaderBack\" title=\"Back to normal view\">",
"    Back",
"   </a>",
"  </div>",
" </div>",
" <!-- TC:TOPIC_PAGE -->",
" <div id=\"topicContent\">",
"  <div id=\"topicTitle\">",
"   Lentigo maligna: Clinical manifestations, diagnosis, and management",
"  </div>",
"  <div id=\"topicContributors\">",
"   <div>",
"    <a id=\"authors\">",
"    </a>",
"    <a class=\"contributor contributor_credentials contributorType\" href=\"UTD.htm?9/52/10057/contributors\">",
"     Authors",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"UTD.htm?9/52/10057/contributors\">",
"     Arthur J Sober, MD",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"UTD.htm?9/52/10057/contributors\">",
"     Suzanne Olbricht, MD",
"    </a>",
"    <br/>",
"   </div>",
"   <div>",
"    <a class=\"contributor contributor_credentials contributorType\" href=\"UTD.htm?9/52/10057/contributors\">",
"     Section Editor",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"UTD.htm?9/52/10057/contributors\">",
"     Hensin Tsao, MD, PhD",
"    </a>",
"    <br/>",
"   </div>",
"   <div>",
"    <a class=\"contributor contributor_credentials contributorType\" href=\"UTD.htm?9/52/10057/contributors\">",
"     Deputy Editor",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"UTD.htm?9/52/10057/contributors\">",
"     Rosamaria Corona, MD, DSc",
"    </a>",
"    <br/>",
"   </div>",
"  </div>",
"  <div id=\"disclosures\">",
"   <a href=\"UTD.htm?9/52/10057/contributor-disclosure\" target=\"_blank\">",
"    Disclosures",
"   </a>",
"  </div>",
"  <div id=\"reviewProcess\">",
"   <span>",
"    All topics are updated as new evidence becomes available and our",
"   </span>",
"   <a href=\"/home/editorial-policy\" target=\"_blank\">",
"    peer review process",
"   </a>",
"   <span>",
"    is complete.",
"   </span>",
"  </div>",
"  <div id=\"literatureReviewDate\">",
"   <span class=\"emphasis\">",
"    Literature review current through:",
"   </span>",
"   Oct 2013.",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <span class=\"emphasis\">",
"    This topic last updated:",
"   </span>",
"   Mar 22, 2012.",
"  </div>",
"  <div id=\"topicText\">",
"   <p class=\"headingAnchor\" id=\"H244299021\">",
"    <span class=\"h1\">",
"     INTRODUCTION",
"    </span>",
"    &nbsp;&mdash;&nbsp;Lentigo maligna (LM) is a type of melanoma in situ that typically occurs in sun-damaged skin of the face and neck of older individuals [",
"    <a class=\"abstract\" href=\"UTD.htm?9/52/10057/abstract/1\">",
"     1",
"    </a>",
"    ]. LM evolves slowly over many years and may progress to invasive lentigo maligna melanoma. &rdquo;Hutchinson melanotic freckle&rdquo; and &ldquo;melanosis circumscripta precancerosa of Dubreuilh&rdquo; are synonyms of LM [",
"    <a class=\"abstract\" href=\"UTD.htm?9/52/10057/abstract/2,3\">",
"     2,3",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    This topic will discuss the clinical features, diagnosis, and treatment of lentigo maligna. Lentigo maligna melanoma is discussed separately. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?16/20/16713?source=see_link&amp;anchor=H81531027#H81531027\">",
"     \"Skin examination and clinical features of melanoma\", section on 'Lentigo maligna melanoma'",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"UTD.htm?21/31/22009?source=see_link&amp;anchor=H9#H9\">",
"     \"Pathologic characteristics of melanoma\", section on 'Lentigo maligna melanoma'",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H244299028\">",
"    <span class=\"h1\">",
"     EPIDEMIOLOGY AND NATURAL HISTORY",
"    </span>",
"    &nbsp;&mdash;&nbsp;Lentigo maligna (LM) usually occurs in older individuals with a peak incidence between 65 and 80 years [",
"    <a class=\"abstract\" href=\"UTD.htm?9/52/10057/abstract/4,5\">",
"     4,5",
"    </a>",
"    ]. The incidence of LM appears to be increasing in younger age groups. One study reported a 52 percent increase in the incidence rate of LM among men and women aged 45 to 64 years between 1990 and 2000 in the United States [",
"    <a class=\"abstract\" href=\"UTD.htm?9/52/10057/abstract/6\">",
"     6",
"    </a>",
"    ]. The risk of LM and lentigo maligna melanoma is higher in fair skinned individuals with markers of actinic skin damage (solar lentigines and actinic keratoses) and a history of nonmelanoma skin cancer [",
"    <a class=\"abstract\" href=\"UTD.htm?9/52/10057/abstract/7,8\">",
"     7,8",
"    </a>",
"    ]. &nbsp; &nbsp;",
"   </p>",
"   <p>",
"    LM is a slowly evolving lesion and is often diagnosed years or decades after its occurrence. In some lesions, partial central regression may occur while the peripheral margin continues to extend [",
"    <a class=\"abstract\" href=\"UTD.htm?9/52/10057/abstract/9,10\">",
"     9,10",
"    </a>",
"    ]. The time to progression of LM to invasive lentigo maligna melanoma ranges from less than 10 to more than 50 years [",
"    <a class=\"abstract\" href=\"UTD.htm?9/52/10057/abstract/9,11\">",
"     9,11",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    The lifetime risk of developing a lentigo maligna melanoma was estimated to be about 5 percent [",
"    <a class=\"abstract\" href=\"UTD.htm?9/52/10057/abstract/12\">",
"     12",
"    </a>",
"    ]. However, these data are old and in some series, up to 20 percent of patients undergoing excision for LM were found to have invasive disease [",
"    <a class=\"abstract\" href=\"UTD.htm?9/52/10057/abstract/13-16\">",
"     13-16",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H244299035\">",
"    <span class=\"h1\">",
"     CLINICAL FEATURES",
"    </span>",
"    &nbsp;&mdash;&nbsp;Lentigo maligna (LM) usually presents as an atypical pigmented macular lesion localized on severely sun-damaged skin of the head or neck. Clinical features of LM include (",
"    <a class=\"graphic graphic_picture graphicRef62052 graphicRef59591 graphicRef68787 \" href=\"UTD.htm?29/48/30474\">",
"     picture 1A-C",
"    </a>",
"    ):",
"   </p>",
"   <p>",
"    <ul class=\"bulletCompact-block\">",
"     <li>",
"      Irregular shape",
"     </li>",
"     <li>",
"      Variable color, from light brown or tan to dark brown, black, pink, red, or white",
"     </li>",
"     <li>",
"      Variable size, from less than one to several centimeters",
"     </li>",
"     <li>",
"      Non-scaly, smooth surface",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    Pink or white areas indicate inflammation or regression. The nose, cheeks, and ears are preferentially involved. Infrequently, LM occurs in non-head and neck locations such as the upper back, forearms, and legs. The surrounding skin typically shows evidence of chronic solar damage (solar elastosis, solar lentigines, or actinic keratoses). The borders may be ill-defined. Because of radial growth and regression phenomena, at times LM appears to be moving across the skin. Amelanotic LM is rare [",
"    <a class=\"abstract\" href=\"UTD.htm?9/52/10057/abstract/17,18\">",
"     17,18",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    The development of darker pigmentation, sharper borders, or elevated or nodular areas are clinical signs of progression to lentigo maligna melanoma (LMM) (",
"    <a class=\"graphic graphic_picture graphicRef62105 graphicRef57765 graphicRef74664 graphicRef54753 \" href=\"UTD.htm?40/29/41434\">",
"     picture 2A-D",
"    </a>",
"    ). Rarely, a desmoplastic melanoma may develop within an LM, presenting as a central firm thickening that is reminiscent of a scar. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?21/31/22009?source=see_link&amp;anchor=H14#H14\">",
"     \"Pathologic characteristics of melanoma\", section on 'Desmoplastic melanoma'",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H2436682\">",
"    <span class=\"h1\">",
"     DERMOSCOPIC FEATURES",
"    </span>",
"    &nbsp;&mdash;&nbsp;In skin areas other than face, the pigment network seen by dermoscopy is the main criterion in determining whether a pigmented lesion is melanocytic and evaluating whether it is benign or malignant [",
"    <a class=\"abstract\" href=\"UTD.htm?9/52/10057/abstract/19\">",
"     19",
"    </a>",
"    ]. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?37/57/38807?source=see_link\">",
"     \"Overview of dermoscopy\"",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"UTD.htm?13/11/13497?source=see_link\">",
"     \"Dermoscopic evaluation of skin lesions\"",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    Because of the unique features of facial skin (absence or flattening of rete ridges and increased number and prominence of hair follicles and sweat gland ostia), pigmented lesions occurring on the face do not show a pigment network when examined with a dermatoscope. In contrast, the distribution of the pigmentation around the prominent hair follicles forms a pseudonetwork that is seen in both melanocytic and nonmelanocytic lesions (eg, seborrheic keratoses) [",
"    <a class=\"abstract\" href=\"UTD.htm?9/52/10057/abstract/20\">",
"     20",
"    </a>",
"    ]. Since the pseudonetwork does not discriminate melanocytic from nonmelanocytic lesions, other dermoscopic criteria are used for the diagnosis of facial lesions. Horn pseudocysts, yellow opaque areas, fingerprint-like structures, moth-eaten pattern and jelly sign suggest solar lentigo or flat seborrheic keratosis, whereas the features most frequently seen in lentigo maligna (LM) and lentigo maligna melanoma include (",
"    <a class=\"graphic graphic_picture graphicRef63812 graphicRef68828 \" href=\"UTD.htm?31/62/32745\">",
"     picture 3A-B",
"    </a>",
"    ) [",
"    <a class=\"abstract\" href=\"UTD.htm?9/52/10057/abstract/21\">",
"     21",
"    </a>",
"    ]:",
"   </p>",
"   <p>",
"    <ul class=\"bulletCompact-block\">",
"     <li>",
"      Asymmetric pigmented follicular openings (atypical pseudonetwork)",
"     </li>",
"     <li>",
"      Dark rhomboidal structures",
"     </li>",
"     <li>",
"      Annular-granular pattern",
"     </li>",
"     <li>",
"      Gray pseudonetwork",
"     </li>",
"     <li>",
"      Slate gray areas",
"     </li>",
"     <li>",
"      Slate-grey dots and globules",
"     </li>",
"     <li>",
"      Streaks",
"     </li>",
"     <li>",
"      Black blotches",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    However, these features may be also seen in pigmented actinic keratosis, an unusual variant of actinic keratosis that is difficult to differentiate from LM on clinical and dermoscopic examination [",
"    <a class=\"abstract\" href=\"UTD.htm?9/52/10057/abstract/22\">",
"     22",
"    </a>",
"    ]. One study found that four dermoscopic features have high sensitivity and specificity (89 and 96 percent, respectively) for the diagnosis of lentigo maligna (LM) or lentigo maligna melanoma (LMM) (",
"    <a class=\"graphic graphic_picture graphicRef68828 graphicRef63812 \" href=\"UTD.htm?31/59/32697\">",
"     picture 3A-B",
"    </a>",
"    ) [",
"    <a class=\"abstract\" href=\"UTD.htm?9/52/10057/abstract/23\">",
"     23",
"    </a>",
"    ]:",
"   </p>",
"   <p>",
"    <ul class=\"bulletCompact-block\">",
"     <li>",
"      Asymmetrical pigmented follicular openings (atypical pseudonetwork)",
"     </li>",
"     <li>",
"      Dark rhomboidal structures",
"     </li>",
"     <li>",
"      Slate-gray globules",
"     </li>",
"     <li>",
"      Slate-gray dots",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    Although dermoscopy is helpful in the clinical diagnosis of benign facial lesions such as solar lentigines and seborrheic keratoses, biopsy and histopathology evaluation remain the gold standard for the diagnosis of LM or pigmented actinic keratosis. For large LM lesions requiring incisional biopsy for the initial diagnosis, dermoscopy may be useful in targeting areas with the most atypical findings for biopsy. (See",
"    <a class=\"local\" href=\"#H244299049\">",
"     'Biopsy and histologic examination'",
"    </a>",
"    below.)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H244299042\">",
"    <span class=\"h1\">",
"     HISTOPATHOLOGIC FEATURES",
"    </span>",
"    &nbsp;&mdash;&nbsp;Histologically, lentigo maligna (LM) is characterized by an increased number of atypical melanocytes, often spindle shaped, arranged in single cells or in small nests along the dermoepidermal junction, often extending into the infundibular portion of hair follicles (",
"    <a class=\"graphic graphic_picture graphicRef60447 graphicRef53790 \" href=\"UTD.htm?29/43/30394\">",
"     picture 4A-B",
"    </a>",
"    ) [",
"    <a class=\"abstract\" href=\"UTD.htm?9/52/10057/abstract/11\">",
"     11",
"    </a>",
"    ]. Melanocytic atypia ranges from near normal to multinucleated melanocytes or melanocytes with dendritic processes [",
"    <a class=\"abstract\" href=\"UTD.htm?9/52/10057/abstract/24\">",
"     24",
"    </a>",
"    ]. Cytoplasm retraction artifacts may be seen.",
"   </p>",
"   <p>",
"    Changes of chronic solar damage usually coexist, including elastosis, atrophy of the epidermis, effacement of rete ridges, and inflammatory dermal infiltrate [",
"    <a class=\"abstract\" href=\"UTD.htm?9/52/10057/abstract/11\">",
"     11",
"    </a>",
"    ]. Determining the histologically clear margin of LM is particularly difficult because the transition between LM and melanocytic hyperplasia of sun-damaged skin is often subtle. A biopsy specimen of normal appearing but sun-damaged skin, taken as a control, may aid in this distinction since it provides a reference for the background level of melanocytic hyperplasia in a given individual [",
"    <a class=\"abstract\" href=\"UTD.htm?9/52/10057/abstract/25\">",
"     25",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    Immunostaining with HMB-45 and MART-1 may be used to assist in diagnosis.",
"   </p>",
"   <p>",
"    Most pathologists consider all LM lesions without evidence of dermal invasion as melanoma in situ. In contrast, some pathologists distinguish a premalignant LM from true melanoma in situ of lentigo maligna type (LMMIS) on the basis of the growth pattern of atypical melanocytes [",
"    <a class=\"abstract\" href=\"UTD.htm?9/52/10057/abstract/26\">",
"     26",
"    </a>",
"    ]. LMMIS is characterized by pagetoid spread of atypical cells involving the full thickness of the epidermis, whereas LM shows a less continuous lentiginous proliferation, lower cellularity, and less than full thickness pagetoid spread of atypical melanocytes [",
"    <a class=\"abstract\" href=\"UTD.htm?9/52/10057/abstract/26\">",
"     26",
"    </a>",
"    ]. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?21/31/22009?source=see_link&amp;anchor=H4#H4\">",
"     \"Pathologic characteristics of melanoma\", section on 'In situ melanoma'",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    Regardless, the treatment approach is not influenced by the histologic interpretation of LM as a premalignant melanoma precursor or a true melanoma in situ, since complete surgical excision is recommended for all LM lesions. (See",
"    <a class=\"local\" href=\"#H244299056\">",
"     'Treatment'",
"    </a>",
"    below.)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H20157199\">",
"    <span class=\"h1\">",
"     DIAGNOSIS",
"    </span>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H1146732\">",
"    <span class=\"h2\">",
"     Clinical and dermoscopic examination",
"    </span>",
"    &nbsp;&mdash;&nbsp;The diagnosis of lentigo maligna (LM) is based upon clinical, dermoscopic, and histologic examination. (See",
"    <a class=\"local\" href=\"#H244299035\">",
"     'Clinical features'",
"    </a>",
"    above and",
"    <a class=\"local\" href=\"#H2436682\">",
"     'Dermoscopic features'",
"    </a>",
"    above and",
"    <a class=\"local\" href=\"#H244299042\">",
"     'Histopathologic features'",
"    </a>",
"    above.)",
"   </p>",
"   <p>",
"    The clinical diagnosis of lentigo maligna at an early stage may be difficult even for the experienced dermatologist. On clinical examination, the recognition of LM is often complicated by the presence of multiple lesions that are similar in appearance, including solar lentigines, flat seborrheic keratoses, and actinic keratoses.",
"   </p>",
"   <p>",
"    Dermoscopy may be helpful in differentiating early LM from benign pigmented lesions occurring on sun-damaged skin such as seborrheic keratoses and solar lentigines. However, differentiating a pigmented actinic keratosis from LM by dermoscopy is difficult and not always possible. Pigmented actinic keratoses are a rare variant of actinic keratosis that share clinical and dermoscopic features with LM. (See",
"    <a class=\"local\" href=\"#H20157231\">",
"     'Differential diagnosis'",
"    </a>",
"    below.)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H60107460\">",
"    <span class=\"h2\">",
"     Confocal scanning laser microscopy",
"    </span>",
"    &nbsp;&mdash;&nbsp;Confocal scanning laser microscopy (CSLM) is a noninvasive, complex technique for the imaging of human skin, with cellular resolution deep to the papillary dermis. CSLM has been evaluated in a small number of patients for the differentiation of LM from other pigmented lesions of the face [",
"    <a class=\"abstract\" href=\"UTD.htm?9/52/10057/abstract/27-29\">",
"     27-29",
"    </a>",
"    ]. However, CSLM is available only at specialized dermatologic institutions and data on its diagnostic accuracy are limited [",
"    <a class=\"abstract\" href=\"UTD.htm?9/52/10057/abstract/30\">",
"     30",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H244299049\">",
"    <span class=\"h2\">",
"     Biopsy and histologic examination",
"    </span>",
"    &nbsp;&mdash;&nbsp;Biopsy is necessary to establish the diagnosis of LM. Excisional biopsy with narrow margins is ideal, although a saucerization (deep shave) may be adequate in some cases. Since abnormal melanocytic cells may extend down the adventitia of the hair follicles, a more superficial shave is not adequate since it may not include this area for evaluation.",
"   </p>",
"   <p>",
"    For LMs that are broad and located on cosmetically sensitive sites, partial biopsy (punch or incisional biopsy) may be performed. However, considerable sampling errors can occur with partial biopsies because the histopathologic findings may vary within the lesion. Evidence of dermal invasion has been reported in up to 20 percent of specimens with a preoperative diagnosis of LM on initial biopsy [",
"    <a class=\"abstract\" href=\"UTD.htm?9/52/10057/abstract/13-16\">",
"     13-16",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    The choice of the site(s) for incisional biopsy is based upon clinical examination and dermoscopy. The most irregular or heavily pigmented areas identified by clinical",
"    <span class=\"nowrap\">",
"     and/or",
"    </span>",
"    dermoscopic examination and any palpable or thickened areas are the preferred biopsy sites.",
"   </p>",
"   <p>",
"    Histologically, the replacement of basal keratinocytes by atypical melanocytes with background changes of chronic sun damage (epidermal atrophy, effacement of rete ridges, and inflammatory dermal infiltrate) is diagnostic of LM. Microscopic features of benign solar lentigo, LM, and lentigo maligna melanoma (LMM) may coexist in the same lesion. (See",
"    <a class=\"local\" href=\"#H244299042\">",
"     'Histopathologic features'",
"    </a>",
"    above.)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H20157231\">",
"    <span class=\"h1\">",
"     DIFFERENTIAL DIAGNOSIS",
"    </span>",
"    &nbsp;&mdash;&nbsp;Lentigo maligna (LM) should be differentiated from other melanocytic and nonmelanocytic lesions, including:",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      <strong>",
"       Solar lentigo",
"      </strong>",
"      &mdash; Solar lentigines are large, macular lesions with irregular margins and uniform brown pigmentation. Solar lentigines are commonly seen on chronically sun-exposed sites (face, dorsum of hands) of older individuals with fair skin and a history of excessive sun exposure (",
"      <a class=\"graphic graphic_picture graphicRef81287 graphicRef61452 \" href=\"UTD.htm?12/32/12808\">",
"       picture 5A-B",
"      </a>",
"      ). In contrast with solar lentigines, the macular lesions of LM tend to be darker and irregularly pigmented. Histologically, solar lentigo is characterized by a linear increase of melanocytes at the dermal&ndash;epidermal junction, in the absence of cytologic atypia. (See",
"      <a class=\"medical medical_review\" href=\"UTD.htm?42/17/43287?source=see_link&amp;anchor=H5#H5\">",
"       \"Benign pigmented skin lesions other than melanocytic nevi (moles)\", section on 'Solar lentigo'",
"      </a>",
"      .)",
"     </li>",
"     <li>",
"      <strong>",
"       Pigmented actinic keratosis",
"      </strong>",
"      &mdash; Pigmented actinic keratoses present as scaly, hyperpigmented macules or patches occurring on sun-exposed skin of adult individuals with fair complexion. Pigmented actinic keratoses are difficult to differentiate from LM by naked eye or dermoscopic examination. Histologically, there is a proliferation of atypical keratinocytes extending from the basal layer upward, with increased melanin in the lower epidermis and dermal melanophages. &nbsp;(See",
"      <a class=\"medical medical_review\" href=\"UTD.htm?17/49/18200?source=see_link&amp;anchor=H17075261#H17075261\">",
"       \"Epidemiology, natural history, and diagnosis of actinic keratosis\", section on 'Clinical features'",
"      </a>",
"      and",
"      <a class=\"medical medical_review\" href=\"UTD.htm?17/49/18200?source=see_link&amp;anchor=H625419#H625419\">",
"       \"Epidemiology, natural history, and diagnosis of actinic keratosis\", section on 'Pathology'",
"      </a>",
"      .)",
"     </li>",
"     <li>",
"      <strong>",
"       Seborrheic keratosis",
"      </strong>",
"      &mdash; Seborrheic keratoses are common benign keratinocytic tumors presenting as macular or elevated lesions, with variable brown pigmentation and a dull surface (",
"      <a class=\"graphic graphic_picture graphicRef58445 \" href=\"UTD.htm?4/52/4934\">",
"       picture 6",
"      </a>",
"      ). On the face, seborrheic keratoses may remain superficial for a long period. Dermoscopic examination is helpful in differentiating seborrheic keratosis from LM. Histologically, there is a proliferation of normal keratinocytes and an increased number of melanocytes. (See",
"      <a class=\"medical medical_review\" href=\"UTD.htm?0/34/553?source=see_link&amp;anchor=H1101421989#H1101421989\">",
"       \"Overview of benign lesions of the skin\", section on 'Seborrheic keratosis'",
"      </a>",
"      .)",
"     </li>",
"     <li>",
"      <strong>",
"       Lentigo maligna melanoma",
"      </strong>",
"      &mdash; Lentigo maligna melanoma results from the progression of LM to the invasive phase. Clinically, it presents as an hyperpigmented patch, with darker, asymmetric foci or nodules (",
"      <a class=\"graphic graphic_picture graphicRef74664 graphicRef54753 \" href=\"UTD.htm?9/49/10008\">",
"       picture 2C-D",
"      </a>",
"      ). Histologically, neoplastic melanocytes are arrayed along the dermal-epidermal junction in a lentiginous pattern and form nests along the dermal-epidermal junction and nodules or fascicles in the dermis (",
"      <a class=\"graphic graphic_picture graphicRef73737 \" href=\"UTD.htm?30/25/31122\">",
"       picture 7",
"      </a>",
"      ). (See",
"      <a class=\"medical medical_review\" href=\"UTD.htm?21/31/22009?source=see_link&amp;anchor=H9#H9\">",
"       \"Pathologic characteristics of melanoma\", section on 'Lentigo maligna melanoma'",
"      </a>",
"      .)",
"     </li>",
"    </ul>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H244299056\">",
"    <span class=\"h1\">",
"     TREATMENT",
"    </span>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H651881\">",
"    <span class=\"h2\">",
"     Overview",
"    </span>",
"    &nbsp;&mdash;&nbsp;There are no randomized trials evaluating treatments for lentigo maligna (LM). However, surgical excision with 5 to 10 mm margins is recommended by multiple guidelines from several countries for all types of melanoma in situ, including LM [",
"    <a class=\"abstract\" href=\"UTD.htm?9/52/10057/abstract/31-34\">",
"     31-34",
"    </a>",
"    ]. Surgical excision can include wide local excision, a staged procedure, or Mohs surgery. Wider margins may be needed for large lesions. (See",
"    <a class=\"local\" href=\"#H651888\">",
"     'Surgery'",
"    </a>",
"    below.)",
"   </p>",
"   <p>",
"    Alternative treatments that have been used for LM include locally destructive therapies (radiation therapy, laser therapy, and cryotherapy,) and topical immunomodulator therapy with",
"    <a class=\"drug drug_general\" href=\"UTD.htm?19/59/20406?source=see_link\">",
"     imiquimod",
"    </a>",
"    . Nonsurgical therapies, such as radiotherapy, may be appropriate in older patients with large lesions of the face that cannot be resected with adequate margins or when reconstruction is problematic. (See",
"    <a class=\"local\" href=\"#H244299072\">",
"     'Radiation therapy'",
"    </a>",
"    below.) &nbsp;",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H651888\">",
"    <span class=\"h2\">",
"     Surgery",
"    </span>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H244299065\">",
"    <span class=\"h3\">",
"     Wide local excision",
"    </span>",
"    &nbsp;&mdash;&nbsp;There are no clinical trials evaluating the optimal excision margins for LM. Guidelines from the United Kingdom and from Australia recommend wide local excision (WLE) with 5 mm margins for all types of melanoma in situ, including LM, based upon 1992 recommendations of the National Institutes of Health (NIH) Consensus Panel on diagnosis and treatment of early melanoma [",
"    <a class=\"abstract\" href=\"UTD.htm?9/52/10057/abstract/31,33,35\">",
"     31,33,35",
"    </a>",
"    ]. Guidelines from the American Academy of Dermatology, as well as the National Comprehensive Cancer Network Guidelines, state that LM may require excision margins &gt;5 mm to achieve histologically negative margins [",
"    <a class=\"abstract\" href=\"UTD.htm?9/52/10057/abstract/32,34\">",
"     32,34",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    Multiple studies using surgical techniques that allow a complete margin examination (eg, staged excision or Mohs surgery) suggest that clearance rates with 5 or 6 mm margin range from 24 to 84 percent [",
"    <a class=\"abstract\" href=\"UTD.htm?9/52/10057/abstract/15,36-39\">",
"     15,36-39",
"    </a>",
"    ]. Margins of 7 to 15 mm may be required to achieve clearance rates of 94 to 99 percent. A prospective study of 1072 patients with 1120 melanomas in situ treated by Mohs micrographic surgery found that a 9 mm margin was adequate for complete clearance in 98.9 percent of all tumors [",
"    <a class=\"abstract\" href=\"UTD.htm?9/52/10057/abstract/40\">",
"     40",
"    </a>",
"    ]. Larger margins of 12 or 15 mm only marginally increased the clearance rate to 99.4 and 99.6 percent, respectively. &nbsp;",
"   </p>",
"   <p>",
"    A few small studies have reported recurrence rates for conventional surgical excision of 6 to 9 percent after a mean follow-up time of 3 to 3.5 years [",
"    <a class=\"abstract\" href=\"UTD.htm?9/52/10057/abstract/41,42\">",
"     41,42",
"    </a>",
"    ]. One study using staged excision for 55 LMs found that margins of 6 to 9 mm provided complete excision of lesions &lt;2 cm diameter (&lt;3 cm",
"    <sup>",
"     2",
"    </sup>",
"    ), whereas margins of 8 to 12 mm cleared 95 percent of lesions &gt;2 cm [",
"    <a class=\"abstract\" href=\"UTD.htm?9/52/10057/abstract/43\">",
"     43",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H190891\">",
"    <span class=\"h3\">",
"     Staged excision",
"    </span>",
"    &nbsp;&mdash;&nbsp;Staged excision with rush permanent sections (also called &ldquo;slow Mohs&rdquo;) is considered the optimal surgical technique for LM. Staged excision permits the evaluation of the surgical margins in a comprehensive manner similar to Mohs surgery, but relies on permanent sections rather than frozen sections. Permanent sections require a longer processing time than frozen sections; however, rush readings can usually be obtained in less than 24 hours. &nbsp;",
"   </p>",
"   <p>",
"    After delineating the LM clinical margins, a surgical margin of 5 mm is drawn around the lesion (",
"    <a class=\"graphic graphic_algorithm graphicRef71333 \" href=\"UTD.htm?4/61/5077\">",
"     algorithm 1",
"    </a>",
"    ). The gross clinical lesion (&ldquo;tumor debulk&rdquo;) is excised down to the underlying adipose tissue, oriented, and placed in a formalin bottle. The margins are then excised to the underlying subcutaneous adipose tissue, divided, marked to preserve orientation, and placed in individually labeled formalin bottles. The tumor debulk tissue is serially sectioned in various ways (multiple vertical &ldquo;bread loaf&rdquo; sections or radial sections) and examined for invasive melanoma [",
"    <a class=\"abstract\" href=\"UTD.htm?9/52/10057/abstract/43-47\">",
"     43-47",
"    </a>",
"    ]. The peripheral margins are inked with the same color consistently applied to the outer surface (true outer surgical margin). Each segment of the peripheral margin is sectioned vertically &ldquo;en face&rdquo; to allow the examination of the entire true margin. The permanent sections are evaluated by a dermatopathologist experienced in pigmented lesions. The margin status and location of residual melanoma is then communicated to the surgeon. The patient returns 24 hours later for reexcision of involved margins and the process is repeated until negative peripheral margins are achieved. Reconstruction of the defect is then performed. &nbsp;",
"   </p>",
"   <p>",
"    There are several variations of the staged excision, including the &ldquo;square procedure,&rdquo; perimeter, contoured, and spaghetti techniques [",
"    <a class=\"abstract\" href=\"UTD.htm?9/52/10057/abstract/48-52\">",
"     48-52",
"    </a>",
"    ]. In some of these techniques the margin specimens are cut en face in vertical sections that contain 100 percent of the peripheral margins.",
"   </p>",
"   <p>",
"    Recurrence rates of 0 to 5 percent have been reported after staged excision at a mean follow-up time of 23 to 57 months [",
"    <a class=\"abstract\" href=\"UTD.htm?9/52/10057/abstract/14,43-46,51,53\">",
"     14,43-46,51,53",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H190898\">",
"    <span class=\"h3\">",
"     Mohs micrographic surgery",
"    </span>",
"    &nbsp;&mdash;&nbsp;Mohs micrographic surgery (MMS) is a technique that involves a beveled excision of the tumor. MMS uses frozen horizontal sections that allow for examination of the entire peripheral and deep margins of the tumor with maximal preservation of uninvolved tissue. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?16/63/17400?source=see_link\">",
"     \"Mohs surgery\"",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    However, the diagnosis of melanocytic lesions using frozen sections may be problematic. Differentiating atypical melanocytic hyperplasia from benign melanocytic hyperplasia and actinic keratinocytic damage is difficult and requires considerable experience in MMS and high quality frozen sections [",
"    <a class=\"abstract\" href=\"UTD.htm?9/52/10057/abstract/54\">",
"     54",
"    </a>",
"    ]. Rapid immunostaining with MART-1 or Mel-5 may help in identifying the melanocytes on frozen sections and appears to provide information similar to that obtained from permanent sections [",
"    <a class=\"abstract\" href=\"UTD.htm?9/52/10057/abstract/55-57\">",
"     55-57",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    Some Mohs surgeons, after a final negative frozen layer, excise an additional margin of 1 to 3 mm and send it for permanent sections. In one study including 116 patients with LM, 5 percent of margins that were negative on frozen sections were positive on permanent sections [",
"    <a class=\"abstract\" href=\"UTD.htm?9/52/10057/abstract/58\">",
"     58",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    The recurrence rates for LM excised by MMS range from 0 to 2 percent after a follow-up time of 29 to 38 months [",
"    <a class=\"abstract\" href=\"UTD.htm?9/52/10057/abstract/55,59-61\">",
"     55,59-61",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H652399\">",
"    <span class=\"h2\">",
"     Nonsurgical therapies",
"    </span>",
"    &nbsp;&mdash;&nbsp;Nonsurgical therapy for LM should only be considered under select clinical circumstances, when surgical excision is not feasible [",
"    <a class=\"abstract\" href=\"UTD.htm?9/52/10057/abstract/32\">",
"     32",
"    </a>",
"    ]. Alternatives to surgery include radiotherapy, topical",
"    <a class=\"drug drug_general\" href=\"UTD.htm?19/59/20406?source=see_link\">",
"     imiquimod",
"    </a>",
"    , cryosurgery, and laser therapy. These techniques have not been evaluated in randomized trials.",
"   </p>",
"   <p>",
"    One study reviewed 1086 cases of melanoma in situ treated with surgery or nonsurgical interventions. The proportion of these that were LM was not specified; 721 cases involved the head or neck. The five-year recurrence rate was 6.8 percent for surgical excision and 31 percent for radiotherapy, laser therapy, and cryosurgery combined as a single category [",
"    <a class=\"abstract\" href=\"UTD.htm?9/52/10057/abstract/62\">",
"     62",
"    </a>",
"    ]. In a small retrospective study of 73 patients, carbon dioxide laser treatment was used in 15 patients refusing surgery and radiotherapy, with one recurrence (6.7 percent) after a median follow-up time of 78 months [",
"    <a class=\"abstract\" href=\"UTD.htm?9/52/10057/abstract/63\">",
"     63",
"    </a>",
"    ]. &nbsp; &nbsp;",
"   </p>",
"   <p>",
"    Drawbacks of nonsurgical therapy include: &nbsp;",
"   </p>",
"   <p>",
"    <ul class=\"bulletCompact-block\">",
"     <li>",
"      Lack of histologic examination of the entire tumor for foci of dermal invasion not evident at the initial biopsy",
"     </li>",
"     <li>",
"      Lack of histologic margin control",
"     </li>",
"     <li>",
"      Post-treatment monitoring based upon clinical examination or random biopsies that may not show tumor persistence or recurrence",
"     </li>",
"    </ul>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H244299072\">",
"    <span class=\"h3\">",
"     Radiation therapy",
"    </span>",
"    &nbsp;&mdash;&nbsp;Radiation therapy (XRT) is a treatment option for large LM lesions in older patients for whom surgical removal would not be feasible. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?8/32/8713?source=see_link&amp;anchor=H5#H5\">",
"     \"Role of radiation therapy in the management of melanoma\", section on 'Curative management of primary melanoma'",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    Multifractionated regimens of high voltage (100 kV to 280 kV) delivered at depths of 5 to 6 mm with minimum margins of 7 to 10 mm have been used in small series of patients in the United States and Canada [",
"    <a class=\"abstract\" href=\"UTD.htm?9/52/10057/abstract/41,64\">",
"     41,64",
"    </a>",
"    ]. In one study, the cure rate at 5 years was 86 percent [",
"    <a class=\"abstract\" href=\"UTD.htm?9/52/10057/abstract/41\">",
"     41",
"    </a>",
"    ]. In Europe, low energy grenz rays (12 kV) or soft x-rays (20-50 kV) delivered at a depth of about 1 mm are used. Recurrence rates of 0 and 5 percent have been reported in small studies after a follow-up time of one to 108 months [",
"    <a class=\"abstract\" href=\"UTD.htm?9/52/10057/abstract/5,65\">",
"     5,65",
"    </a>",
"    ]. In a large series of 350 patients with LMs and early lentigo maligna melanoma (LMM) treated with grenz rays as primary therapy, the clearance rate was 83 percent after a median follow-up time of about 5 years [",
"    <a class=\"abstract\" href=\"UTD.htm?9/52/10057/abstract/66\">",
"     66",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H244299079\">",
"    <span class=\"h3\">",
"     Topical imiquimod",
"    </span>",
"    &nbsp;&mdash;&nbsp;",
"    <a class=\"drug drug_general\" href=\"UTD.htm?19/59/20406?source=see_link\">",
"     Imiquimod",
"    </a>",
"    5% cream is approved by the US Food and Drug Administration for the treatment of actinic keratoses, superficial basal cell carcinomas, and warts. Several reports of its use &ldquo;off-label&rdquo; for LM show some apparent response to topical imiquimod. The mechanism of action proposed is that imiquimod induces a local inflammatory response of T-helper lymphocytes mixed with cytotoxic cells, monocytes, and macrophages, leading to a cytotoxic T-cell mediated immune response [",
"    <a class=\"abstract\" href=\"UTD.htm?9/52/10057/abstract/67\">",
"     67",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    In a few small studies, the response rates by visual inspection to topical",
"    <a class=\"drug drug_general\" href=\"UTD.htm?19/59/20406?source=see_link\">",
"     imiquimod",
"    </a>",
"    were 56 to 93 percent after a follow-up of 12 to 49 months [",
"    <a class=\"abstract\" href=\"UTD.htm?9/52/10057/abstract/68-71\">",
"     68-71",
"    </a>",
"    ]. However, histologic verification after treatment showed persistent disease in 25 to 47 percent of treated patients [",
"    <a class=\"abstract\" href=\"UTD.htm?9/52/10057/abstract/72-74\">",
"     72-74",
"    </a>",
"    ]. Recurrences with development of LMM were reported in all case series.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H244299100\">",
"    <span class=\"h1\">",
"     PROGNOSIS",
"    </span>",
"    &nbsp;&mdash;&nbsp;Lentigo maligna (LM) has a tendency for subclinical spread. Atypical melanocytes often extend for a considerable distance from the clinical margin of LM, sometimes involving &ldquo;skip&rdquo; areas. This phenomenon is described as the &ldquo;field effect&rdquo; and is responsible for recurrence of LM at the edge after an initial apparently successful treatment.",
"   </p>",
"   <p>",
"    Recurrence may occur after a prolonged disease-free interval, making assessment of the efficacy of therapy difficult in studies with follow-up time &le;5 years. However, in the absence of progression to lentigo maligna melanoma, LM does not shorten life expectancy.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H244299107\">",
"    <span class=\"h1\">",
"     FOLLOW-UP",
"    </span>",
"    &nbsp;&mdash;&nbsp;There is no evidence base to determine the optimal follow-up for patients with lentigo maligna (LM). Following excision of LM, most clinicians see patients twice a year for the first five years, and annually thereafter.",
"   </p>",
"   <p>",
"    Examination for recurrent lesions or new primary lesions is enhanced by the use of dermoscopy or by examination in a darkened room using a Wood&rsquo;s light.",
"   </p>",
"   <p>",
"    Since LM typically occurs in patients with substantially sun-damaged skin who are at increased risk of melanoma and nonmelanoma skin cancer, full-body skin examination should be performed in these patients at each follow-up visit.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H652546\">",
"    <span class=\"h1\">",
"     SUMMARY AND RECOMMENDATIONS",
"    </span>",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      Lentigo maligna is a slowly evolving type of melanoma in situ that typically occurs in the sun-damaged skin of the face and neck of older individuals (",
"      <a class=\"graphic graphic_picture graphicRef62052 graphicRef59591 graphicRef68787 \" href=\"UTD.htm?29/48/30474\">",
"       picture 1A-C",
"      </a>",
"      ). The risk of progression to invasive lentigo maligna melanoma ranges from 5 to 20 percent. The development of darker pigmentation, sharper borders, or elevated or nodular areas are clinical signs of progression. &nbsp;(See",
"      <a class=\"local\" href=\"#H244299028\">",
"       'Epidemiology and natural history'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      Clinically, lentigo maligna presents as an atypical macular lesion characterized by irregular shape, variegated color, and variable size (",
"      <a class=\"graphic graphic_picture graphicRef62052 graphicRef59591 graphicRef68787 \" href=\"UTD.htm?29/48/30474\">",
"       picture 1A-C",
"      </a>",
"      ). Dermoscopic features of lentigo maligna include asymmetrical pigmented follicular openings, dark rhomboidal structures, and slate-gray dots and globules (",
"      <a class=\"graphic graphic_picture graphicRef68828 \" href=\"UTD.htm?32/22/33126\">",
"       picture 3B",
"      </a>",
"      ). &nbsp;The surrounding skin typically shows evidence of chronic solar damage (solar elastosis, solar lentigines, or actinic keratoses). (See",
"      <a class=\"local\" href=\"#H244299035\">",
"       'Clinical features'",
"      </a>",
"      above and",
"      <a class=\"local\" href=\"#H2436682\">",
"       'Dermoscopic features'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      The diagnosis of lentigo maligna is made by histologic examination. Excisional biopsy with narrow margins is ideal for diagnosis. For large lesions or lesions located in cosmetically sensitive areas, it is acceptable to perform one or more incisional biopsies of the most irregular or heavily pigmented areas. Dermoscopy may be helpful in the selection of the biopsy site. Histologically, lentigo maligna is characterized by the replacement of basal keratinocytes by atypical melanocytes without dermal invasion. (See",
"      <a class=\"local\" href=\"#H20157199\">",
"       'Diagnosis'",
"      </a>",
"      above and",
"      <a class=\"local\" href=\"#H244299042\">",
"       'Histopathologic features'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      There are no randomized trials evaluating treatment for lentigo maligna. We suggest surgical excision with margins of 5 to 10 mm, depending upon lesion size and location (",
"      <a class=\"grade\" href=\"._grade_6?title=Grade 2C\">",
"       Grade 2C",
"      </a>",
"      ). If available, surgical techniques that allow complete margin control such as staged excision with permanent sections (&ldquo;slow&rdquo; Mohs) are a preferred option. (See",
"      <a class=\"local\" href=\"#H244299065\">",
"       'Wide local excision'",
"      </a>",
"      above and",
"      <a class=\"local\" href=\"#H190891\">",
"       'Staged excision'",
"      </a>",
"      above and",
"      <a class=\"local\" href=\"#H190898\">",
"       'Mohs micrographic surgery'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      Among nonsurgical treatments for lentigo maligna, options include radiation therapy with multifractionated high voltage regimens or grenz rays or soft x-rays for large lesions in older patients for whom surgical removal and reconstruction would be difficult. (See",
"      <a class=\"local\" href=\"#H244299072\">",
"       'Radiation therapy'",
"      </a>",
"      above.)",
"     </li>",
"    </ul>",
"   </p>",
"  </div>",
"  <div id=\"topicAgreement\">",
"   Use of UpToDate is subject to the",
"   <a class=\"licenseLink\" href=\"./license\" id=\"sla_in_page\" target=\"_blank\">",
"    Subscription and License Agreement",
"   </a>",
"   .",
"  </div>",
"  <div class=\"headingAnchor\" id=\"references\">",
"   <h1>",
"    REFERENCES",
"   </h1>",
"   <ol id=\"reference\">",
"    <li>",
"     World Health Organization Classification of Tumors. Pathology &amp; Genetics. Skin Tumors. Chapter 2. Melanocytic Tumors. file://www.iarc.fr/en/publications/pdfs-online/pat-gen/bb6/bb6-chap2.pdf (Accessed on November 29, 2011).",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?9/52/10057/abstract/2\">",
"      Hutchinson J. Notes on the cancerous process and on new growths in general. Arch Surg (London) 1890; 2:83.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?9/52/10057/abstract/3\">",
"      Dubreuilh MW. De la melanose circonscrite precancereuse. Ann Dermatol Syphil 1912; 3:129, 205.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?9/52/10057/abstract/4\">",
"      Cohen LM. Lentigo maligna and lentigo maligna melanoma. J Am Acad Dermatol 1995; 33:923.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?9/52/10057/abstract/5\">",
"      Farshad A, Burg G, Panizzon R, Dummer R. A retrospective study of 150 patients with lentigo maligna and lentigo maligna melanoma and the efficacy of radiotherapy using Grenz or soft X-rays. Br J Dermatol 2002; 146:1042.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?9/52/10057/abstract/6\">",
"      Swetter SM, Boldrick JC, Jung SY, et al. Increasing incidence of lentigo maligna melanoma subtypes: northern California and national trends 1990-2000. J Invest Dermatol 2005; 125:685.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?9/52/10057/abstract/7\">",
"      Kvaskoff M, Siskind V, Green AC. Risk factors for lentigo maligna melanoma compared with superficial spreading melanoma: a case-control study in Australia. Arch Dermatol 2012; 148:164.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?9/52/10057/abstract/8\">",
"      Gaudy-Marqueste C, Madjlessi N, Guillot B, et al. Risk factors in elderly people for lentigo maligna compared with other melanomas: a double case-control study. Arch Dermatol 2009; 145:418.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?9/52/10057/abstract/9\">",
"      Jackson R, Williamson GS, Beattie WG. Lentigo maligna and malignant melanoma. Can Med Assoc J 1966; 95:846.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?9/52/10057/abstract/10\">",
"      Grinspan D, Paz A, Abulafia J, Mosto S. [Melanoma (Hutchinson's lentigo maligna) having spontaneous regression. A case of immunologic importance]. Med Cutan Ibero Lat Am 1980; 8:33.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?9/52/10057/abstract/11\">",
"      Clark WH Jr, Mihm MC Jr. Lentigo maligna and lentigo-maligna melanoma. Am J Pathol 1969; 55:39.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?9/52/10057/abstract/12\">",
"      Weinstock MA, Sober AJ. The risk of progression of lentigo maligna to lentigo maligna melanoma. Br J Dermatol 1987; 116:303.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?9/52/10057/abstract/13\">",
"      Penneys NS. Microinvasive lentigo maligna melanoma. J Am Acad Dermatol 1987; 17:675.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?9/52/10057/abstract/14\">",
"      Bosbous MW, Dzwierzynski WW, Neuburg M. Staged excision of lentigo maligna and lentigo maligna melanoma: a 10-year experience. Plast Reconstr Surg 2009; 124:1947.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?9/52/10057/abstract/15\">",
"      Hazan C, Dusza SW, Delgado R, et al. Staged excision for lentigo maligna and lentigo maligna melanoma: A retrospective analysis of 117 cases. J Am Acad Dermatol 2008; 58:142.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?9/52/10057/abstract/16\">",
"      Somach SC, Taira JW, Pitha JV, Everett MA. Pigmented lesions in actinically damaged skin. Histopathologic comparison of biopsy and excisional specimens. Arch Dermatol 1996; 132:1297.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?9/52/10057/abstract/17\">",
"      Burket JM. Amelanotic lentigo maligna. Arch Dermatol 1979; 115:496.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?9/52/10057/abstract/18\">",
"      Su WP, Bradley RR. Amelanotic lentigo maligna. Arch Dermatol 1980; 116:82.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?9/52/10057/abstract/19\">",
"      Argenziano G, Soyer HP, Chimenti S, et al. Dermoscopy of pigmented skin lesions: results of a consensus meeting via the Internet. J Am Acad Dermatol 2003; 48:679.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?9/52/10057/abstract/20\">",
"      Stolz W, Schiffner R, Burgdorf WH. Dermatoscopy for facial pigmented skin lesions. Clin Dermatol 2002; 20:276.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?9/52/10057/abstract/21\">",
"      Akay BN, Kocyigit P, Heper AO, Erdem C. Dermatoscopy of flat pigmented facial lesions: diagnostic challenge between pigmented actinic keratosis and lentigo maligna. Br J Dermatol 2010; 163:1212.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?9/52/10057/abstract/22\">",
"      Zalaudek I, Ferrara G, Leinweber B, et al. Pitfalls in the clinical and dermoscopic diagnosis of pigmented actinic keratosis. J Am Acad Dermatol 2005; 53:1071.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?9/52/10057/abstract/23\">",
"      Schiffner R, Schiffner-Rohe J, Vogt T, et al. Improvement of early recognition of lentigo maligna using dermatoscopy. J Am Acad Dermatol 2000; 42:25.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?9/52/10057/abstract/24\">",
"      Weyers W, Bonczkowitz M, Weyers I, et al. Melanoma in situ versus melanocytic hyperplasia in sun-damaged skin. Assessment of the significance of histopathologic criteria for differential diagnosis. Am J Dermatopathol 1996; 18:560.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?9/52/10057/abstract/25\">",
"      Trotter MJ. Melanoma margin assessment. Clin Lab Med 2011; 31:289.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?9/52/10057/abstract/26\">",
"      Flotte TJ, Mihm MC Jr. Lentigo maligna and malignant melanoma in situ, lentigo maligna type. Hum Pathol 1999; 30:533.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?9/52/10057/abstract/27\">",
"      Langley RG, Burton E, Walsh N, et al. In vivo confocal scanning laser microscopy of benign lentigines: comparison to conventional histology and in vivo characteristics of lentigo maligna. J Am Acad Dermatol 2006; 55:88.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?9/52/10057/abstract/28\">",
"      Ahlgrimm-Siess V, Massone C, Scope A, et al. Reflectance confocal microscopy of facial lentigo maligna and lentigo maligna melanoma: a preliminary study. Br J Dermatol 2009; 161:1307.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?9/52/10057/abstract/29\">",
"      Wurm EM, Curchin CE, Lambie D, et al. Confocal features of equivocal facial lesions on severely sun-damaged skin: four case studies with dermatoscopic, confocal, and histopathologic correlation. J Am Acad Dermatol 2012; 66:463.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?9/52/10057/abstract/30\">",
"      Guitera P, Pellacani G, Crotty KA, et al. The impact of in vivo reflectance confocal microscopy on the diagnostic accuracy of lentigo maligna and equivocal pigmented and nonpigmented macules of the face. J Invest Dermatol 2010; 130:2080.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?9/52/10057/abstract/31\">",
"      Marsden JR, Newton-Bishop JA, Burrows L, et al. Revised U.K. guidelines for the management of cutaneous melanoma 2010. Br J Dermatol 2010; 163:238.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?9/52/10057/abstract/32\">",
"      Bichakjian CK, Halpern AC, Johnson TM, et al. Guidelines of care for the management of primary cutaneous melanoma. American Academy of Dermatology. J Am Acad Dermatol 2011; 65:1032.",
"     </a>",
"    </li>",
"    <li>",
"     Australian Cancer Network Melanoma Guidelines Revision Working Party. Clinical Practice Guidelines",
"for the Management of Melanoma in Australia and New Zealand. Cancer Council Australia and",
"Australian Cancer Network, Sydney and New Zealand Guidelines Group, Wellington (2008). file://www.cancer.org.au/File/HealthProfessionals/ClinicalPracticeGuidelines-ManagementofMelanoma.pdf (Accessed on November 29, 2011).",
"    </li>",
"    <li>",
"     National Comprhensive Cancer Network Clinical Practice Guidelines in Oncology. Melanoma. Version 3.2012. file://www.nccn.org/professionals/physician_gls/pdf/melanoma.pdf (Accessed on December 09, 2011).",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?9/52/10057/abstract/35\">",
"      NIH Consensus conference. Diagnosis and treatment of early melanoma. JAMA 1992; 268:1314.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?9/52/10057/abstract/36\">",
"      Huilgol SC, Selva D, Chen C, et al. Surgical margins for lentigo maligna and lentigo maligna melanoma: the technique of mapped serial excision. Arch Dermatol 2004; 140:1087.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?9/52/10057/abstract/37\">",
"      Albertini JG, Elston DM, Libow LF, et al. Mohs micrographic surgery for melanoma: a case series, a comparative study of immunostains, an informative case report, and a unique mapping technique. Dermatol Surg 2002; 28:656.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?9/52/10057/abstract/38\">",
"      Zalla MJ, Lim KK, Dicaudo DJ, Gagnot MM. Mohs micrographic excision of melanoma using immunostains. Dermatol Surg 2000; 26:771.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?9/52/10057/abstract/39\">",
"      Bricca GM, Brodland DG, Ren D, Zitelli JA. Cutaneous head and neck melanoma treated with Mohs micrographic surgery. J Am Acad Dermatol 2005; 52:92.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?9/52/10057/abstract/40\">",
"      Kunishige JH, Brodland DG, Zitelli JA. Surgical margins for melanoma in situ. J Am Acad Dermatol 2012; 66:438.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?9/52/10057/abstract/41\">",
"      Tsang RW, Liu FF, Wells W, Payne DG. Lentigo maligna of the head and neck. Results of treatment by radiotherapy. Arch Dermatol 1994; 130:1008.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?9/52/10057/abstract/42\">",
"      Coleman WP 3rd, Davis RS, Reed RJ, Krementz ET. Treatment of lentigo maligna and lentigo maligna melanoma. J Dermatol Surg Oncol 1980; 6:476.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?9/52/10057/abstract/43\">",
"      Bub JL, Berg D, Slee A, Odland PB. Management of lentigo maligna and lentigo maligna melanoma with staged excision: a 5-year follow-up. Arch Dermatol 2004; 140:552.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?9/52/10057/abstract/44\">",
"      Agarwal-Antal N, Bowen GM, Gerwels JW. Histologic evaluation of lentigo maligna with permanent sections: implications regarding current guidelines. J Am Acad Dermatol 2002; 47:743.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?9/52/10057/abstract/45\">",
"      Hill DC, Gramp AA. Surgical treatment of lentigo maligna and lentigo maligna melanoma. Australas J Dermatol 1999; 40:25.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?9/52/10057/abstract/46\">",
"      Malhotra R, Chen C, Huilgol SC, et al. Mapped serial excision for periocular lentigo maligna and lentigo maligna melanoma. Ophthalmology 2003; 110:2011.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?9/52/10057/abstract/47\">",
"      McGuire LK, Disa JJ, Lee EH, et al. Melanoma of the lentigo maligna subtype: diagnostic challenges and current treatment paradigms. Plast Reconstr Surg 2012; 129:288e.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?9/52/10057/abstract/48\">",
"      Johnson TM, Headington JT, Baker SR, Lowe L. Usefulness of the staged excision for lentigo maligna and lentigo maligna melanoma: the \"square\" procedure. J Am Acad Dermatol 1997; 37:758.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?9/52/10057/abstract/49\">",
"      Anderson KW, Baker SR, Lowe L, et al. Treatment of head and neck melanoma, lentigo maligna subtype: a practical surgical technique. Arch Facial Plast Surg 2001; 3:202.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?9/52/10057/abstract/50\">",
"      Gaudy-Marqueste C, Perchenet AS, Tas&eacute;i AM, et al. The \"spaghetti technique\": an alternative to Mohs surgery or staged surgery for problematic lentiginous melanoma (lentigo maligna and acral lentiginous melanoma). J Am Acad Dermatol 2011; 64:113.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?9/52/10057/abstract/51\">",
"      M&ouml;ller MG, Pappas-Politis E, Zager JS, et al. Surgical management of melanoma-in-situ using a staged marginal and central excision technique. Ann Surg Oncol 2009; 16:1526.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?9/52/10057/abstract/52\">",
"      Mahoney MH, Joseph M, Temple CL. The perimeter technique for lentigo maligna: an alternative to Mohs micrographic surgery. J Surg Oncol 2005; 91:120.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?9/52/10057/abstract/53\">",
"      Demirci H, Johnson TM, Frueh BR, et al. Management of periocular cutaneous melanoma with a staged excision technique and permanent sections the square procedure. Ophthalmology 2008; 115:2295.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?9/52/10057/abstract/54\">",
"      Kwon SY, Miller SJ. Mohs surgery for melanoma in situ. Dermatol Clin 2011; 29:175.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?9/52/10057/abstract/55\">",
"      Bhardwaj SS, Tope WD, Lee PK. Mohs micrographic surgery for lentigo maligna and lentigo maligna melanoma using Mel-5 immunostaining: University of Minnesota experience. Dermatol Surg 2006; 32:690.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?9/52/10057/abstract/56\">",
"      Cherpelis BS, Moore R, Ladd S, et al. Comparison of MART-1 frozen sections to permanent sections using a rapid 19-minute protocol. Dermatol Surg 2009; 35:207.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?9/52/10057/abstract/57\">",
"      Bricca GM, Brodland DG, Zitelli JA. Immunostaining melanoma frozen sections: the 1-hour protocol. Dermatol Surg 2004; 30:403.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?9/52/10057/abstract/58\">",
"      Bene NI, Healy C, Coldiron BM. Mohs micrographic surgery is accurate 95.1% of the time for melanoma in situ: a prospective study of 167 cases. Dermatol Surg 2008; 34:660.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?9/52/10057/abstract/59\">",
"      Temple CL, Arlette JP. Mohs micrographic surgery in the treatment of lentigo maligna and melanoma. J Surg Oncol 2006; 94:287.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?9/52/10057/abstract/60\">",
"      Bienert TN, Trotter MJ, Arlette JP. Treatment of cutaneous melanoma of the face by Mohs micrographic surgery. J Cutan Med Surg 2003; 7:25.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?9/52/10057/abstract/61\">",
"      Dawn ME, Dawn AG, Miller SJ. Mohs surgery for the treatment of melanoma in situ: a review. Dermatol Surg 2007; 33:395.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?9/52/10057/abstract/62\">",
"      Zalaudek I, Horn M, Richtig E, et al. Local recurrence in melanoma in situ: influence of sex, age, site of involvement and therapeutic modalities. Br J Dermatol 2003; 148:703.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?9/52/10057/abstract/63\">",
"      Lee H, Sowerby LJ, Temple CL, et al. Carbon dioxide laser treatment for lentigo maligna: a retrospective review comparing 3 different treatment modalities. Arch Facial Plast Surg 2011; 13:398.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?9/52/10057/abstract/64\">",
"      Harwood AR. Conventional radiotherapy in the treatment of lentigo maligna and lentigo maligna melanoma. J Am Acad Dermatol 1982; 6:310.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?9/52/10057/abstract/65\">",
"      Schmid-Wendtner MH, Brunner B, Konz B, et al. Fractionated radiotherapy of lentigo maligna and lentigo maligna melanoma in 64 patients. J Am Acad Dermatol 2000; 43:477.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?9/52/10057/abstract/66\">",
"      Hedblad MA, Mallbris L. Grenz ray treatment of lentigo maligna and early lentigo maligna melanoma. J Am Acad Dermatol 2012; 67:60.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?9/52/10057/abstract/67\">",
"      Wolf IH, Cerroni L, Kodama K, Kerl H. Treatment of lentigo maligna (melanoma in situ) with the immune response modifier imiquimod. Arch Dermatol 2005; 141:510.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?9/52/10057/abstract/68\">",
"      Rajpar SF, Marsden JR. Imiquimod in the treatment of lentigo maligna. Br J Dermatol 2006; 155:653.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?9/52/10057/abstract/69\">",
"      Buettiker UV, Yawalkar NY, Braathen LR, Hunger RE. Imiquimod treatment of lentigo maligna: an open-label study of 34 primary lesions in 32 patients. Arch Dermatol 2008; 144:943.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?9/52/10057/abstract/70\">",
"      Powell AM, Robson AM, Russell-Jones R, Barlow RJ. Imiquimod and lentigo maligna: a search for prognostic features in a clinicopathological study with long-term follow-up. Br J Dermatol 2009; 160:994.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?9/52/10057/abstract/71\">",
"      Naylor MF, Crowson N, Kuwahara R, et al. Treatment of lentigo maligna with topical imiquimod. Br J Dermatol 2003; 149 Suppl 66:66.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?9/52/10057/abstract/72\">",
"      Cotter MA, McKenna JK, Bowen GM. Treatment of lentigo maligna with imiquimod before staged excision. Dermatol Surg 2008; 34:147.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?9/52/10057/abstract/73\">",
"      Fleming CJ, Bryden AM, Evans A, et al. A pilot study of treatment of lentigo maligna with 5% imiquimod cream. Br J Dermatol 2004; 151:485.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?9/52/10057/abstract/74\">",
"      Ly L, Kelly JW, O'Keefe R, et al. Efficacy of imiquimod cream, 5%, for lentigo maligna after complete excision: a study of 43 patients. Arch Dermatol 2011; 147:1191.",
"     </a>",
"    </li>",
"   </ol>",
"  </div>",
"  <div id=\"topicVersionRevision\">",
"   Topic 13520 Version 2.0",
"  </div>",
" </div>",
" <div id=\"footer\">",
"  <div id=\"supportFooter\">",
"   <span class=\"sfInfo\">",
"    &copy; 2013 UpToDate, Inc. All rights reserved.",
"   </span>",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <a class=\"licenseLink\" href=\"./license\" id=\"sla_footer\">",
"    Subscription and License Agreement",
"   </a>",
"   <span class=\"sfInfo\">",
"    <span class=\"pipeSpace\">",
"     |",
"    </span>",
"    Release: 21.3 - C21.34",
"   </span>",
"   <br/>",
"   <span class=\"sfInfo\">",
"    Licensed to:",
"    <span class=\"emphasis\">",
"     Morehouse School of Medicine",
"    </span>",
"   </span>",
"   <span class=\"sfInfo\">",
"    <span class=\"pipeSpace\">",
"     |",
"    </span>",
"    Support Tag: [0604-190.92.87.103-2CE9AB38EC-S473950.14]",
"    <br/>",
"   </span>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f9_52_10057=[""].join("\n");
var outline_f9_52_10057=[" <div id=\"toggleOutline\">",
"  <a href=\"#\" title=\"Collapse Topic Outline\">",
"   <img alt=\"\" src=\"./../images/orange_arrow_left.myextg\"/>",
"  </a>",
" </div>",
" <div id=\"innerOutline\">",
"  <h1>",
"   TOPIC OUTLINE",
"  </h1>",
"  <div id=\"outline\">",
"   <ul>",
"    <li>",
"     <a class=\"sr_button\" href=\"#H652546\" id=\"summRecButton\">",
"      <span>",
"       SUMMARY &amp; RECOMMENDATIONS",
"      </span>",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H244299021\">",
"      INTRODUCTION",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H244299028\">",
"      EPIDEMIOLOGY AND NATURAL HISTORY",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H244299035\">",
"      CLINICAL FEATURES",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H2436682\">",
"      DERMOSCOPIC FEATURES",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H244299042\">",
"      HISTOPATHOLOGIC FEATURES",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H20157199\">",
"      DIAGNOSIS",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H1146732\">",
"      Clinical and dermoscopic examination",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H60107460\">",
"      Confocal scanning laser microscopy",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H244299049\">",
"      Biopsy and histologic examination",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H20157231\">",
"      DIFFERENTIAL DIAGNOSIS",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H244299056\">",
"      TREATMENT",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H651881\">",
"      Overview",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H651888\">",
"      Surgery",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H244299065\">",
"      - Wide local excision",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H190891\">",
"      - Staged excision",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H190898\">",
"      - Mohs micrographic surgery",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H652399\">",
"      Nonsurgical therapies",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H244299072\">",
"      - Radiation therapy",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H244299079\">",
"      - Topical imiquimod",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H244299100\">",
"      PROGNOSIS",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H244299107\">",
"      FOLLOW-UP",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H652546\">",
"      SUMMARY AND RECOMMENDATIONS",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a href=\"#references\">",
"      REFERENCES",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
"  <h1>",
"   <div class=\"openRelatedGraphics\" id=\"DERM/13520\" rel=\"outline_link\">",
"    GRAPHICS",
"    <a class=\"graphics_icon\" href=\"#\" title=\"View All Related Graphics\">",
"     View All",
"    </a>",
"   </div>",
"  </h1>",
"  <div id=\"relatedGraphics\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <div class=\"openRelatedGraphics\" id=\"DERM/13520|ALG\">",
"      <a href=\"#\" title=\"ALGORITHMS\">",
"       ALGORITHMS",
"      </a>",
"     </div>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_algorithm\" href=\"UTD.htm?4/61/5077\" title=\"algorithm 1\">",
"      Lentigo maligna staged excision",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <div class=\"openRelatedGraphics\" id=\"DERM/13520|PIC\">",
"      <a href=\"#\" title=\"PICTURES\">",
"       PICTURES",
"      </a>",
"     </div>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_picture\" href=\"UTD.htm?5/56/6020\" title=\"picture 1A\">",
"      Lentigo maligna eyebrow",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_picture\" href=\"UTD.htm?1/5/1109\" title=\"picture 1B\">",
"      Lentigo maligna nose",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_picture\" href=\"UTD.htm?40/30/41444\" title=\"picture 1C\">",
"      Lentigo maligna cheek",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_picture\" href=\"UTD.htm?4/54/4967\" title=\"picture 2A\">",
"      New lentigo maligna melanoma",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_picture\" href=\"UTD.htm?27/19/27957\" title=\"picture 2B\">",
"      Lentigo maligna melanoma 4",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_picture\" href=\"UTD.htm?17/50/18211\" title=\"picture 2C\">",
"      Lentigo maligna melanoma 2",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_picture\" href=\"UTD.htm?34/3/34866\" title=\"picture 2D\">",
"      Lentigo maligna melanoma 3",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_picture\" href=\"UTD.htm?21/36/22083\" title=\"picture 3A\">",
"      Lentigo maligna melanoma dermoscopy 1",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_picture\" href=\"UTD.htm?32/22/33126\" title=\"picture 3B\">",
"      Lentigo maligna dermoscopy",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_picture\" href=\"UTD.htm?9/10/9385\" title=\"picture 4A\">",
"      Lentigo maligna histology",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_picture\" href=\"UTD.htm?5/57/6037\" title=\"picture 4B\">",
"      Histol melanoma in situ lentigo",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_picture\" href=\"UTD.htm?5/30/5604\" title=\"picture 5A\">",
"      Solar lentigines face",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_picture\" href=\"UTD.htm?6/10/6306\" title=\"picture 5B\">",
"      Solar lentigo hand 2",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_picture\" href=\"UTD.htm?4/52/4934\" title=\"picture 6\">",
"      Seborrheic keratosis superficial",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_picture\" href=\"UTD.htm?30/25/31122\" title=\"picture 7\">",
"      Histol lentigo maligna melanoma",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
"  <h1>",
"   RELATED TOPICS",
"  </h1>",
"  <div id=\"relatedTopics\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?42/17/43287?source=related_link\">",
"      Benign pigmented skin lesions other than melanocytic nevi (moles)",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?13/11/13497?source=related_link\">",
"      Dermoscopic evaluation of skin lesions",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?17/49/18200?source=related_link\">",
"      Epidemiology, natural history, and diagnosis of actinic keratosis",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?16/63/17400?source=related_link\">",
"      Mohs surgery",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?0/34/553?source=related_link\">",
"      Overview of benign lesions of the skin",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?37/57/38807?source=related_link\">",
"      Overview of dermoscopy",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?21/31/22009?source=related_link\">",
"      Pathologic characteristics of melanoma",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?8/32/8713?source=related_link\">",
"      Role of radiation therapy in the management of melanoma",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?16/20/16713?source=related_link\">",
"      Skin examination and clinical features of melanoma",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
" </div>"].join("\n");
var title_f9_52_10058="Extragonadal germ cell tumors involving the mediastinum and retroperitoneum";
var content_f9_52_10058=[" <noscript>",
"  <div id=\"javascriptDisabled\">",
"   It seems to us that you have your JavaScript turned off on your browser. JavaScript is required in order for our site to behave correctly.  Please enable your JavaScript to continue use our site.",
"  </div>",
" </noscript>",
" <div id=\"printHeader\">",
"  <div id=\"printHeaderLogo\">",
"   <img alt=\"UpToDate\" src=\"./../images/wk_utd-rgb.myextg\" width=\"220px\">",
"   </img>",
"  </div>",
"  <div id=\"printHeaderText\">",
"   Official reprint from  UpToDate",
"   <sup>",
"    &reg;",
"   </sup>",
"   <a href=\"file://www.uptodate.com\">",
"    www.uptodate.com",
"   </a>",
"   <br>",
"    &copy;2013 UpToDate",
"    <sup>",
"     &reg;",
"    </sup>",
"   </br>",
"  </div>",
"  <div id=\"printHeaderLinks\">",
"   <a class=\"TOPIC\" href=\"#\" id=\"printHeaderPrint\" rel=\"5\" title=\"Click here to print\">",
"    Print",
"   </a>",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <a href=\"#\" id=\"printHeaderBack\" title=\"Back to normal view\">",
"    Back",
"   </a>",
"  </div>",
" </div>",
" <!-- TC:TOPIC_PAGE -->",
" <div id=\"topicContent\">",
"  <div id=\"topicTitle\">",
"   Extragonadal germ cell tumors involving the mediastinum and retroperitoneum",
"  </div>",
"  <div id=\"topicContributors\">",
"   <div>",
"    <a id=\"authors\">",
"    </a>",
"    <a class=\"contributor contributor_credentials contributorType\" href=\"UTD.htm?9/52/10058/contributors\">",
"     Authors",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"UTD.htm?9/52/10058/contributors\">",
"     Timothy D Gilligan, MD",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"UTD.htm?9/52/10058/contributors\">",
"     Philip W Kantoff, MD",
"    </a>",
"    <br/>",
"   </div>",
"   <div>",
"    <a class=\"contributor contributor_credentials contributorType\" href=\"UTD.htm?9/52/10058/contributors\">",
"     Section Editor",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"UTD.htm?9/52/10058/contributors\">",
"     William K Oh, MD",
"    </a>",
"    <br/>",
"   </div>",
"   <div>",
"    <a class=\"contributor contributor_credentials contributorType\" href=\"UTD.htm?9/52/10058/contributors\">",
"     Deputy Editors",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"UTD.htm?9/52/10058/contributors\">",
"     Don S Dizon, MD, FACP",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"UTD.htm?9/52/10058/contributors\">",
"     Helen Hollingsworth, MD",
"    </a>",
"    <br/>",
"   </div>",
"  </div>",
"  <div id=\"disclosures\">",
"   <a href=\"UTD.htm?9/52/10058/contributor-disclosure\" target=\"_blank\">",
"    Disclosures",
"   </a>",
"  </div>",
"  <div id=\"reviewProcess\">",
"   <span>",
"    All topics are updated as new evidence becomes available and our",
"   </span>",
"   <a href=\"/home/editorial-policy\" target=\"_blank\">",
"    peer review process",
"   </a>",
"   <span>",
"    is complete.",
"   </span>",
"  </div>",
"  <div id=\"literatureReviewDate\">",
"   <span class=\"emphasis\">",
"    Literature review current through:",
"   </span>",
"   Oct 2013.",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <span class=\"emphasis\">",
"    This topic last updated:",
"   </span>",
"   Feb 27, 2012.",
"  </div>",
"  <div id=\"topicText\">",
"   <p class=\"headingAnchor\" id=\"H1\">",
"    <span class=\"h1\">",
"     INTRODUCTION",
"    </span>",
"    &nbsp;&mdash;&nbsp;Germ cell tumors (GCTs) are classified as extragonadal if there is no evidence of a primary tumor in the testes or ovaries [",
"    <a class=\"abstract\" href=\"UTD.htm?9/52/10058/abstract/1\">",
"     1",
"    </a>",
"    ]. Extragonadal GCTs typically arise in midline locations, and specific sites vary with age. In adults, the most common sites, in order of frequency, are the anterior mediastinum, retroperitoneum, and the pineal and suprasellar regions. In infants and young children, sacrococcygeal and intracranial GCTs are most common. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?35/6/35946?source=see_link\">",
"     \"Uncommon brain tumors\"",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"UTD.htm?17/30/17894?source=see_link\">",
"     \"Sacrococcygeal germ cell tumors\"",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"UTD.htm?29/25/30105?source=see_link\">",
"     \"Pediatric intracranial germ cell tumors\"",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    Histologically, extragonadal GCTs include seminomas and nonseminomatous GCTs. Seminomas must be distinguished from nonseminomatous GCTs because of the differences in prognosis and treatment. The counterparts to seminomas and nonseminomas in women are dysgerminomas and nondysgerminomas, whereas in children they are often referred to as germinomas and nongerminomas. The nonseminomatous tumors, like the nondysgerminomas and nongerminomas, include yolk sac tumors, choriocarcinomas, embryonal carcinomas, and mixed tumors that contain more than one cell line. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?4/43/4794?source=see_link\">",
"     \"Pathology of mediastinal tumors\"",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    Unlike testicular germ cell tumors where there is no clear prognostic distinction between mature and immature teratoma, mature teratomas of the mediastinum generally behave in a benign manner. In adults, immature teratomas of the mediastinum can be aggressive tumors and have a poor prognosis whereas in prepubertal children, immature elements in a teratoma are not associated with malignant behavior [",
"    <a class=\"abstract\" href=\"UTD.htm?9/52/10058/abstract/2,3\">",
"     2,3",
"    </a>",
"    ]. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?4/43/4794?source=see_link\">",
"     \"Pathology of mediastinal tumors\"",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    The etiology of extragonadal GCTs is unknown. In rare cases, they have been associated with Klinefelter syndrome [",
"    <a class=\"abstract\" href=\"UTD.htm?9/52/10058/abstract/4-7\">",
"     4-7",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    The clinical manifestation and treatment of mediastinal and retroperitoneal GCTs are reviewed here. The pathology, differential diagnosis, and evaluation of mediastinal tumors are discussed elsewhere. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?4/43/4794?source=see_link\">",
"     \"Pathology of mediastinal tumors\"",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"UTD.htm?31/40/32392?source=see_link\">",
"     \"Anterior mediastinal mass lesions\"",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"UTD.htm?30/24/31111?source=see_link\">",
"     \"Evaluation of mediastinal masses\"",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H2\">",
"    <span class=\"h1\">",
"     HISTOGENESIS",
"    </span>",
"    &nbsp;&mdash;&nbsp;The histogenesis of extragonadal GCTs is not clearly defined. Two competing hypotheses have been proposed, but there are inadequate data to determine which, if either, is correct.",
"   </p>",
"   <p>",
"    The first hypothesis is that extragonadal GCTs are derived from primordial germ cells that fail to complete the normal migration along the urogenital ridge to the gonadal ridges during embryonal development. This may be due to an abnormality in the primordial germ cell itself or in its microenvironment [",
"    <a class=\"abstract\" href=\"UTD.htm?9/52/10058/abstract/8\">",
"     8",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    The second main hypothesis is that germ cells transformed in the testes undergo reverse migration [",
"    <a class=\"abstract\" href=\"UTD.htm?9/52/10058/abstract/9\">",
"     9",
"    </a>",
"    ]. This hypothesis is supported by genetic data suggesting that extragonadal GCTs and testicular GCTs share a common cell of origin [",
"    <a class=\"abstract\" href=\"UTD.htm?9/52/10058/abstract/10,11\">",
"     10,11",
"    </a>",
"    ]. The second hypothesis does not explain the biological differences seen between mediastinal nonseminomatous GCTs compared to nonseminomatous GCTs occurring in the testes or retroperitoneum. Such differences include the poorer prognosis and the greater incidence of yolk sac tumor elements and leukemia in patients with mediastinal primaries and might result from differences either in the cell of origin or in the tumor's microenvironment.",
"   </p>",
"   <p>",
"    The following findings are noteworthy:",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      Testicular carcinoma in situ, the precursor of testicular GCTs, is found in up to 50 percent of testes of men with retroperitoneal GCTs [",
"      <a class=\"abstract\" href=\"UTD.htm?9/52/10058/abstract/12\">",
"       12",
"      </a>",
"      ]. However, testicular biopsy is not generally indicated in the absence of evidence of a tumor on ultrasonography [",
"      <a class=\"abstract\" href=\"UTD.htm?9/52/10058/abstract/13\">",
"       13",
"      </a>",
"      ]. (See",
"      <a class=\"medical medical_review\" href=\"UTD.htm?41/27/42425?source=see_link\">",
"       \"Testicular intratubular germ cell neoplasia, unclassified (testicular carcinoma in situ, testicular intraepithelial neoplasia)\"",
"      </a>",
"      .)",
"     </li>",
"     <li>",
"      The risk of developing a metachronous testicular GCT is significantly increased in men with extragonadal GCTs, particularly among those with retroperitoneal location and nonseminomatous histology (incidence ratios 100 and 75, respectively) [",
"      <a class=\"abstract\" href=\"UTD.htm?9/52/10058/abstract/14\">",
"       14",
"      </a>",
"      ]. The cumulative risk of developing a metachronous testicular cancer is approximately 10 percent at 10 years after the diagnosis of an extragonadal GCT.",
"     </li>",
"    </ul>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H3\">",
"    <span class=\"h1\">",
"     DIAGNOSIS",
"    </span>",
"    &nbsp;&mdash;&nbsp;Once the diagnosis of a germ cell tumor has been established, a primary testicular tumor must be excluded. Testicular palpation is insufficient to exclude a testicular primary; ultrasonography should be performed in all patients [",
"    <a class=\"abstract\" href=\"UTD.htm?9/52/10058/abstract/15\">",
"     15",
"    </a>",
"    ]. It may be difficult to distinguish true extragonadal GCTs from metastatic tumors in which the primary testicular lesion has regressed [",
"    <a class=\"abstract\" href=\"UTD.htm?9/52/10058/abstract/16-18\">",
"     16-18",
"    </a>",
"    ]. It is worth noting that primary mediastinal GCTs occur in the anterior mediastinum, whereas testicular GCTs rarely metastasize to the anterior mediastinum.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H4\">",
"    <span class=\"h2\">",
"     Tumor markers",
"    </span>",
"    &nbsp;&mdash;&nbsp;Like gonadal GCTs, extragonadal nonseminomatous GCTs are often associated with elevations in serum alpha fetoprotein (AFP)",
"    <span class=\"nowrap\">",
"     and/or",
"    </span>",
"    beta subunit of human chorionic gonadotropin (beta-hCG). One or both are elevated in 85 percent of cases of extragonadal nonseminomatous GCT.",
"   </p>",
"   <p>",
"    Mediastinal nonseminomatous GCTs are more likely to result in pronounced elevations of serum AFP and less likely to result in elevations of beta-hCG compared to gonadal and retroperitoneal nonseminomatous GCTs. This was illustrated in a series of 635 patients in which 74 percent of mediastinal nonseminomatous GCTs were associated with an elevated AFP (median 2548",
"    <span class=\"nowrap\">",
"     ng/mL)",
"    </span>",
"    [",
"    <a class=\"abstract\" href=\"UTD.htm?9/52/10058/abstract/19\">",
"     19",
"    </a>",
"    ]. In contrast, 51 percent of patients with retroperitoneal nonseminomatous GCTs had an elevated AFP (median 25",
"    <span class=\"nowrap\">",
"     ng/mL).",
"    </span>",
"    Serum beta-hCG was elevated in 38 percent of patients with mediastinal nonseminomatous GCTs (median 5",
"    <span class=\"nowrap\">",
"     mIU/mL)",
"    </span>",
"    compared to 74 percent of patients with retroperitoneal nonseminomatous GCTs (median 335",
"    <span class=\"nowrap\">",
"     mIU/mL).",
"    </span>",
"    (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?37/58/38822?source=see_link\">",
"     \"Serum tumor markers in testicular germ cell tumors\"",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    Although an elevation in AFP excludes the diagnosis of a pure seminoma, up to 50 percent of patients with extragonadal seminoma have small increases in serum beta-hCG [",
"    <a class=\"abstract\" href=\"UTD.htm?9/52/10058/abstract/19\">",
"     19",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H5\">",
"    <span class=\"h2\">",
"     Histologic diagnosis",
"    </span>",
"    &nbsp;&mdash;&nbsp;Biopsy is required for definitive diagnosis and treatment. The majority of patients have clear evidence of germ cell features or teratoma, while a small subset has a poorly differentiated tumor without distinctive germ cell features.",
"   </p>",
"   <p>",
"    Extragonadal nonseminomatous GCT should be considered in the differential diagnosis of histologically poorly differentiated cancer and of neoplasms of unknown primary site, particularly in young men with midline disease. Because an extragonadal GCT may be curable with",
"    <a class=\"drug drug_general\" href=\"UTD.htm?20/51/21305?source=see_link\">",
"     cisplatin",
"    </a>",
"    -based chemotherapy, many recommend that the diagnostic evaluation in such cases should include measurement of the serum tumor markers AFP and beta-hCG and immunohistochemical assessment of the biopsy [",
"    <a class=\"abstract\" href=\"UTD.htm?9/52/10058/abstract/20\">",
"     20",
"    </a>",
"    ]. Use of cytogenetic analysis for abnormalities of chromosome arm 12p is limited to the situation of a poorly differentiated carcinoma of unknown primary without an anatomic distribution typical of a GCT&nbsp;[",
"    <a class=\"abstract\" href=\"UTD.htm?9/52/10058/abstract/21\">",
"     21",
"    </a>",
"    ]. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?8/56/9096?source=see_link&amp;anchor=H1568145737#H1568145737\">",
"     \"Poorly differentiated cancer from an unknown primary site\", section on 'Extragonadal germ cell tumors'",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"UTD.htm?8/56/9096?source=see_link&amp;anchor=H2#H2\">",
"     \"Poorly differentiated cancer from an unknown primary site\", section on 'Diagnostic evaluation'",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    However, non-germ cell cancers can also produce beta-hCG and AFP, and it has never been established that poorly differentiated tumors with elevated GCT serum markers are more likely to respond to GCT chemotherapy regimens than tumors in patients with normal AFP and beta-hCG levels. Indeed, studies of this issue have reported that elevated AFP and beta-hCG are not associated with response to",
"    <a class=\"drug drug_general\" href=\"UTD.htm?20/51/21305?source=see_link\">",
"     cisplatin",
"    </a>",
"    -based chemotherapy or with improved survival [",
"    <a class=\"abstract\" href=\"UTD.htm?9/52/10058/abstract/22-25\">",
"     22-25",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    Factors that have been reported to be associated with response to GCT chemotherapy include a predominant tumor location in the retroperitoneum or in peripheral lymph nodes, tumor limited to two or fewer metastatic sites, no history of smoking, and younger age [",
"    <a class=\"abstract\" href=\"UTD.htm?9/52/10058/abstract/22\">",
"     22",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H7\">",
"    <span class=\"h1\">",
"     ASSOCIATION WITH OTHER MALIGNANCIES",
"    </span>",
"    &nbsp;&mdash;&nbsp;Mediastinal nonseminomatous GCTs, particularly those with teratomatous elements, can transform into sarcomas and carcinomas that are highly resistant to treatment with chemotherapy or radiation therapy [",
"    <a class=\"abstract\" href=\"UTD.htm?9/52/10058/abstract/26,27\">",
"     26,27",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    Patients with mediastinal nonseminomatous GCTs also have a relatively high incidence of a number of hematologic disorders unrelated to cytotoxic chemotherapy. These include acute megakaryoblastic and myelogenous leukemia, myelodysplasia, malignant mastocytosis, and malignant histiocytosis.",
"   </p>",
"   <p>",
"    In one series of 287 patients with primary mediastinal nonseminomatous GCTS treated at 11 institutions in the United States and Europe, the relative risk of developing a hematologic disorder was increased 250-fold compared to the age-matched general population, with a hematologic disorder developing in 6 percent over a three year period [",
"    <a class=\"abstract\" href=\"UTD.htm?9/52/10058/abstract/28\">",
"     28",
"    </a>",
"    ]. The median time to onset of the hematologic disorder was six months, the median survival following diagnosis was five months, and no patient survived more than two years.",
"   </p>",
"   <p>",
"    In many cases, the malignant cells in these hematologic disorders have an isochromosome 12p or other evidence of derivation from the GCT [",
"    <a class=\"abstract\" href=\"UTD.htm?9/52/10058/abstract/28-30\">",
"     28-30",
"    </a>",
"    ]. Furthermore, in one report of six patients with mediastinal GCTs associated with hematologic malignancy, four had hematopoietic precursor cells within the yolk sac component of the tumor which had a similar morphology and immunohistochemical profile as the leukemic cells in bone marrow [",
"    <a class=\"abstract\" href=\"UTD.htm?9/52/10058/abstract/31\">",
"     31",
"    </a>",
"    ]. Thus, leukemia may originate from a yolk sac, tumor-derived progenitor cell capable of undergoing hematopoietic differentiation, with subsequent homing to the bone marrow.",
"   </p>",
"   <p>",
"    In contrast to these findings in mediastinal nonseminomatous GCTs, mediastinal seminomas are not associated with transformation into non-germ cell malignancies [",
"    <a class=\"abstract\" href=\"UTD.htm?9/52/10058/abstract/28\">",
"     28",
"    </a>",
"    ]. In addition, with the exception of hematologic malignancies, patients with extragonadal GCTs do not appear to be at increased risk for developing second non-germ cell malignancies except as an effect of the chemotherapy used to treat these tumors [",
"    <a class=\"abstract\" href=\"UTD.htm?9/52/10058/abstract/32\">",
"     32",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H8\">",
"    <span class=\"h1\">",
"     MATURE TERATOMAS",
"    </span>",
"    &nbsp;&mdash;&nbsp;Mature teratomas of the mediastinum contain well-differentiated histologic elements derived from at least two of the three embryonic cell layers (also known as the germinal layers) ectoderm, mesoderm, and endoderm (",
"    <a class=\"graphic graphic_picture graphicRef57501 \" href=\"UTD.htm?37/52/38724\">",
"     picture 1",
"    </a>",
"    ). Tumors containing a mixture of mature teratoma and other germ-cell-tumor elements (mixed tumors) should be treated as mediastinal nonseminomatous GCTs (",
"    <a class=\"graphic graphic_table graphicRef59492 \" href=\"UTD.htm?9/52/10060\">",
"     table 1",
"    </a>",
"    ). (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?4/43/4794?source=see_link\">",
"     \"Pathology of mediastinal tumors\"",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    In males, mediastinal teratomas and testicular teratomas are distinct clinical entities. Mature teratomas of the testis are not considered benign; they are thought to have metastatic potential (although less than other testicular GCTs) and are treated in a similar manner to other testicular nonseminomatous GCTs. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?5/40/5770?source=see_link&amp;anchor=H11#H11\">",
"     \"Anatomy and pathology of testicular tumors\", section on 'Teratoma'",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H9\">",
"    <span class=\"h2\">",
"     Clinical manifestations",
"    </span>",
"    &nbsp;&mdash;&nbsp;Mature teratomas of the mediastinum are generally benign, although they have malignant potential. They often grow slowly; as a result, they are more likely than other mediastinal GCTs to be diagnosed incidentally while they are still asymptomatic (",
"    <a class=\"graphic graphic_diagnosticimage graphicRef78698 \" href=\"UTD.htm?28/39/29296\">",
"     image 1",
"    </a>",
"    ) [",
"    <a class=\"abstract\" href=\"UTD.htm?9/52/10058/abstract/33\">",
"     33",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    Symptoms (chest pain, cough, dyspnea, and bronchial obstruction and postobstructive pneumonia) are generally due to compression and obstruction of surrounding organs [",
"    <a class=\"abstract\" href=\"UTD.htm?9/52/10058/abstract/34,35\">",
"     34,35",
"    </a>",
"    ]. Erosion into an adjacent bronchus can rarely lead to expectoration of hair (trichoptysis) or sebaceous debris [",
"    <a class=\"abstract\" href=\"UTD.htm?9/52/10058/abstract/35\">",
"     35",
"    </a>",
"    ]. Erosion into the pericardium, adjacent vascular structures, or through the skin to form a draining fistula is a rare but serious complication [",
"    <a class=\"abstract\" href=\"UTD.htm?9/52/10058/abstract/34,36\">",
"     34,36",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H10\">",
"    <span class=\"h2\">",
"     Imaging studies",
"    </span>",
"    &nbsp;&mdash;&nbsp;Chest radiography, if performed incidentally or for symptoms, typically shows an anterior mediastinal mass, with calcification reported in 26 percent of mature teratomas [",
"    <a class=\"abstract\" href=\"UTD.htm?9/52/10058/abstract/34\">",
"     34",
"    </a>",
"    ]. In some patients, well-formed teeth or bone are seen on plain film, findings that are very suggestive of the diagnosis. CT and MRI are helpful in localizing lesions and determining the spatial relationships to surrounding structures. They can also characterize densities within the lesion suggestive of fat, sebaceous material, or cystic elements (",
"    <a class=\"graphic graphic_diagnosticimage graphicRef78698 \" href=\"UTD.htm?28/39/29296\">",
"     image 1",
"    </a>",
"    ) [",
"    <a class=\"abstract\" href=\"UTD.htm?9/52/10058/abstract/37,38\">",
"     37,38",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H11\">",
"    <span class=\"h2\">",
"     Treatment",
"    </span>",
"    &nbsp;&mdash;&nbsp;Treatment of mediastinal mature teratomas is surgical excision and this is almost always curative [",
"    <a class=\"abstract\" href=\"UTD.htm?9/52/10058/abstract/39,40\">",
"     39,40",
"    </a>",
"    ]. Subtotal resection with relief of compressive symptoms is performed if benign teratomas cannot be excised completely without endangering surrounding vital structures. Resection generally is through a median sternotomy or posterolateral thoracotomy, depending upon the location of the tumor, although thoracoscopic resection is occasionally possible [",
"    <a class=\"abstract\" href=\"UTD.htm?9/52/10058/abstract/34,41\">",
"     34,41",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    Mature teratomas are relatively insensitive to both chemotherapy and radiation therapy (RT).",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H12\">",
"    <span class=\"h1\">",
"     IMMATURE TERATOMAS",
"    </span>",
"    &nbsp;&mdash;&nbsp;Teratomas of the mediastinum exist on a continuum ranging from purely mature to predominantly immature. These tumors are rare enough that clinically meaningful criteria for defining immaturity are not well established. Immature teratomas are characterized by mature elements from all three germinal layers, which are mixed with immature tissue. Macroscopically, immature teratomas form cystic masses with areas of hemorrhage and necrosis. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?4/43/4794?source=see_link\">",
"     \"Pathology of mediastinal tumors\"",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H13\">",
"    <span class=\"h2\">",
"     Treatment",
"    </span>",
"    &nbsp;&mdash;&nbsp;The optimal treatment for immature mediastinal teratomas is uncertain. Radical resection is indicated but is often carried out after four cycles of",
"    <a class=\"drug drug_general\" href=\"UTD.htm?38/15/39159?source=see_link\">",
"     bleomycin",
"    </a>",
"    ,",
"    <a class=\"drug drug_general\" href=\"UTD.htm?29/57/30617?source=see_link\">",
"     etoposide",
"    </a>",
"    , and",
"    <a class=\"drug drug_general\" href=\"UTD.htm?20/51/21305?source=see_link\">",
"     cisplatin",
"    </a>",
"    (BEP, (",
"    <a class=\"graphic graphic_table graphicRef65516 \" href=\"UTD.htm?14/2/14382\">",
"     table 2",
"    </a>",
"    )) chemotherapy, although the benefits of chemotherapy and the optimal timing in relation to surgery have not been evaluated in randomized trials due to the rarity of the disease. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?23/63/24568?source=see_link\">",
"     \"Initial risk-stratified treatment for advanced testicular germ cell tumors\"",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    Although primary immature mediastinal teratomas in adults often have a poor prognosis, long-term survival has been reported with preoperative chemotherapy and aggressive surgical resection [",
"    <a class=\"abstract\" href=\"UTD.htm?9/52/10058/abstract/42\">",
"     42",
"    </a>",
"    ]. Immature teratomas containing elements of other GCTs should be treated like other mediastinal nonseminomatous GCTs. (See",
"    <a class=\"local\" href=\"#H21\">",
"     'Mediastinal nonseminomatous GCT'",
"    </a>",
"    below.)",
"   </p>",
"   <p>",
"    If malignant degeneration occurs (ie, teratoma with malignant transformation), resection is the treatment of choice. When resection is possible, the outcome is similar to other patients with teratoma. However, if these tumors are unresectable or have metastasized, they are generally incurable. If the transformation is limited to a single cell type, tailored chemotherapy directed towards that cell type may result in major responses and even long-term survival in selected patients [",
"    <a class=\"abstract\" href=\"UTD.htm?9/52/10058/abstract/43\">",
"     43",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    In children, immature mediastinal teratomas behave similarly to mature teratomas and should be completely excised. (See",
"    <a class=\"local\" href=\"#H8\">",
"     'Mature teratomas'",
"    </a>",
"    above.)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H14\">",
"    <span class=\"h1\">",
"     MEDIASTINAL SEMINOMA",
"    </span>",
"    &nbsp;&mdash;&nbsp;Mediastinal seminomas constitute approximately one-third of malignant mediastinal GCTs and 2 to 4 percent of mediastinal masses [",
"    <a class=\"abstract\" href=\"UTD.htm?9/52/10058/abstract/44\">",
"     44",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    Mediastinal seminomas occur predominantly in men between the ages of 20 and 40 [",
"    <a class=\"abstract\" href=\"UTD.htm?9/52/10058/abstract/39\">",
"     39",
"    </a>",
"    ]. Although it is uncommon for testicular seminoma to metastasize to the mediastinum in the absence of retroperitoneal lymph node involvement [",
"    <a class=\"abstract\" href=\"UTD.htm?9/52/10058/abstract/15\">",
"     15",
"    </a>",
"    ], all men with mediastinal seminoma should undergo careful testicular palpation and ultrasonography. Orchiectomy is generally indicated in the event of suspicious findings. Mediastinal dysgerminomas (the female counterpart to seminomas) are rare in women with histologically normal ovaries.",
"   </p>",
"   <p>",
"    In order for a GCT to be classified as a seminoma (or dysgerminoma in women), no other histologic element of a GCT can be present (",
"    <a class=\"graphic graphic_picture graphicRef66422 graphicRef54661 \" href=\"UTD.htm?19/54/20330\">",
"     picture 2A-B",
"    </a>",
"    ). Tumors consisting of a mixture of seminoma and other tumor types are termed mixed GCTs and are treated as nonseminomatous GCTs.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H15\">",
"    <span class=\"h2\">",
"     Clinical manifestations",
"    </span>",
"    &nbsp;&mdash;&nbsp;Primary mediastinal seminomas are typically slow growing and can be very bulky by the time they cause discomfort. The majority (75 percent) are symptomatic at the time of diagnosis.",
"   </p>",
"   <p>",
"    The common presenting symptoms are illustrated by a series of 52 patients with mediastinal seminoma [",
"    <a class=\"abstract\" href=\"UTD.htm?9/52/10058/abstract/19\">",
"     19",
"    </a>",
"    ]:",
"   </p>",
"   <p>",
"    <ul class=\"bulletCompact-block\">",
"     <li>",
"      Chest pain - 39 percent",
"     </li>",
"     <li>",
"      Dyspnea - 29 percent",
"     </li>",
"     <li>",
"      Cough - 22 percent",
"     </li>",
"     <li>",
"      Weight loss - 19 percent",
"     </li>",
"     <li>",
"      Superior vena cava syndrome - 12 percent",
"     </li>",
"     <li>",
"      Fever - 6 percent",
"     </li>",
"     <li>",
"      Nausea - 6 percent",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    Serum beta-hCG is elevated in approximately one-third of patients [",
"    <a class=\"abstract\" href=\"UTD.htm?9/52/10058/abstract/19\">",
"     19",
"    </a>",
"    ]. Seminomas do not produce AFP. An elevated serum AFP is inconsistent with the diagnosis of a pure seminoma and indicates that nonseminomatous elements are present even if the histopathologic diagnosis is pure seminoma. Such tumors are treated as nonseminomatous GCTs. (See",
"    <a class=\"local\" href=\"#H4\">",
"     'Tumor markers'",
"    </a>",
"    above and",
"    <a class=\"medical medical_review\" href=\"UTD.htm?37/58/38822?source=see_link&amp;anchor=H6#H6\">",
"     \"Serum tumor markers in testicular germ cell tumors\", section on 'False-positive results'",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    The majority of mediastinal seminomas have metastasized by the time they are detected, most often to the lymph nodes and less commonly to lungs, bone,",
"    <span class=\"nowrap\">",
"     and/or",
"    </span>",
"    liver [",
"    <a class=\"abstract\" href=\"UTD.htm?9/52/10058/abstract/19\">",
"     19",
"    </a>",
"    ]. Detection of extramediastinal spread is important because the presence of nonpulmonary visceral metastases is associated with a poorer prognosis. CT imaging is essential to evaluate the primary tumor, retroperitoneal lymph nodes and liver.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H16\">",
"    <span class=\"h2\">",
"     Treatment",
"    </span>",
"    &nbsp;&mdash;&nbsp;Seminomas are exquisitely sensitive to both",
"    <a class=\"drug drug_general\" href=\"UTD.htm?20/51/21305?source=see_link\">",
"     cisplatin",
"    </a>",
"    -based chemotherapy and RT, regardless of location. The relative merits of chemotherapy, RT, and surgery have not been evaluated in randomized controlled trials, and treatment recommendations are based largely upon small case series, retrospective reviews, and extrapolations from data on advanced testicular seminomas.",
"   </p>",
"   <p>",
"    Men with mediastinal seminomas without evidence of nonpulmonary visceral metastases are classified as good-risk GCTs by the International Germ Cell Consensus Classification and have a five-year survival rate of greater than 90 percent [",
"    <a class=\"abstract\" href=\"UTD.htm?9/52/10058/abstract/45,46\">",
"     45,46",
"    </a>",
"    ]. Most centers prefer chemotherapy to RT for patients with mediastinal seminoma, largely due to concerns about an increased risk of cardiovascular events following mediastinal radiation therapy. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?24/17/24852?source=see_link\">",
"     \"Risk stratification of metastatic testicular germ cell tumors\"",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"UTD.htm?23/63/24568?source=see_link\">",
"     \"Initial risk-stratified treatment for advanced testicular germ cell tumors\"",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H17\">",
"    <span class=\"h3\">",
"     Chemotherapy",
"    </span>",
"    &nbsp;&mdash;&nbsp;The most widely recommended chemotherapy regimen for patients with mediastinal seminomas and no nonpulmonary visceral metastases is three cycles of",
"    <a class=\"drug drug_general\" href=\"UTD.htm?20/51/21305?source=see_link\">",
"     cisplatin",
"    </a>",
"    ,",
"    <a class=\"drug drug_general\" href=\"UTD.htm?29/57/30617?source=see_link\">",
"     etoposide",
"    </a>",
"    , plus",
"    <a class=\"drug drug_general\" href=\"UTD.htm?38/15/39159?source=see_link\">",
"     bleomycin",
"    </a>",
"    (BEP) chemotherapy or four cycles of etoposide plus cisplatin without bleomycin, as is used for advanced testicular seminoma (",
"    <a class=\"graphic graphic_table graphicRef65516 \" href=\"UTD.htm?14/2/14382\">",
"     table 2",
"    </a>",
"    and",
"    <a class=\"graphic graphic_table graphicRef63222 \" href=\"UTD.htm?38/62/39917\">",
"     table 3",
"    </a>",
"    ). The latter regimen is preferred for patients who have received RT to the chest or mediastinum, which increases the risk of bleomycin lung toxicity, or who have underlying lung disease [",
"    <a class=\"abstract\" href=\"UTD.htm?9/52/10058/abstract/47\">",
"     47",
"    </a>",
"    ]. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?23/63/24568?source=see_link&amp;anchor=H6#H6\">",
"     \"Initial risk-stratified treatment for advanced testicular germ cell tumors\", section on 'Good-risk'",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"UTD.htm?12/31/12794?source=see_link&amp;anchor=H5#H5\">",
"     \"Bleomycin-induced lung injury\", section on 'Risk factors'",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    Patients with mediastinal seminoma and metastases to the liver, bones or other nonpulmonary organs should be treated with four cycles of BEP chemotherapy. Patients with metastases to organs other than the lungs who cannot tolerate",
"    <a class=\"drug drug_general\" href=\"UTD.htm?38/15/39159?source=see_link\">",
"     bleomycin",
"    </a>",
"    should receive four courses of the VIP regimen (",
"    <a class=\"drug drug_general\" href=\"UTD.htm?29/57/30617?source=see_link\">",
"     etoposide",
"    </a>",
"    75",
"    <span class=\"nowrap\">",
"     mg/m",
"     <sup>",
"      2",
"     </sup>",
"     ,",
"    </span>",
"    <a class=\"drug drug_general\" href=\"UTD.htm?37/25/38297?source=see_link\">",
"     ifosfamide",
"    </a>",
"    1.2",
"    <span class=\"nowrap\">",
"     g/m",
"     <sup>",
"      2",
"     </sup>",
"     ,",
"    </span>",
"    and",
"    <a class=\"drug drug_general\" href=\"UTD.htm?20/51/21305?source=see_link\">",
"     cisplatin",
"    </a>",
"    20",
"    <span class=\"nowrap\">",
"     mg/m",
"     <sup>",
"      2",
"     </sup>",
"     ,",
"    </span>",
"    all administered daily for five consecutive days every three weeks). For patients who have received RT to the chest or mediastinum or have underlying lung disease, we typically use a bleomycin-free regimen [",
"    <a class=\"abstract\" href=\"UTD.htm?9/52/10058/abstract/47\">",
"     47",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    The results of chemotherapy for extragonadal seminoma are illustrated by a series that included 103 patients with either mediastinal or retroperitoneal seminomas, in which",
"    <a class=\"drug drug_general\" href=\"UTD.htm?20/51/21305?source=see_link\">",
"     cisplatin",
"    </a>",
"    -based chemotherapy was administered to 91 percent [",
"    <a class=\"abstract\" href=\"UTD.htm?9/52/10058/abstract/19\">",
"     19",
"    </a>",
"    ]. Chemotherapy alone was used in 75 percent of cases. For the entire cohort, the remission rate with chemotherapy and postchemotherapy resection of residual masses was 92 percent, and the five-year overall survival rate was 88 percent for mediastinal and retroperitoneal primary tumors alike. There were no differences in outcomes between patients with mediastinal and retroperitoneal tumors. (See",
"    <a class=\"local\" href=\"#H20\">",
"     'Residual mass'",
"    </a>",
"    below.)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H18\">",
"    <span class=\"h3\">",
"     Radiation therapy",
"    </span>",
"    &nbsp;&mdash;&nbsp;In those rare patients who are not candidates for chemotherapy, primary RT (35 to 50 Gy) is an acceptable alternative strategy in the absence of bulky or metastatic disease [",
"    <a class=\"abstract\" href=\"UTD.htm?9/52/10058/abstract/33\">",
"     33",
"    </a>",
"    ]. If RT is used, the radiation portals should include the mediastinum and bilateral supraclavicular fossae. Careful treatment planning is essential to avoid unnecessary toxicity to the lungs, heart, and other surrounding tissues. Mediastinal radiation has been associated with coronary artery disease, valvular disease, diastolic dysfunction, and constrictive pericarditis. In addition, an increased frequency of late breast, esophageal, and lung cancers, as well as other malignancies, has been reported. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?33/21/34137?source=see_link\">",
"     \"Cardiotoxicity of radiation therapy for malignancy\"",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    Although most patients treated with primary RT are cured, the distant relapse rate is high and the five-year disease-free survival rate is only 60 to 67 percent [",
"    <a class=\"abstract\" href=\"UTD.htm?9/52/10058/abstract/19,48\">",
"     19,48",
"    </a>",
"    ]. By comparison, long-term disease-free survival is achieved in roughly 90 percent of patients treated with chemotherapy [",
"    <a class=\"abstract\" href=\"UTD.htm?9/52/10058/abstract/19\">",
"     19",
"    </a>",
"    ]. Most patients who relapse following primary RT can be salvaged with chemotherapy, but there is some evidence that the overall survival rate may be higher with initial chemotherapy [",
"    <a class=\"abstract\" href=\"UTD.htm?9/52/10058/abstract/49\">",
"     49",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H19\">",
"    <span class=\"h3\">",
"     Surgery",
"    </span>",
"    &nbsp;&mdash;&nbsp;In the unusual case in which a mediastinal seminoma is discovered when very small and localized, complete surgical excision may be performed, followed by adjuvant chemotherapy. In general, however, surgical resection or debulking plays no role in the initial management of seminomas because of the typical presence of bulky",
"    <span class=\"nowrap\">",
"     and/or",
"    </span>",
"    metastatic disease [",
"    <a class=\"abstract\" href=\"UTD.htm?9/52/10058/abstract/19\">",
"     19",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H20\">",
"    <span class=\"h3\">",
"     Residual mass",
"    </span>",
"    &nbsp;&mdash;&nbsp;Following chemotherapy, many patients are left with a residual mass. Most of these masses consist of necrosis or a scirrhous or desmoplastic reaction. Residual masses should not be treated with chemotherapy or RT without histologic confirmation of residual disease [",
"    <a class=\"abstract\" href=\"UTD.htm?9/52/10058/abstract/50,51\">",
"     50,51",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    The optimal treatment of a residual mass is a subject of contention. Surgical resection is often technically difficult and may be unnecessary for masses &lt;3 cm. As a result, many recommend surveillance for such cases [",
"    <a class=\"abstract\" href=\"UTD.htm?9/52/10058/abstract/52-54\">",
"     52-54",
"    </a>",
"    ]. However, residual masses &ge;3 cm in diameter contain residual malignancy in up to 30 percent of cases [",
"    <a class=\"abstract\" href=\"UTD.htm?9/52/10058/abstract/52-54\">",
"     52-54",
"    </a>",
"    ], although not all studies have found a relationship between the size of a mass and the probability of viable seminoma [",
"    <a class=\"abstract\" href=\"UTD.htm?9/52/10058/abstract/50\">",
"     50",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    Alternative approaches for masses &ge;3 cm include careful monitoring with periodic CT scans and open biopsy of the mass [",
"    <a class=\"abstract\" href=\"UTD.htm?9/52/10058/abstract/52,54\">",
"     52,54",
"    </a>",
"    ]. One surveillance regimen that has been used is CT scan every three months the first year and every six months the second year or until normal. Further therapeutic intervention is performed only for progressive disease [",
"    <a class=\"abstract\" href=\"UTD.htm?9/52/10058/abstract/52\">",
"     52",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    One study reported that positron emission tomography (PET) with 18-fluoro-2-deoxyglucose (FDG) performed after chemotherapy is highly accurate in distinguishing benign from malignant residual masses [",
"    <a class=\"abstract\" href=\"UTD.htm?9/52/10058/abstract/54\">",
"     54",
"    </a>",
"    ], but this has not yet been confirmed, and a subsequent study reported a high false-positive rate [",
"    <a class=\"abstract\" href=\"UTD.htm?9/52/10058/abstract/55\">",
"     55",
"    </a>",
"    ]. If a PET scan is utilized, it should be obtained about two months after completion of chemotherapy. Masses showing increased FDG uptake should be completely resected, if possible, or else extensively biopsied. A positive PET scan alone is not strong enough evidence to justify additional treatment with chemotherapy or radiation therapy due to a significant false positive rate. On the other hand, the false negative rate in masses over 3 cm in size has been reported to be zero [",
"    <a class=\"abstract\" href=\"UTD.htm?9/52/10058/abstract/55,56\">",
"     55,56",
"    </a>",
"    ]. Thus, in a patient with a residual mass larger than 3 cm for whom a resection or open biopsy is planned, a negative PET scan provides a reasonable basis for foregoing the operation unless the mass is increasing in size.",
"   </p>",
"   <p>",
"    Patients who have histologically confirmed residual viable malignancy or who develop progressive disease should generally be treated with salvage chemotherapy, but RT represents an alternative approach for selected patients.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H21\">",
"    <span class=\"h1\">",
"     MEDIASTINAL NONSEMINOMATOUS GCT",
"    </span>",
"    &nbsp;&mdash;&nbsp;Nonseminomatous GCTs of the mediastinum may contain yolk sac tumor, choriocarcinoma, or embryonal carcinoma. Mixed GCTs may contain more than one cell type, as well as elements of teratoma",
"    <span class=\"nowrap\">",
"     and/or",
"    </span>",
"    seminoma.",
"   </p>",
"   <p>",
"    In contrast to gonadal nonseminomatous GCTs, mediastinal nonseminomatous GCTs infrequently contain embryonal carcinoma, whereas yolk sac tumors (either pure or mixed with other histologies) are common (",
"    <a class=\"graphic graphic_picture graphicRef78211 \" href=\"UTD.htm?8/44/8903\">",
"     picture 3",
"    </a>",
"    ). In one series of 64 cases, 60 percent were pure yolk sac tumors, 12 percent were pure choriocarcinomas, and 9 percent were pure embryonal carcinomas. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?4/43/4794?source=see_link\">",
"     \"Pathology of mediastinal tumors\"",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    Mediastinal nonseminomatous GCTs are less common than seminomas or teratomas, and they carry a distinctly worse prognosis with a five year overall survival of about 40 to 45 percent [",
"    <a class=\"abstract\" href=\"UTD.htm?9/52/10058/abstract/19,45\">",
"     19,45",
"    </a>",
"    ]. Mediastinal nonseminomatous GCTs are always considered poor-risk GCTs. They occur far more often in men than women and usually are diagnosed between the ages of 20 and 40 years. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?24/17/24852?source=see_link\">",
"     \"Risk stratification of metastatic testicular germ cell tumors\"",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    Patients with mediastinal GCTs are at risk for developing fatal hematologic disorders, which typically display a megakaryocytic lineage and share cytogenetic abnormalities with nonseminomatous GCTs. (See",
"    <a class=\"local\" href=\"#H7\">",
"     'Association with other malignancies'",
"    </a>",
"    above.)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H22\">",
"    <span class=\"h2\">",
"     Clinical manifestations",
"    </span>",
"    &nbsp;&mdash;&nbsp;Most patients with mediastinal nonseminomatous GCTs are symptomatic at presentation [",
"    <a class=\"abstract\" href=\"UTD.htm?9/52/10058/abstract/57,58\">",
"     57,58",
"    </a>",
"    ]. Signs and symptoms may include fever, chills, weight loss, chest pain, dyspnea,",
"    <span class=\"nowrap\">",
"     and/or",
"    </span>",
"    superior vena cava syndrome. Gynecomastia can be seen in tumors with foci of choriocarcinoma that secrete large amounts of human chorionic gonadotropin. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?26/47/27384?source=see_link\">",
"     \"Causes and evaluation of gynecomastia\"",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    Most patients have an elevated serum AFP at presentation, and a sizable minority have an elevated serum beta-hCG. This pattern is so characteristic that some institutions accept an elevated AFP and beta-hCG in a young adult male with an anterior mediastinal mass as de facto evidence of an extragonadal nonseminomatous GCT, and chemotherapy is sometimes started without a tissue diagnosis. We recommend histologic confirmation in all patients if it can be safely accomplished unless the clinical scenario demands immediate treatment. Histologic confirmation is clearly required in the roughly 10 percent of patients with normal serum tumor markers.",
"   </p>",
"   <p>",
"    Serial monitoring of serum AFP and beta-hCG is helpful in monitoring the response to therapy and detecting early recurrence. The suggested schedule is similar to that used in testicular nonseminomatous GCTs. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?37/58/38822?source=see_link&amp;anchor=H17#H17\">",
"     \"Serum tumor markers in testicular germ cell tumors\", section on 'Monitoring response to therapy'",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H23\">",
"    <span class=\"h2\">",
"     Treatment",
"    </span>",
"    &nbsp;&mdash;&nbsp;Mediastinal nonseminomatous GCTs are aggressive tumors that are often metastatic at presentation [",
"    <a class=\"abstract\" href=\"UTD.htm?9/52/10058/abstract/57,59\">",
"     57,59",
"    </a>",
"    ]. A multimodality approach is generally used, utilizing chemotherapy initially followed by surgery to resect any residual masses.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H24\">",
"    <span class=\"h3\">",
"     Systemic chemotherapy",
"    </span>",
"    &nbsp;&mdash;&nbsp;Standard initial treatment consists of four cycles of chemotherapy, as is used in patients with advanced testicular intermediate- or poor-risk GCTs. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?23/63/24568?source=see_link&amp;anchor=H13#H13\">",
"     \"Initial risk-stratified treatment for advanced testicular germ cell tumors\", section on 'Intermediate- and poor-risk advanced disease'",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    Four cycles of VIP is preferred by some oncologists for mediastinal nonseminomas because these patients will typically undergo a thoracotomy or sternotomy for resection of residual disease and may require prolonged exposure to high partial pressures of oxygen during surgery, which can provoke",
"    <a class=\"drug drug_general\" href=\"UTD.htm?38/15/39159?source=see_link\">",
"     bleomycin",
"    </a>",
"    -related pneumonitis. Four cycles of BEP is an alternative. Indiana University reported that among 158 men undergoing postchemotherapy operations for mediastinal nonseminomas, 19 (13 percent) developed postoperative respiratory failure, of whom nine died. All 19 had received bleomycin, whereas respiratory failure occurred in none of the 17 patients who received VIP chemotherapy [",
"    <a class=\"abstract\" href=\"UTD.htm?9/52/10058/abstract/60\">",
"     60",
"    </a>",
"    ]. The efficacy and toxicity of VIP as an alternative to BEP and the results of trials comparing these regimens in patients with advanced nonseminomatous GCTs are discussed separately but the two regimens appear to have similar efficacy against nonseminomatous germ cell tumors and different toxicity profiles. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?23/63/24568?source=see_link&amp;anchor=H13#H13\">",
"     \"Initial risk-stratified treatment for advanced testicular germ cell tumors\", section on 'Intermediate- and poor-risk advanced disease'",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H25\">",
"    <span class=\"h3\">",
"     Surgery for residual mass",
"    </span>",
"    &nbsp;&mdash;&nbsp;Most patients with mediastinal nonseminomatous GCTs have residual masses at the conclusion of chemotherapy. Radical resection of all residual masses following chemotherapy plays an integral role in the treatment of these tumors and should be completed whenever technically feasible, even if serum tumor markers are rising at the completion of chemotherapy given the poor results with salvage chemotherapy [",
"    <a class=\"abstract\" href=\"UTD.htm?9/52/10058/abstract/19,61-64\">",
"     19,61-64",
"    </a>",
"    ]. These masses should be completely resected if possible. Aggressive surgery is required, and these operations are often complex. Referral to thoracic surgeon with substantial experience with mediastinal nonseminomas is advisable when possible.",
"   </p>",
"   <p>",
"    Following post-chemotherapy surgery, no further therapy is necessary if the residual masses contain teratoma or necrosis. If viable malignancy is identified, two additional cycles of VIP chemotherapy should be given.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H26\">",
"    <span class=\"h3\">",
"     Salvage chemotherapy",
"    </span>",
"    &nbsp;&mdash;&nbsp;Salvage chemotherapy (using either standard- or high-dose chemotherapy regimens) for mediastinal nonseminomatous GCTs has been minimally effective, with a long-term disease-free survival rates ranging from 0 to 11 percent [",
"    <a class=\"abstract\" href=\"UTD.htm?9/52/10058/abstract/19,59,63,65-68\">",
"     19,59,63,65-68",
"    </a>",
"    ]. The series with the most favorable results involved a retrospective review of 79 patients treated at 11 centers, who had relapsed after receiving",
"    <a class=\"drug drug_general\" href=\"UTD.htm?20/51/21305?source=see_link\">",
"     cisplatin",
"    </a>",
"    -based therapy [",
"    <a class=\"abstract\" href=\"UTD.htm?9/52/10058/abstract/19,68\">",
"     19,68",
"    </a>",
"    ]. Only 8 percent were long-term disease-free survivors compared to 30 percent of those with primary retroperitoneal disease. Of the 25 patients with primary mediastinal tumors who received high-dose chemotherapy with autologous stem cell transplantation at relapse, only three (12 percent) were long-term survivors.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H27\">",
"    <span class=\"h2\">",
"     Prognosis",
"    </span>",
"    &nbsp;&mdash;&nbsp;The effectiveness of this combined modality approach as the initial approach to treating mediastinal nonseminomatous GCTs was illustrated in a retrospective multicenter study that included 287 patients with mediastinal nonseminomatous GCTs, in which 278 patients (97 percent) were initially treated with chemotherapy [",
"    <a class=\"abstract\" href=\"UTD.htm?9/52/10058/abstract/19\">",
"     19",
"    </a>",
"    ]. The complete response rate to chemotherapy was 19 percent, and tumor markers normalized during a partial response in 45 percent. Surgery was used to resect a residual mass in 143 patients (50 percent). The five-year progression-free and overall survival rates were 44 and 45 percent, respectively.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H28\">",
"    <span class=\"h1\">",
"     RETROPERITONEAL TUMORS",
"    </span>",
"    &nbsp;&mdash;&nbsp;Retroperitoneal GCTs are generally bulky at the time of diagnosis. Their clinical behavior, prognosis, and management are similar to disseminated testicular GCTs [",
"    <a class=\"abstract\" href=\"UTD.htm?9/52/10058/abstract/16\">",
"     16",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H29\">",
"    <span class=\"h2\">",
"     Retroperitoneal seminoma",
"    </span>",
"    &nbsp;&mdash;&nbsp;For patients with a retroperitoneal seminoma, systemic chemotherapy with a",
"    <a class=\"drug drug_general\" href=\"UTD.htm?20/51/21305?source=see_link\">",
"     cisplatin",
"    </a>",
"    -based regimen is the preferred approach, using the same regimens as for patients with advanced testicular seminoma. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?21/45/22230?source=see_link&amp;anchor=H6#H6\">",
"     \"Treatment of stage II seminoma\", section on 'Bulky (stage IIB/IIC) seminoma'",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    The results with this approach are similar to those for advanced testicular seminoma. In a multinational series that included 52 patients with retroperitoneal seminoma and 51 with mediastinal seminoma, the progression-free and overall five-year survival rates for the entire cohort were 87 and 90 percent, respectively [",
"    <a class=\"abstract\" href=\"UTD.htm?9/52/10058/abstract/19,46\">",
"     19,46",
"    </a>",
"    ]. In this series, 75 percent of patients were treated with chemotherapy alone. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?21/45/22230?source=see_link\">",
"     \"Treatment of stage II seminoma\"",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    Nonbulky retroperitoneal seminomas can also be treated with primary RT in a manner similar to stage II testicular seminoma. However, there is insufficient published experience to determine the complete remission and cure rates using this approach. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?21/45/22230?source=see_link\">",
"     \"Treatment of stage II seminoma\"",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H30\">",
"    <span class=\"h2\">",
"     Retroperitoneal nonseminomatous GCTs",
"    </span>",
"    &nbsp;&mdash;&nbsp;The initial therapy of patients with retroperitoneal nonseminomatous GCTs consists of either three or four cycles of",
"    <a class=\"drug drug_general\" href=\"UTD.htm?20/51/21305?source=see_link\">",
"     cisplatin",
"    </a>",
"    -based chemotherapy, depending upon whether the patient falls into the good or",
"    <span class=\"nowrap\">",
"     intermediate/poor",
"    </span>",
"    prognosis group. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?23/63/24568?source=see_link\">",
"     \"Initial risk-stratified treatment for advanced testicular germ cell tumors\"",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    The results with this approach are illustrated by a multicenter series of 227 patients with retroperitoneal nonseminomatous GCTs, of which 98 percent were treated with chemotherapy initially [",
"    <a class=\"abstract\" href=\"UTD.htm?9/52/10058/abstract/19\">",
"     19",
"    </a>",
"    ]. Of these, 101 (45 percent) underwent surgery for resection of a residual mass. The five-year progression-free and overall survival rates were 42 and 65 percent, respectively.",
"   </p>",
"   <p>",
"    For those who relapse following first-line chemotherapy, salvage",
"    <a class=\"drug drug_general\" href=\"UTD.htm?20/51/21305?source=see_link\">",
"     cisplatin",
"    </a>",
"    -based chemotherapy is identical to that for gonadal nonseminomatous GCTs. In one large review, 30 percent of patients with relapsed retroperitoneal nonseminomatous GCTs achieved long-term disease-free survival [",
"    <a class=\"abstract\" href=\"UTD.htm?9/52/10058/abstract/68\">",
"     68",
"    </a>",
"    ]. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?2/56/2954?source=see_link\">",
"     \"Treatment of relapsed and refractory testicular germ cell tumors\"",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H31\">",
"    <span class=\"h1\">",
"     SUMMARY AND RECOMMENDATIONS",
"    </span>",
"    &nbsp;&mdash;&nbsp;Extragonadal germ cell tumors (GCTs) are rare tumors that most frequently arise in the mediastinum and retroperitoneum in adult males.",
"   </p>",
"   <p>",
"    There are no randomized trials to guide treatment in patients with mediastinal or retroperitoneal GCTs. The evidence supporting therapeutic recommendations are based upon observational series and experience with gonadal GCTs.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H32\">",
"    <span class=\"h2\">",
"     Mature mediastinal teratomas",
"    </span>",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      For patients with a mature teratoma of the mediastinum, we recommend complete surgical resection (",
"      <a class=\"grade\" href=\"._grade_1?title=Grade 1A\">",
"       Grade 1A",
"      </a>",
"      ). Partial resection should be limited to patients in whom a complete resection is not technically feasible. Mature teratomas are relatively insensitive to both chemotherapy and radiation therapy (RT). (See",
"      <a class=\"local\" href=\"#H8\">",
"       'Mature teratomas'",
"      </a>",
"      above.)",
"     </li>",
"    </ul>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H33\">",
"    <span class=\"h2\">",
"     Immature mediastinal teratomas",
"    </span>",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      For patients with immature teratomas of the mediastinum, we recommend four cycles of preoperative VIP chemotherapy followed by complete surgical resection if technically feasible (",
"      <a class=\"grade\" href=\"._grade_2?title=Grade 1B\">",
"       Grade 1B",
"      </a>",
"      ). Neither chemotherapy alone nor surgery alone has consistently resulted in long-term survival. (See",
"      <a class=\"local\" href=\"#H12\">",
"       'Immature teratomas'",
"      </a>",
"      above and",
"      <a class=\"medical medical_review\" href=\"UTD.htm?23/63/24568?source=see_link\">",
"       \"Initial risk-stratified treatment for advanced testicular germ cell tumors\"",
"      </a>",
"      .)",
"     </li>",
"    </ul>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H34\">",
"    <span class=\"h2\">",
"     Mediastinal seminomas",
"    </span>",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      For patients with a mediastinal seminoma, we suggest",
"      <a class=\"drug drug_general\" href=\"UTD.htm?20/51/21305?source=see_link\">",
"       cisplatin",
"      </a>",
"      -based chemotherapy rather than radiation therapy or surgery (",
"      <a class=\"grade\" href=\"._grade_5?title=Grade 2B\">",
"       Grade 2B",
"      </a>",
"      ). Good risk patients should receive four cycles of",
"      <a class=\"drug drug_general\" href=\"UTD.htm?29/57/30617?source=see_link\">",
"       etoposide",
"      </a>",
"      and cisplatin (EP) or three cycles of",
"      <a class=\"drug drug_general\" href=\"UTD.htm?38/15/39159?source=see_link\">",
"       bleomycin",
"      </a>",
"      , etoposide, and cisplatin (BEP) chemotherapy. Intermediate risk patients (ie, those with nonpulmonary visceral metastases) should receive four cycles of BEP chemotherapy or etoposide,",
"      <a class=\"drug drug_general\" href=\"UTD.htm?37/25/38297?source=see_link\">",
"       ifosfamide",
"      </a>",
"      , and cisplatin (VIP) chemotherapy. Radiation therapy is an alternative for patients who do not have bulky or metastatic disease. (See",
"      <a class=\"local\" href=\"#H14\">",
"       'Mediastinal seminoma'",
"      </a>",
"      above and",
"      <a class=\"medical medical_review\" href=\"UTD.htm?23/63/24568?source=see_link\">",
"       \"Initial risk-stratified treatment for advanced testicular germ cell tumors\"",
"      </a>",
"      .)",
"     </li>",
"     <li>",
"      Residual masses larger than 3 cm should be evaluated with a PET scan or an open biopsy or should be closely observed. Residual masses smaller than 3 cm should be closely observed or evaluated with a PET scan. PET-negative lesions should be observed. (See",
"      <a class=\"local\" href=\"#H20\">",
"       'Residual mass'",
"      </a>",
"      above.) PET-positive lesions should not be treated with chemotherapy or radiation unless a biopsy or resection provides histopathological documentation of residual cancer.",
"     </li>",
"     <li>",
"      Mediastinal seminomas with elements of other cell types or with an elevation of serum alpha fetoprotein (AFP) should be treated like a nonseminomatous GCT. (See",
"      <a class=\"local\" href=\"#H21\">",
"       'Mediastinal nonseminomatous GCT'",
"      </a>",
"      above.)",
"     </li>",
"    </ul>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H35\">",
"    <span class=\"h2\">",
"     Mediastinal nonseminomatous germ cell tumors",
"    </span>",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      For patients with a mediastinal nonseminomatous GCT, we recommend four cycles of",
"      <a class=\"drug drug_general\" href=\"UTD.htm?29/57/30617?source=see_link\">",
"       etoposide",
"      </a>",
"      ,",
"      <a class=\"drug drug_general\" href=\"UTD.htm?37/25/38297?source=see_link\">",
"       ifosfamide",
"      </a>",
"      and",
"      <a class=\"drug drug_general\" href=\"UTD.htm?20/51/21305?source=see_link\">",
"       cisplatin",
"      </a>",
"      (VIP) chemotherapy as the initial therapy, rather than surgery or radiation therapy (",
"      <a class=\"grade\" href=\"._grade_1?title=Grade 1A\">",
"       Grade 1A",
"      </a>",
"      ). (See",
"      <a class=\"local\" href=\"#H21\">",
"       'Mediastinal nonseminomatous GCT'",
"      </a>",
"      above and",
"      <a class=\"medical medical_review\" href=\"UTD.htm?23/63/24568?source=see_link\">",
"       \"Initial risk-stratified treatment for advanced testicular germ cell tumors\"",
"      </a>",
"      .)",
"     </li>",
"     <li>",
"      For patients with a residual mediastinal mass following initial chemotherapy, we recommend complete surgical resection if technically feasible (",
"      <a class=\"grade\" href=\"._grade_1?title=Grade 1A\">",
"       Grade 1A",
"      </a>",
"      ). If viable malignancy is identified, two additional cycles of VIP chemotherapy should be given. (See",
"      <a class=\"local\" href=\"#H25\">",
"       'Surgery for residual mass'",
"      </a>",
"      above.)",
"     </li>",
"    </ul>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H36\">",
"    <span class=\"h2\">",
"     Retroperitoneal seminoma",
"    </span>",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      For patients with a retroperitoneal seminoma, we recommend",
"      <a class=\"drug drug_general\" href=\"UTD.htm?20/51/21305?source=see_link\">",
"       cisplatin",
"      </a>",
"      -based chemotherapy (",
"      <a class=\"grade\" href=\"._grade_2?title=Grade 1B\">",
"       Grade 1B",
"      </a>",
"      ). Radiation therapy may be an alternative for patients with nonbulky disease. (See",
"      <a class=\"local\" href=\"#H29\">",
"       'Retroperitoneal seminoma'",
"      </a>",
"      above and",
"      <a class=\"medical medical_review\" href=\"UTD.htm?21/45/22230?source=see_link\">",
"       \"Treatment of stage II seminoma\"",
"      </a>",
"      .)",
"     </li>",
"    </ul>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H37\">",
"    <span class=\"h2\">",
"     Retroperitoneal nonseminomatous GCTs",
"    </span>",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      For patients with a retroperitoneal nonseminomatous GCT, we recommend",
"      <a class=\"drug drug_general\" href=\"UTD.htm?20/51/21305?source=see_link\">",
"       cisplatin",
"      </a>",
"      -based chemotherapy, as would be used for a testicular nonseminomatous GCT, rather than radiation therapy or surgery (",
"      <a class=\"grade\" href=\"._grade_2?title=Grade 1B\">",
"       Grade 1B",
"      </a>",
"      ). Depending upon whether the patient falls into the good or",
"      <span class=\"nowrap\">",
"       intermediate/poor",
"      </span>",
"      prognosis group, this would include three or four cycles of treatment. This should be followed by surgical resection of any residual mass. (See",
"      <a class=\"medical medical_review\" href=\"UTD.htm?9/3/9272?source=see_link\">",
"       \"Retroperitoneal lymph node dissection in testicular germ cell tumors\"",
"      </a>",
"      and",
"      <a class=\"medical medical_review\" href=\"UTD.htm?23/63/24568?source=see_link\">",
"       \"Initial risk-stratified treatment for advanced testicular germ cell tumors\"",
"      </a>",
"      .)",
"     </li>",
"    </ul>",
"   </p>",
"  </div>",
"  <div id=\"topicAgreement\">",
"   Use of UpToDate is subject to the",
"   <a class=\"licenseLink\" href=\"./license\" id=\"sla_in_page\" target=\"_blank\">",
"    Subscription and License Agreement",
"   </a>",
"   .",
"  </div>",
"  <div class=\"headingAnchor\" id=\"references\">",
"   <h1>",
"    REFERENCES",
"   </h1>",
"   <ol id=\"reference\">",
"    <li>",
"     Droz JP, Horwich A. Extragonadal germ cell tumors. In: Comprehensive Textbook of Genitourinary Oncology, 2nd, Vogelzang NJ, Scardino PT, Shipley WU, Doffey DS (Eds), Lippincott Williams and Wilkins, New York 2000.",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?9/52/10058/abstract/2\">",
"      Marina N, London WB, Frazier AL, et al. Prognostic factors in children with extragonadal malignant germ cell tumors: a pediatric intergroup study. J Clin Oncol 2006; 24:2544.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?9/52/10058/abstract/3\">",
"      McKenney JK, Heerema-McKenney A, Rouse RV. Extragonadal germ cell tumors: a review with emphasis on pathologic features, clinical prognostic variables, and differential diagnostic considerations. Adv Anat Pathol 2007; 14:69.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?9/52/10058/abstract/4\">",
"      Chen CK, Chang YL, Jou ST, et al. Treatment of mediastinal immature teratoma in a child with precocious puberty and Klinefelter's syndrome. Ann Thorac Surg 2006; 82:1906.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?9/52/10058/abstract/5\">",
"      Phowthongkum P. The second case of de novo intracranial germinoma association with Klinefelter's syndrome. Surg Neurol 2006; 66:332; author reply 332.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?9/52/10058/abstract/6\">",
"      Aguirre D, Nieto K, Lazos M, et al. Extragonadal germ cell tumors are often associated with Klinefelter syndrome. Hum Pathol 2006; 37:477.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?9/52/10058/abstract/7\">",
"      V&ouml;lkl TM, Langer T, Aigner T, et al. Klinefelter syndrome and mediastinal germ cell tumors. Am J Med Genet A 2006; 140:471.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?9/52/10058/abstract/8\">",
"      Glenn OA, Barkovich AJ. Intracranial germ cell tumors: a comprehensive review of proposed embryologic derivation. Pediatr Neurosurg 1996; 24:242.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?9/52/10058/abstract/9\">",
"      Chaganti RS, Houldsworth J. Genetics and biology of adult human male germ cell tumors. Cancer Res 2000; 60:1475.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?9/52/10058/abstract/10\">",
"      Hailemariam S, Engeler DS, Bannwart F, Amin MB. Primary mediastinal germ cell tumor with intratubular germ cell neoplasia of the testis--further support for germ cell origin of these tumors: a case report. Cancer 1997; 79:1031.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?9/52/10058/abstract/11\">",
"      Chaganti RS, Rodriguez E, Mathew S. Origin of adult male mediastinal germ-cell tumours. Lancet 1994; 343:1130.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?9/52/10058/abstract/12\">",
"      Daugaard G, R&oslash;rth M, von der Maase H, Skakkebaek NE. Management of extragonadal germ-cell tumors and the significance of bilateral testicular biopsies. Ann Oncol 1992; 3:283.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?9/52/10058/abstract/13\">",
"      Schmoll HJ, Souchon R, Krege S, et al. European consensus on diagnosis and treatment of germ cell cancer: a report of the European Germ Cell Cancer Consensus Group (EGCCCG). Ann Oncol 2004; 15:1377.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?9/52/10058/abstract/14\">",
"      Hartmann JT, Fossa SD, Nichols CR, et al. Incidence of metachronous testicular cancer in patients with extragonadal germ cell tumors. J Natl Cancer Inst 2001; 93:1733.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?9/52/10058/abstract/15\">",
"      B&ouml;hle A, Studer UE, Sonntag RW, Scheidegger JR. Primary or secondary extragonadal germ cell tumors? J Urol 1986; 135:939.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?9/52/10058/abstract/16\">",
"      McAleer JJ, Nicholls J, Horwich A. Does extragonadal presentation impart a worse prognosis to abdominal germ-cell tumours? Eur J Cancer 1992; 28A:825.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?9/52/10058/abstract/17\">",
"      Comiter CV, Renshaw AA, Benson CB, Loughlin KR. Burned-out primary testicular cancer: sonographic and pathological characteristics. J Urol 1996; 156:85.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?9/52/10058/abstract/18\">",
"      Balzer BL, Ulbright TM. Spontaneous regression of testicular germ cell tumors: an analysis of 42 cases. Am J Surg Pathol 2006; 30:858.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?9/52/10058/abstract/19\">",
"      Bokemeyer C, Nichols CR, Droz JP, et al. Extragonadal germ cell tumors of the mediastinum and retroperitoneum: results from an international analysis. J Clin Oncol 2002; 20:1864.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?9/52/10058/abstract/20\">",
"      Cheng L. Establishing a germ cell origin for metastatic tumors using OCT4 immunohistochemistry. Cancer 2004; 101:2006.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?9/52/10058/abstract/21\">",
"      Motzer RJ, Rodriguez E, Reuter VE, et al. Molecular and cytogenetic studies in the diagnosis of patients with poorly differentiated carcinomas of unknown primary site. J Clin Oncol 1995; 13:274.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?9/52/10058/abstract/22\">",
"      Hainsworth JD, Johnson DH, Greco FA. Cisplatin-based combination chemotherapy in the treatment of poorly differentiated carcinoma and poorly differentiated adenocarcinoma of unknown primary site: results of a 12-year experience. J Clin Oncol 1992; 10:912.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?9/52/10058/abstract/23\">",
"      Currow DC, Findlay M, Cox K, Harnett PR. Elevated germ cell markers in carcinoma of uncertain primary site do not predict response to platinum based chemotherapy. Eur J Cancer 1996; 32A:2357.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?9/52/10058/abstract/24\">",
"      Pavlidis N, Kalef-Ezra J, Briassoulis E, et al. Evaluation of six tumor markers in patients with carcinoma of unknown primary. Med Pediatr Oncol 1994; 22:162.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?9/52/10058/abstract/25\">",
"      Yonemori K, Ando M, Shibata T, et al. Tumor-marker analysis and verification of prognostic models in patients with cancer of unknown primary, receiving platinum-based combination chemotherapy. J Cancer Res Clin Oncol 2006; 132:635.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?9/52/10058/abstract/26\">",
"      Motzer RJ, Amsterdam A, Prieto V, et al. Teratoma with malignant transformation: diverse malignant histologies arising in men with germ cell tumors. J Urol 1998; 159:133.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?9/52/10058/abstract/27\">",
"      Ehrlich Y, Beck SD, Ulbright TM, et al. Outcome analysis of patients with transformed teratoma to primitive neuroectodermal tumor. Ann Oncol 2010; 21:1846.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?9/52/10058/abstract/28\">",
"      Hartmann JT, Nichols CR, Droz JP, et al. Hematologic disorders associated with primary mediastinal nonseminomatous germ cell tumors. J Natl Cancer Inst 2000; 92:54.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?9/52/10058/abstract/29\">",
"      Nichols CR, Roth BJ, Heerema N, et al. Hematologic neoplasia associated with primary mediastinal germ-cell tumors. N Engl J Med 1990; 322:1425.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?9/52/10058/abstract/30\">",
"      Ladanyi M, Samaniego F, Reuter VE, et al. Cytogenetic and immunohistochemical evidence for the germ cell origin of a subset of acute leukemias associated with mediastinal germ cell tumors. J Natl Cancer Inst 1990; 82:221.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?9/52/10058/abstract/31\">",
"      Orazi A, Neiman RS, Ulbright TM, et al. Hematopoietic precursor cells within the yolk sac tumor component are the source of secondary hematopoietic malignancies in patients with mediastinal germ cell tumors. Cancer 1993; 71:3873.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?9/52/10058/abstract/32\">",
"      Hartmann JT, Nichols CR, Droz JP, et al. The relative risk of second nongerminal malignancies in patients with extragonadal germ cell tumors. Cancer 2000; 88:2629.",
"     </a>",
"    </li>",
"    <li>",
"     Cameron RB, Loehrer PJ, Thomas CR. Neoplasms of the mediastinum. In: Cancer: Principles and Practice of Oncology, DeVita VT, Hellman S, Rosenber SA (Eds), Lippincott Williams &amp; Wilkins, New York 2001.",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?9/52/10058/abstract/34\">",
"      Lewis BD, Hurt RD, Payne WS, et al. Benign teratomas of the mediastinum. J Thorac Cardiovasc Surg 1983; 86:727.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?9/52/10058/abstract/35\">",
"      Adebonojo SA, Nicola ML. Teratoid tumors of the mediastinum. Am Surg 1976; 42:361.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?9/52/10058/abstract/36\">",
"      Gunes S, Varon J, Walsh G. Mediastinal teratoma presenting as massive hemoptysis in an adult. J Emerg Med 1997; 15:313.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?9/52/10058/abstract/37\">",
"      Polansky SM, Barwick KW, Ravin CE. Primary mediastinal seminoma. AJR Am J Roentgenol 1979; 132:17.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?9/52/10058/abstract/38\">",
"      Moeller KH, Rosado-de-Christenson ML, Templeton PA. Mediastinal mature teratoma: imaging features. AJR Am J Roentgenol 1997; 169:985.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?9/52/10058/abstract/39\">",
"      Dulmet EM, Macchiarini P, Suc B, Verley JM. Germ cell tumors of the mediastinum. A 30-year experience. Cancer 1993; 72:1894.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?9/52/10058/abstract/40\">",
"      Takeda S, Miyoshi S, Ohta M, et al. Primary germ cell tumors in the mediastinum: a 50-year experience at a single Japanese institution. Cancer 2003; 97:367.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?9/52/10058/abstract/41\">",
"      Feo CF, Chironi G, Porcu A, et al. Videothoracoscopic removal of a mediastinal teratoma. Am Surg 1997; 63:459.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?9/52/10058/abstract/42\">",
"      Arai K, Ohta S, Suzuki M, Suzuki H. Primary immature mediastinal teratoma in adulthood. Eur J Surg Oncol 1997; 23:64.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?9/52/10058/abstract/43\">",
"      Donadio AC, Motzer RJ, Bajorin DF, et al. Chemotherapy for teratoma with malignant transformation. J Clin Oncol 2003; 21:4285.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?9/52/10058/abstract/44\">",
"      Moran CA, Suster S, Przygodzki RM, Koss MN. Primary germ cell tumors of the mediastinum: II. Mediastinal seminomas--a clinicopathologic and immunohistochemical study of 120 cases. Cancer 1997; 80:691.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?9/52/10058/abstract/45\">",
"      International Germ Cell Consensus Classification: a prognostic factor-based staging system for metastatic germ cell cancers. International Germ Cell Cancer Collaborative Group. J Clin Oncol 1997; 15:594.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?9/52/10058/abstract/46\">",
"      Bokemeyer C, Droz JP, Horwich A, et al. Extragonadal seminoma: an international multicenter analysis of prognostic factors and long term treatment outcome. Cancer 2001; 91:1394.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?9/52/10058/abstract/47\">",
"      Samuels ML, Johnson DE, Holoye PY, Lanzotti VJ. Large-dose bleomycin therapy and pulmonary toxicity. A possible role of prior radiotherapy. JAMA 1976; 235:1117.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?9/52/10058/abstract/48\">",
"      Hainsworth JD, Greco FA. Extragonadal germ cell tumors and unrecognized germ cell tumors. Semin Oncol 1992; 19:119.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?9/52/10058/abstract/49\">",
"      Jain KK, Bosl GJ, Bains MS, et al. The treatment of extragonadal seminoma. J Clin Oncol 1984; 2:820.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?9/52/10058/abstract/50\">",
"      Horwich A, Paluchowska B, Norman A, et al. Residual mass following chemotherapy of seminoma. Ann Oncol 1997; 8:37.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?9/52/10058/abstract/51\">",
"      Duchesne GM, Stenning SP, Aass N, et al. Radiotherapy after chemotherapy for metastatic seminoma--a diminishing role. MRC Testicular Tumour Working Party. Eur J Cancer 1997; 33:829.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?9/52/10058/abstract/52\">",
"      Schultz SM, Einhorn LH, Conces DJ Jr, et al. Management of postchemotherapy residual mass in patients with advanced seminoma: Indiana University experience. J Clin Oncol 1989; 7:1497.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?9/52/10058/abstract/53\">",
"      Motzer R, Bosl G, Heelan R, et al. Residual mass: an indication for further therapy in patients with advanced seminoma following systemic chemotherapy. J Clin Oncol 1987; 5:1064.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?9/52/10058/abstract/54\">",
"      Puc HS, Heelan R, Mazumdar M, et al. Management of residual mass in advanced seminoma: results and recommendations from the Memorial Sloan-Kettering Cancer Center. J Clin Oncol 1996; 14:454.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?9/52/10058/abstract/55\">",
"      Hinz S, Schrader M, Kempkensteffen C, et al. The role of positron emission tomography in the evaluation of residual masses after chemotherapy for advanced stage seminoma. J Urol 2008; 179:936.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?9/52/10058/abstract/56\">",
"      De Santis M, Bokemeyer C, Becherer A, et al. Predictive impact of 2-18fluoro-2-deoxy-D-glucose positron emission tomography for residual postchemotherapy masses in patients with bulky seminoma. J Clin Oncol 2001; 19:3740.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?9/52/10058/abstract/57\">",
"      Moran CA, Suster S, Koss MN. Primary germ cell tumors of the mediastinum: III. Yolk sac tumor, embryonal carcinoma, choriocarcinoma, and combined nonteratomatous germ cell tumors of the mediastinum--a clinicopathologic and immunohistochemical study of 64 cases. Cancer 1997; 80:699.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?9/52/10058/abstract/58\">",
"      Knapp RH, Hurt RD, Payne WS, et al. Malignant germ cell tumors of the mediastinum. J Thorac Cardiovasc Surg 1985; 89:82.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?9/52/10058/abstract/59\">",
"      Fizazi K, Culine S, Droz JP, et al. Primary mediastinal nonseminomatous germ cell tumors: results of modern therapy including cisplatin-based chemotherapy. J Clin Oncol 1998; 16:725.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?9/52/10058/abstract/60\">",
"      Kesler KA, Rieger KM, Hammoud ZT, et al. A 25-year single institution experience with surgery for primary mediastinal nonseminomatous germ cell tumors. Ann Thorac Surg 2008; 85:371.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?9/52/10058/abstract/61\">",
"      Vuky J, Bains M, Bacik J, et al. Role of postchemotherapy adjunctive surgery in the management of patients with nonseminoma arising from the mediastinum. J Clin Oncol 2001; 19:682.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?9/52/10058/abstract/62\">",
"      Radaideh SM, Cook VC, Kesler KA, Einhorn LH. Outcome following resection for patients with primary mediastinal nonseminomatous germ-cell tumors and rising serum tumor markers post-chemotherapy. Ann Oncol 2010; 21:804.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?9/52/10058/abstract/63\">",
"      Ganjoo KN, Rieger KM, Kesler KA, et al. Results of modern therapy for patients with mediastinal nonseminomatous germ cell tumors. Cancer 2000; 88:1051.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?9/52/10058/abstract/64\">",
"      Schneider BP, Kesler KA, Brooks JA, et al. Outcome of patients with residual germ cell or non-germ cell malignancy after resection of primary mediastinal nonseminomatous germ cell cancer. J Clin Oncol 2004; 22:1195.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?9/52/10058/abstract/65\">",
"      Hidalgo M, Paz-Ares L, Rivera F, et al. Mediastinal non-seminomatous germ cell tumours (MNSGCT) treated with cisplatin-based combination chemotherapy. Ann Oncol 1997; 8:555.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?9/52/10058/abstract/66\">",
"      Broun ER, Nichols CR, Einhorn LH, Tricot GJ. Salvage therapy with high-dose chemotherapy and autologous bone marrow support in the treatment of primary nonseminomatous mediastinal germ cell tumors. Cancer 1991; 68:1513.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?9/52/10058/abstract/67\">",
"      Saxman SB, Nichols CR, Einhorn LH. Salvage chemotherapy in patients with extragonadal nonseminomatous germ cell tumors: the Indiana University experience. J Clin Oncol 1994; 12:1390.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?9/52/10058/abstract/68\">",
"      Hartmann JT, Einhorn L, Nichols CR, et al. Second-line chemotherapy in patients with relapsed extragonadal nonseminomatous germ cell tumors: results of an international multicenter analysis. J Clin Oncol 2001; 19:1641.",
"     </a>",
"    </li>",
"   </ol>",
"  </div>",
"  <div id=\"topicVersionRevision\">",
"   Topic 2998 Version 6.0",
"  </div>",
" </div>",
" <div id=\"footer\">",
"  <div id=\"supportFooter\">",
"   <span class=\"sfInfo\">",
"    &copy; 2013 UpToDate, Inc. All rights reserved.",
"   </span>",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <a class=\"licenseLink\" href=\"./license\" id=\"sla_footer\">",
"    Subscription and License Agreement",
"   </a>",
"   <span class=\"sfInfo\">",
"    <span class=\"pipeSpace\">",
"     |",
"    </span>",
"    Release: 21.3 - C21.34",
"   </span>",
"   <br/>",
"   <span class=\"sfInfo\">",
"    Licensed to:",
"    <span class=\"emphasis\">",
"     Morehouse School of Medicine",
"    </span>",
"   </span>",
"   <span class=\"sfInfo\">",
"    <span class=\"pipeSpace\">",
"     |",
"    </span>",
"    Support Tag: [1002-210.101.131.232-0D05C0E861-S473950.14]",
"    <br/>",
"   </span>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f9_52_10058=[""].join("\n");
var outline_f9_52_10058=[" <div id=\"toggleOutline\">",
"  <a href=\"#\" title=\"Collapse Topic Outline\">",
"   <img alt=\"\" src=\"./../images/orange_arrow_left.myextg\"/>",
"  </a>",
" </div>",
" <div id=\"innerOutline\">",
"  <h1>",
"   TOPIC OUTLINE",
"  </h1>",
"  <div id=\"outline\">",
"   <ul>",
"    <li>",
"     <a class=\"sr_button\" href=\"#H31\" id=\"summRecButton\">",
"      <span>",
"       SUMMARY &amp; RECOMMENDATIONS",
"      </span>",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H1\">",
"      INTRODUCTION",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H2\">",
"      HISTOGENESIS",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H3\">",
"      DIAGNOSIS",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H4\">",
"      Tumor markers",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H5\">",
"      Histologic diagnosis",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H7\">",
"      ASSOCIATION WITH OTHER MALIGNANCIES",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H8\">",
"      MATURE TERATOMAS",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H9\">",
"      Clinical manifestations",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H10\">",
"      Imaging studies",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H11\">",
"      Treatment",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H12\">",
"      IMMATURE TERATOMAS",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H13\">",
"      Treatment",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H14\">",
"      MEDIASTINAL SEMINOMA",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H15\">",
"      Clinical manifestations",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H16\">",
"      Treatment",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H17\">",
"      - Chemotherapy",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H18\">",
"      - Radiation therapy",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H19\">",
"      - Surgery",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H20\">",
"      - Residual mass",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H21\">",
"      MEDIASTINAL NONSEMINOMATOUS GCT",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H22\">",
"      Clinical manifestations",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H23\">",
"      Treatment",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H24\">",
"      - Systemic chemotherapy",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H25\">",
"      - Surgery for residual mass",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H26\">",
"      - Salvage chemotherapy",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H27\">",
"      Prognosis",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H28\">",
"      RETROPERITONEAL TUMORS",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H29\">",
"      Retroperitoneal seminoma",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H30\">",
"      Retroperitoneal nonseminomatous GCTs",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H31\">",
"      SUMMARY AND RECOMMENDATIONS",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H32\">",
"      Mature mediastinal teratomas",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H33\">",
"      Immature mediastinal teratomas",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H34\">",
"      Mediastinal seminomas",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H35\">",
"      Mediastinal nonseminomatous germ cell tumors",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H36\">",
"      Retroperitoneal seminoma",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H37\">",
"      Retroperitoneal nonseminomatous GCTs",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a href=\"#references\">",
"      REFERENCES",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
"  <h1>",
"   <div class=\"openRelatedGraphics\" id=\"ONC/2998\" rel=\"outline_link\">",
"    GRAPHICS",
"    <a class=\"graphics_icon\" href=\"#\" title=\"View All Related Graphics\">",
"     View All",
"    </a>",
"   </div>",
"  </h1>",
"  <div id=\"relatedGraphics\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <div class=\"openRelatedGraphics\" id=\"ONC/2998|DiagnosticImage\">",
"      <a href=\"#\" title=\"DIAGNOSTIC IMAGES\">",
"       DIAGNOSTIC IMAGES",
"      </a>",
"     </div>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_diagnosticimage\" href=\"UTD.htm?28/39/29296\" title=\"diagnostic image 1\">",
"      Teratoma PA and CT",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <div class=\"openRelatedGraphics\" id=\"ONC/2998|PIC\">",
"      <a href=\"#\" title=\"PICTURES\">",
"       PICTURES",
"      </a>",
"     </div>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_picture\" href=\"UTD.htm?37/52/38724\" title=\"picture 1\">",
"      Mature teratoma Low",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_picture\" href=\"UTD.htm?30/47/31479\" title=\"picture 2A\">",
"      Mediastinal seminoma I Low",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_picture\" href=\"UTD.htm?38/55/39797\" title=\"picture 2B\">",
"      Mediastinal seminoma II Low",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_picture\" href=\"UTD.htm?8/44/8903\" title=\"picture 3\">",
"      Yolk sac tumor Low",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <div class=\"openRelatedGraphics\" id=\"ONC/2998|TAB\">",
"      <a href=\"#\" title=\"TABLES\">",
"       TABLES",
"      </a>",
"     </div>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_table\" href=\"UTD.htm?9/52/10060\" title=\"table 1\">",
"      Classification of teratomas",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_table\" href=\"UTD.htm?14/2/14382\" title=\"table 2\">",
"      Bleomycin etoposide and cisplatin regimen",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_table\" href=\"UTD.htm?38/62/39917\" title=\"table 3\">",
"      Cisplatin and etoposide for relapsed germ cell tumors",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
"  <h1>",
"   RELATED TOPICS",
"  </h1>",
"  <div id=\"relatedTopics\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?5/40/5770?source=related_link\">",
"      Anatomy and pathology of testicular tumors",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?31/40/32392?source=related_link\">",
"      Anterior mediastinal mass lesions",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?12/31/12794?source=related_link\">",
"      Bleomycin-induced lung injury",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?33/21/34137?source=related_link\">",
"      Cardiotoxicity of radiation therapy for malignancy",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?26/47/27384?source=related_link\">",
"      Causes and evaluation of gynecomastia",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?30/24/31111?source=related_link\">",
"      Evaluation of mediastinal masses",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?23/63/24568?source=related_link\">",
"      Initial risk-stratified treatment for advanced testicular germ cell tumors",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?4/43/4794?source=related_link\">",
"      Pathology of mediastinal tumors",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?29/25/30105?source=related_link\">",
"      Pediatric intracranial germ cell tumors",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?8/56/9096?source=related_link\">",
"      Poorly differentiated cancer from an unknown primary site",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?9/3/9272?source=related_link\">",
"      Retroperitoneal lymph node dissection in testicular germ cell tumors",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?24/17/24852?source=related_link\">",
"      Risk stratification of metastatic testicular germ cell tumors",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?17/30/17894?source=related_link\">",
"      Sacrococcygeal germ cell tumors",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?37/58/38822?source=related_link\">",
"      Serum tumor markers in testicular germ cell tumors",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?41/27/42425?source=related_link\">",
"      Testicular intratubular germ cell neoplasia, unclassified (testicular carcinoma in situ, testicular intraepithelial neoplasia)",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?2/56/2954?source=related_link\">",
"      Treatment of relapsed and refractory testicular germ cell tumors",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?21/45/22230?source=related_link\">",
"      Treatment of stage II seminoma",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?35/6/35946?source=related_link\">",
"      Uncommon brain tumors",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
" </div>"].join("\n");
var title_f9_52_10059="PHACE syndrome";
var content_f9_52_10059=[" <div id=\"graphicsToolbar\">",
"  <div id=\"graphicsCopy\">",
"   &copy;2013 UpToDate",
"   <sup>",
"    &reg;",
"   </sup>",
"  </div>",
"  <div id=\"graphicsLinks\">",
"   <a href=\"?imageKey=PEDS%2F80245&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=1\" onclick=\"\">",
"    <img alt=\"Print this page\" src=\"./../images/icn_print.myextg\" title=\"Print this page\"/>",
"   </a>",
"   <a class=\"icontxt textLink\" href=\"?imageKey=PEDS%2F80245&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=1\" onclick=\"\" title=\"Print this page\">",
"    Print",
"   </a>",
"   <a class=\"etacLink\" href=\"#\">",
"    <img alt=\"Email graphic(s)\" src=\"./../images/icn_email.myextg\" title=\"Email graphic(s)\"/>",
"   </a>",
"   <a class=\"icontxt textLink etacLink\" href=\"#\" title=\"Email graphic(s)\">",
"    Email",
"   </a>",
"  </div>",
" </div>",
" <div class=\"graphic\">",
"  <div class=\"figure\">",
"   <div class=\"ttl\">",
"    Characteristics of PHACE syndrome",
"   </div>",
"   <div class=\"cntnt\">",
"    <table cellspacing=\"0\">",
"     <tbody>",
"      <tr>",
"       <td class=\"subtitle1_left\">",
"        P",
"       </td>",
"       <td>",
"        Posterior fossa brain malformations, most commonly the Dandy-Walker variant",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"subtitle1_left\">",
"        H",
"       </td>",
"       <td>",
"        Hemangiomas, particularly large, segmental facial lesions",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"subtitle1_left\">",
"        A",
"       </td>",
"       <td>",
"        Arterial anomalies",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"subtitle1_left\">",
"        C",
"       </td>",
"       <td>",
"        Cardiac anomalies and coarctation of the aorta",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"subtitle1_left\">",
"        E",
"       </td>",
"       <td>",
"        Eye abnormalities and endocrine abnormalities",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"subtitle1_left\">",
"        S*",
"       </td>",
"       <td>",
"        Sternal cleft, supraumbilical raphe, or both",
"       </td>",
"      </tr>",
"     </tbody>",
"    </table>",
"   </div>",
"   <div class=\"lgnd\">",
"    <div class=\"footnotes\">",
"     * The term \"PHACE(S)\" is sometimes used in the presence of ventral developmental defects.",
"    </div>",
"    <div class=\"reference\">",
"    </div>",
"   </div>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f9_52_10059=[""].join("\n");
var outline_f9_52_10059=null;
var title_f9_52_10060="Classification of teratomas";
var content_f9_52_10060=[" <div id=\"graphicsToolbar\">",
"  <div id=\"graphicsCopy\">",
"   &copy;2013 UpToDate",
"   <sup>",
"    &reg;",
"   </sup>",
"  </div>",
"  <div id=\"graphicsLinks\">",
"   <a href=\"?imageKey=PULM%2F59492&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=1\" onclick=\"\">",
"    <img alt=\"Print this page\" src=\"./../images/icn_print.myextg\" title=\"Print this page\"/>",
"   </a>",
"   <a class=\"icontxt textLink\" href=\"?imageKey=PULM%2F59492&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=1\" onclick=\"\" title=\"Print this page\">",
"    Print",
"   </a>",
"   <a class=\"etacLink\" href=\"#\">",
"    <img alt=\"Email graphic(s)\" src=\"./../images/icn_email.myextg\" title=\"Email graphic(s)\"/>",
"   </a>",
"   <a class=\"icontxt textLink etacLink\" href=\"#\" title=\"Email graphic(s)\">",
"    Email",
"   </a>",
"  </div>",
" </div>",
" <div class=\"graphic\">",
"  <div class=\"figure\">",
"   <div class=\"ttl\">",
"    Classification of extragonadal teratomas",
"   </div>",
"   <div class=\"cntnt\">",
"    <table cellspacing=\"0\">",
"     <tbody>",
"      <tr>",
"       <td class=\"subtitle1_single\">",
"        I. Benign teratomas",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"subtitle2_single\">",
"        Mature",
"teratoma",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"indent1\">",
"        Grade 0 - All component tissues appear well",
"differentiated",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"indent1\">",
"        Grade 1 - Occasional microscopic foci contain",
"incompletely differentiated tissues, not exceeding 10 percent of the",
"sampled surface",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"subtitle2_single\">",
"        Immature",
"teratoma, benign",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"indent1\">",
"        Grade 2 - Immature tissues make up between 10 and 50",
"percent of the sampled tumor surface",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"indent1\">",
"        Grade 3 - Over half of the surface examined is composed",
"of undifferentiated tissues of uncertain metastatic potential; a benign",
"course is still possible",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"subtitle1_single\">",
"        II. Malignant",
"teratomas",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"subtitle2_single\">",
"        With",
"areas of germ cell tumor",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"indent1\">",
"        Germinoma (seminoma, dysgerminoma)",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"indent1\">",
"        Embryonal carcinoma",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"indent1\">",
"        Choriocarcinoma",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"indent1\">",
"        Yolk sac tumor",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"indent1\">",
"        Mixed (any combination of the above)",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"subtitle2_single\">",
"        With",
"nongerminal malignant tumor pattern",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"indent1\">",
"        Carcinoma",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"indent1\">",
"        Sarcoma",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"indent1\">",
"        Malignant embryonal tumor",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"indent1\">",
"        Mixed",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"subtitle2_single\">",
"        Immature",
"teratoma, malignant",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"indent1\">",
"        A teratoma that would otherwise be classified as benign",
"immature teratoma, but which subsequently became metastatic",
"       </td>",
"      </tr>",
"     </tbody>",
"    </table>",
"   </div>",
"   <div class=\"lgnd\">",
"    <div class=\"footnotes\">",
"    </div>",
"    <div class=\"reference\">",
"     Gonzalez-Crussi, F. Atlas of Tumor Pathology: Extragonadal Teratomas, 2nd ed, Armed Forces Institute of Pathology, Washington, DC, 1982.",
"    </div>",
"   </div>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f9_52_10060=[""].join("\n");
var outline_f9_52_10060=null;
var title_f9_52_10061="TIMI flow and survival after thrombolysis";
var content_f9_52_10061=[" <div id=\"graphicsToolbar\">",
"  <div id=\"graphicsCopy\">",
"   &copy;2013 UpToDate",
"   <sup>",
"    &reg;",
"   </sup>",
"  </div>",
"  <div id=\"graphicsLinks\">",
"   <a href=\"?imageKey=CARD%2F70952&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=1\" onclick=\"\">",
"    <img alt=\"Print this page\" src=\"./../images/icn_print.myextg\" title=\"Print this page\"/>",
"   </a>",
"   <a class=\"icontxt textLink\" href=\"?imageKey=CARD%2F70952&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=1\" onclick=\"\" title=\"Print this page\">",
"    Print",
"   </a>",
"   <a class=\"etacLink\" href=\"#\">",
"    <img alt=\"Email graphic(s)\" src=\"./../images/icn_email.myextg\" title=\"Email graphic(s)\"/>",
"   </a>",
"   <a class=\"icontxt textLink etacLink\" href=\"#\" title=\"Email graphic(s)\">",
"    Email",
"   </a>",
"  </div>",
" </div>",
" <div class=\"graphic\">",
"  <div class=\"figure\" style=\"width: 470px\">",
"   <div class=\"ttl\">",
"    Survival after thrombolytic therapy is better with TIMI grade 3 flow",
"   </div>",
"   <div class=\"cntnt\" style=\"width: 339px; height: 234px; background-image: url(data:image/gif;base64,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);\">",
"   </div>",
"   <div class=\"lgnd\">",
"    Among all patients with acute ST elevation myocardial infarction entered into the GUSTO-I trial, those with TIMI grade 3 (normal) flow in the infarct-related artery at 90 minutes after thrombolytic therapy had a significantly higher rate of two-year survival than patients with TIMI grades 0, 1, or 2. Partial restoration of flow (TIMI grade 2) did not improve outcomes compared to no or or faint flow (TIMI grade 0 or 1). A similar relationship was seen when the analysis was limited to patients who were alive at 30 days after the infarction (not shown).",
"    <div class=\"footnotes\">",
"    </div>",
"    <div class=\"reference\">",
"     Data from Ross AM, Coyne KS, Moreyra E, et al, for the GUSTO-I Angiography Investigators. Circulation 1998; 97:1549.",
"    </div>",
"   </div>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f9_52_10061=[""].join("\n");
var outline_f9_52_10061=null;
var title_f9_52_10062="Coronary death vs sex race";
var content_f9_52_10062=[" <div id=\"graphicsToolbar\">",
"  <div id=\"graphicsCopy\">",
"   &copy;2013 UpToDate",
"   <sup>",
"    &reg;",
"   </sup>",
"  </div>",
"  <div id=\"graphicsLinks\">",
"   <a href=\"?imageKey=CARD%2F77937&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=2\" onclick=\"\">",
"    <img alt=\"Print this page\" src=\"./../images/icn_print.myextg\" title=\"Print this page\"/>",
"   </a>",
"   <a class=\"icontxt textLink\" href=\"?imageKey=CARD%2F77937&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=2\" onclick=\"\" title=\"Print this page\">",
"    Print",
"   </a>",
"   <a class=\"etacLink\" href=\"#\">",
"    <img alt=\"Email graphic(s)\" src=\"./../images/icn_email.myextg\" title=\"Email graphic(s)\"/>",
"   </a>",
"   <a class=\"icontxt textLink etacLink\" href=\"#\" title=\"Email graphic(s)\">",
"    Email",
"   </a>",
"  </div>",
" </div>",
" <div class=\"graphic\">",
"  <div class=\"figure\" style=\"width: 559px\">",
"   <div class=\"ttl\">",
"    Reduction in death rates from coronary heart disease",
"   </div>",
"   <div class=\"cntnt\" style=\"width: 539px; height: 356px; background-image: url(data:image/gif;base64,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);\">",
"   </div>",
"   <div class=\"lgnd\">",
"    During the period from 1980 to 1997 there has been a significant decrease in mortality from coronary heart disease in both men and women and in blacks and whites. Rates are age-adjusted to 2000 standard.",
"    <div class=\"footnotes\">",
"    </div>",
"    <div class=\"reference\">",
"     Data from Cooper, R, Cutler, J, Desvigne-Nickens, P, et al, Circulation 2000; 102:3137.",
"    </div>",
"   </div>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f9_52_10062=[""].join("\n");
var outline_f9_52_10062=null;
var title_f9_52_10063="Closing a corner of a flap";
var content_f9_52_10063=[" <div id=\"graphicsToolbar\">",
"  <div id=\"graphicsCopy\">",
"   &copy;2013 UpToDate",
"   <sup>",
"    &reg;",
"   </sup>",
"  </div>",
"  <div id=\"graphicsLinks\">",
"   <a href=\"?imageKey=EM%2F51901&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=1\" onclick=\"\">",
"    <img alt=\"Print this page\" src=\"./../images/icn_print.myextg\" title=\"Print this page\"/>",
"   </a>",
"   <a class=\"icontxt textLink\" href=\"?imageKey=EM%2F51901&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=1\" onclick=\"\" title=\"Print this page\">",
"    Print",
"   </a>",
"   <a class=\"etacLink\" href=\"#\">",
"    <img alt=\"Email graphic(s)\" src=\"./../images/icn_email.myextg\" title=\"Email graphic(s)\"/>",
"   </a>",
"   <a class=\"icontxt textLink etacLink\" href=\"#\" title=\"Email graphic(s)\">",
"    Email",
"   </a>",
"  </div>",
" </div>",
" <div class=\"graphic\">",
"  <div class=\"figure\" style=\"width: 607px\">",
"   <div class=\"ttl\">",
"    Technique for closing the corner of a flap: half-buried horizontal mattress",
"   </div>",
"   <div class=\"cntnt\" style=\"width: 587px; height: 330px; background-image: url(data:image/jpeg;base64,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);\">",
"   </div>",
"   <div class=\"lgnd\">",
"    The half-buried horizontal mattress suture combines elements of the horizontal mattress suture with a dermal skin closure and can be used to approximate the corner of a flap. The needle is introduced through the skin in the non-flap portion of the wound. In the dermal (or buried) portion of the suture, the corner of the flap is picked up horizontally through the dermis. The suture loop is completed by bringing the needle out through the skin on the opposite side of the non-flap portion.",
"    <div class=\"footnotes\">",
"    </div>",
"    <div class=\"reference\">",
"    </div>",
"   </div>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f9_52_10063=[""].join("\n");
var outline_f9_52_10063=null;
